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ABSTRACT
KINETIC AND DYNAMIC INSIGHTS INTO THE SUBSTRATE
INTERACTIONS AND CATALYSIS OF FACTOR INHIBITING HIF-1 (FIH-1)
CRISTINA B. MARTIN, B.S., UNIVERSITY OF THE PHILIPPINES
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Michael J. Knapp

Factor inhibiting HIF-1 (FIH-1) modulates the master regulator of hypoxia
sensing, hypoxia inducible factor-1 (HIF-1), by transcriptional repression making it an
attractive potential target for treatment of hypoxia-related diseases. Given that similar
enzymes are present within the cell and that they have other important physiological
roles, defining the therapeutic window by which it can be selectively targeted becomes an
issue. Consequently, it’s necessary to have a deeper understanding of the substrate
interactions in FIH-1 that contributes to catalysis as this is one avenue that can be
explored for future therapeutic investigations. The overall goal of this dissertation is to
gain kinetic and dynamic insights into the substrate interactions and catalysis of FIH-1
that can be used in the future to improve its selective inhibition over the related prolyl
hydroxylase domain enzymes (PHDs). The term dynamic here loosely refers to the
conformational flexibility of the enzyme.
An initial screen of inhibitor compounds that mimic the cosubtrate, αKG, was
performed with the goal of teasing out compound properties that might be useful for
selectively inhibiting FIH-1 over the PHD isoform studied in the lab, PHD2, and vice
versa. Results from steady state kinetic assays supported by EPR spectroscopy showed
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that planar compounds are more effective at inhibiting PHD2 than FIH-1. One or two
compounds belonging to the pyrone/pyridinone framework may prove promising for
future development of selective FIH-1 inhibitors.
The succeeding studies were done in an effort to uncover unique substrate
interactions of FIH-1 that might provide further useful information for future selective
inhibition studies. Firstly, the effect of α-ketoglutarate (αKG) binding on the primary
substrate interactions of FIH-1 was tested. Initial observations in the lab, as well as
previous reports on the effect of αKG binding on the stability of similar enzymes, led us
to hypothesize that αKG binding induces conformational changes in FIH-1 which are in
turn required for the optimal binding of the primary substrate HIF-1α/C-terminal
transactivation domain (CTAD). To address this, fluorescence and thermal shift
experiments in addition to global hydrogen/deuterium exchange and limited proteolysis
coupled to mass spectrometry were performed. The data strongly implies a more tightly
folded structure of FIH-1 when bound to αKG. This is corroborated by the observations
that for the ternary enzyme-metal-αKG complex, (1) it is more thermally stable, (2) it is
less prone to solvent and protease attack, and (3) it apparently exhibits higher affinity for
the substrate HIF-1α/CTAD compared to apo or metal-bound form of the enzyme. The
data allowed for the conception of a model in which at least two conformational states of
the enzyme exist in equilibrium depending on the presence of αKG. The more rigid
structure likely primes the enzyme for optimal substrate binding via pre-formation of the
binding site, the configuration of which is tightly coupled to efficient turnover.
Lastly, the role of a protein loop on the substrate interactions and catalysis of
FIH-1 was tested. Based on (1) a previous computational study indicating that a loop
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containing residues 100-110 of FIH-1 (which we called the 100s loop) becomes less
flexible in the presence of substrate and (2) an analysis of the crystal structure revealing
the FIH-1 loop residue Tyr102 stacked on top of the substrate target residue Asn803, we
hypothesized that the 100s loop via Tyr102 is involved in substrate binding and turnover.
The results from steady state kinetic assays combined with UV-vis and EPR spectroscopy
as well as succinate quantitation experiments performed on loop mutants indicates that
(1) the contribution of the loop residue Tyr102 to substrate binding is mainly through
steric interaction and that (2) this steric interaction ensures the tight coupling of substrate
binding to turnover via proper positioning of the substrate target residue for subsequent
hydroxylation.
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CHAPTER 1
HYPOXIA SENSING: MAINTENANCE OF O2 HOMEOSTASIS AT THE
CELLULAR LEVEL

1.1 Introduction
The survival of metazoans is crucially dependent on oxygen levels. Oxygen is a
critical part of the aerobic energy production process of the cell where it serves as the
terminal electron acceptor. During this process called oxidative phosphorylation, energy
from organic substrates is chemically transformed into ATP, which is required by the cell
to maintain viability. ATP is also produced anaerobically via glycolysis but, unless there
is endless supply of available glucose and constitutively enhanced glycolytic enzyme
activities, this pathway cannot sufficiently meet the energy demands of a multicellular
organism whereas aerobic respiration can. Hence, physiological mechanisms have
evolved early on to efficiently maintain oxygen homeostasis within the organism at the
tissue and cellular level.[1,2]
Decreased oxygen availability leads to the condition known as hypoxia, which can be
disastrous to normal cells even for transient periods of time. Hypoxia occurs not only
during disease states like ischemic disorders and cancer but also during normal
embryonic development[3,4]. Thus, metazoans evolved an elaborate network that is
critically sensitive to low partial pressures of oxygen to ensure the critical adaptation and
response to such conditions. Hypoxia response in humans can be categorized as acute or
chronic depending on the severity and timeframe of oxygen deprivation. The acute
response occurs in the seconds to minutes time scale. The response largely involves
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excitation of ion channels that result in rapid cardiorespiratory changes such as
hyperventilation and enhanced cardiac output at the tissue level; and metabolic switch
from aerobic to anaerobic respiration at the cellular level. The chronic response, on the
other hand, occurs in the hours to days time scale and mainly involves induction of
oxygen-dependent gene expression with the overall effect of enhancing the O2-carrying
capacity of the blood and decreasing cellular O2 utilization. In addition to mediating the
aforementioned physiological responses triggered at the onset of hypoxia, the chronic
response also results in activation of angiogenesis and erythropoiesis among many
others.[2,4] Hypoxia sensing regulated by the transcription factor HIF generally falls under
the chronic response category whereby prolonged hypoxia allows for the stabilization and
accumulation of HIF that results to maximal trans-activational effect[98,99].

1.2 Key Regulators of Hypoxia Sensing
1.2.1

Hypoxia-Inducible Factor-1 (HIF-1)
The hypoxia-inducible factors (HIFs) mediate the crucial ability of metazoans to

respond to changes in oxygen availability via activation of genes that are essential for cell
survival under hypoxia[5,7,26-33]. Of the three members of this family, HIF-1 largely takes
the role of the master regulator of hypoxia sensing in humans primarily because of its
widespread tissue expression[104,105]. HIF-1 is an α/β heterodimeric protein belonging to
the basic helix-loop-helix (bHLH)/Per-ARNT-Sim (PAS) superfamily of transcription
factors (Figure 1.1A)[6]. This contiguous structural motif allows HIF-1 to bind to the
major groove of DNA, specifically to the canonical 5’-(G/A)CGTG-3’ site within
hypoxia responsive elements (HREs) in the promoter regions of target genes[7-11,102]. The
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bHLH/PAS motif also allows for the heterodimerization of the 120 kDa oxygen-regulated
HIF-1α subunit with the constitutively expressed 91-94 kDa HIF-1β also known as aryl
hydrocarbon acceptor nuclear translocator (ARNT)[6,12,13]. Formation of the HIF-1
heterodimer is critically required for DNA binding while recruitment of the co-activators
like p300/CBP, SRC-1 and TIF2 are needed for gene trans-activation[14,15,21,22,115]. The
co-activators in general serve as molecular platforms for the assembly of the
transcriptional machinery[118,119]. The HIF-1α subunit has two trans-activation domains
(TADs), one in the N-terminus called NTAD (residues 531-575) and another in the Cterminus called CTAD (residues 786-826) (Figure 1.1A)[101,103]. Unlike HIF-1α, which is
ubiquitously expressed[104,105], the HIF-2α and HIF-3α subunits are selectively expressed
and localized in certain tissues like the lungs and blood vessels[16-18,108]. Although the
exact reason for the existence of the three isoforms is yet to be elucidated, it has been
suggested that each HIF protein plays a complementary rather than a redundant role in
hypoxia sensing[18,100].
HIF-1 is tightly regulated in the cell by two oxygen-dependent hydroxylation
mechanisms illustrated in Figure 1.1B: (i) protein degradation and (ii) transcriptional
repression. The first mechanism is mediated by the prolyl hydroxylase domain (PHD)
enzymes, which under normoxic conditions hydroxylate conserved proline residues of the
α subunit. This targets HIF-1α for proteasomal degradation, hence, the protein has a
short half life of about 5 mins.[19,20,51] The second hydroxylation-based regulatory
mechanism is mediated by factor inhibiting HIF-1 (FIH-1), which is the protein under
study in this dissertation. Under normoxic conditions, FIH-1 catalyzes the hydroxylation
of a highly conserved asparagine residue in the C-terminal transactivation domain or
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Figure 1.1 (A) Simplified diagram illustrating the domains of the HIF-1 subunits. Also
shown are the proline residues in the N-terminal trans-activation domain of the α subunit
hydroxylated by PHDs and the asparagine residue in the C-terminal trans-activation
domain hydroxylated by FIH-1. (B) Schematic diagram of the oxygen-dependent
regulation of HIF-1α by PHDs and FIH-1.

CTAD of the α subunit. This modification hinders the binding of the co-activator
p300/CBP, which in turn represses the transcriptional activity of HIF-1[21-24]. The fact
that both the PHDs and FIH-1 regulate HIF-1 activity by O2-dependent mechanisms
made these hydroxylases primary cellular oxygen sensors.
Under hypoxic conditions, HIF hydroxylase activity is significantly reduced and
so the HIF-1α subunit escapes the O2-dependent posttranslational modifications. HIF-1α
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accumulates and translocates from the cytoplasm to the nucleus where the HIF-1 subunits
dimerize and, along with the co-activators like p300/CBP, are able to activate the
transcription of about a thousand genes to date as surveyed using chromatin
immunoprecipitation sequencing (Figure 1.1B)[109,110]. Protein products of these activated
genes are involved in glucose metabolism[5,26-28,111], angiogenesis[29,30], erythropoiesis[7],
cell survival, and iron uptake[31-33] among many others. These processes have been very
much implicated in the pathophysiology of disease states such as cancer[106,107],
myocardial and cerebral ischemia[34], pulmonary hypertension and anemia[35,36]. It is not
surprising then that HIF-1 and its molecular regulators, PHDs and FIH-1, are attractive
potential drug targets for these diseases. In fact, just very recently, several drug
companies like Fibrogen and Bayer have already began developing inhibitor compounds
mostly targeting the PHDs for the treatment of anemia, wound healing, heart disease and
pulmonary hypertension[84,85]. Though many of the compounds tested seem very
promising, only one or two have so far entered phase III clinical trials. A lot more of the
compounds turned out to be failures. It becomes apparent that at this stage, the ability to
manipulate the HIF hydroxylases selectively for productive therapeutic purposes still
necessitates a more profound understanding of their structures and functions.
Consequently, any information that will provide insight into the mechanism of the HIF
hydroxylases, FIH-1 being the focus in this dissertation, (1) may contribute to the current
understanding of how the HIF hydroxylases work in general and more importantly, (2)
may become useful in future therapeutic investigations.
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1.2.2

HIF Hydroxylases

1.2.2.1 Prolyl Hydroxylase Domain (PHD)
PHD is the mammalian homolog of the worm C. elegans HIF prolyl hydroxylase
EGLN. It exists in four isoforms with PHD2 being the best-studied HIF hydroxylase on
the basis of it being the most abundant isoform in human tissues[37-39,112]. PHDs are also
given the name HIF-P4Hs to signify the fact that they hydroxylate specific proline
residues of HIF at position 4[40]. However, ever since the group of Taylor discovered nonHIF substrates in 2006, the name PHD is generally regarded as the most appropriate
name for the enzyme[41,42].
All isoforms of PHD contain the double-stranded β-helix (DSBH) jellyroll or
cupin barrel core (Figure 1.3) characteristic of this highly conserved superfamily of
enzymes that requires iron as a cofactor, and oxygen, α-ketoglutarate (αKG) and a
primary substrate[37,38,43]. Ascorbate is also reported to be a cofactor requirement for
optimal activity of the PHDs[40,64,124]. Deep within the enzyme core lies the mononuclear
Fe(II) metal coordinated by the conserved two-histidine-one-carboxylate facial triad
motif, HX(D/E)X….H, on one face of the octahedral arrangement (Figure 1.3)[44-47]. The
remaining three coordination sites of the metal provides for the binding of the bidentate
ligand, αKG, and O2 in the enzyme’s active state or water in the resting state.
PHDs regulate the stability of human HIF-1α subunit by hydroxylation of the
conserved proline residues, Pro402 and Pro564, located in the oxygen-dependent
degradation (ODD) domain, which also overlaps with the NTAD[48-50,19-20,103] (Figure
1.1B). All isoforms of PHD have been shown to hydroxylate Pro564 of HIF-1α while
Pro402 is hydroxylated by PHD1 and PHD2[50]. Hydroxylation in any of the two prolines
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is enough to make HIF-1α susceptible to proteasomal degradation via
ubiquitination[48,50-54]. The hydroxylated proline residue, which is contained within the
consensus binding motif LXXLAP, recruits the von Hippel-Lindau tumor suppressor
protein or pVHL[55-57,19,20,50] via H-bond interactions with specific Ser and His residues
located in the β domain of pVHL[58,59]. This interaction earmarks HIF-1α for destruction.
The pVHL protein serves as the substrate recognition component of the cellular
ubiquitination machinery. Upon pVHL binding to hydroxyproline, HIF-1α is linked to
elongin B and C and other proteins that are part of the multiprotein E3 ubiquitin ligase
complex (VHLE3), which ultimately targets HIF-1α for protein breakdown[60-62].
The KM values for O2 of PHDs were determined to be 230-250 µM[40], which are
well above the average intracellular oxygen concentration estimated to be around 4 to
45 µM[43,123,125], making them well-suited as cellular oxygen sensors. The nonequilibrium
conditions found for the enzymes mean that they can respond to small changes in the
oxygen levels thus providing the link between intracellular oxygen concentration and the
hypoxia response mechanism.[35]

1.2.2.2 Factor Inhibiting HIF-1 (FIH-1)
FIH-1 belongs to the same non-heme Fe(II)- and α-ketoglutarate (αKG)dependent family of dioxygenases as the PHDs[50, 24]. Unlike PHD however, FIH-1 is an
asparaginyl hydroxylase that is only catalytically active as a homodimer (Figure 1.2)[63].
The dimerization buries a significant portion of the C-terminus of both monomer
units[68,71] of the enzyme. FIH-1 is also more promiscuous than the PHDs in terms of
substrate specificity. In addition to the well-defined target Asn residue located in a tight
	
  

7	
  

hairpin loop of the HIF-1α/CTAD substrate, FIH-1 has also been shown to hydroxylate
Ser, His, Asp and Leu residues located in a similar loop configuration in proteins
containing the conserved interaction motif, ankyrin repeat domain (ARD), such as the
Notch proteins (Notch1 to 3), IκBα, NFκB, ASB4, Tankyrase-2, Rabankyrin-5, RNase L,
MYPT1, p105 and ASPP2 among many others[78,81,82,113,114,116,117]. The biological
significance of ARD hydroxylation by FIH-1 remains to be elucidated though several
theories have been suggested including FIH-1 sequestration for subsequent HIF

Figure 1.2 Dimer structure of FIH-1 highlighting the DSBH core (in violet) with the
active site metal (red sphere) (1H2L, 2.25Å)[71]. Also shown is the close-up image of the
active site with the facial triad residues and αKG bound to Fe(II).

activation and modification of cellular protein interactions[78,81]. The PHDs do not appear
to be as promiscuous because only a handful of alternate substrates have been reported so
far[41,83]. FIH-1 has been known to hydroxylate HIF-1α even under oxygen levels in
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which the PHDs were reportedly inhibited[23,24,37,66,126]. This is quite consistent with the
observed KM for O2 of FIH-1 (90 µM), which is lower than those of the PHDs[64].
As mentioned before, FIH-1 hydroxylates a conserved asparagine residue, Asn803,
in the CTAD of the HIF-1α subunit, which prevents the binding of the trans-coactivator
p300/CBP[65-67,77]. In the absence of the trans-coactivators, HIF-1 cannot trans-activate
genes downstream of the hypoxia response elements (HREs), which are the DNA regions
where HIF binds. The HIF-1α/CTAD region (residues 786-826) is mostly unstructured
when free in solution but it assumes an extended helical conformation when bound to the
hydrophobic CH1 domain of p300/CBP[69]. The target Asn residue is normally buried
within the extended helical structure adopted by HIF-1α/CTAD. One can see then how a
hydroxyl group located in the pro-S position of the β-carbon of the Asn residue[70] would
destabilize the helix and thus disrupt the hydrophobic interactions with the CH1 domain
of p300/CBP, hindering its recruitment.
Crystal structures of FIH-1 bound to substrate[68,71] revealed enzyme-substrate
contacts that provide for catalysis. Prior to substrate binding, the unbound oxygen of the
enzyme facial triad Asp201 residue forms a hydrogen bond with the iron-bound water
ligand. This interaction was thought to play a key role in the coupling of substrate
binding to turnover as the breaking of this H-bond (which occurs when native substrate
binds) likely facilitates aquo ligand release[89,90,120]. This renders the active site O2reactive. In the presence of native substrate, Asp201 residue forms a new H-bond with the
backbone amide of the substrate target residue, Asn803, thereby resulting to loss of the
water ligand. Apparently, this phenomenon is only particular for FIH-1 and the ribosomal
oxygenases (ROXs).[87] Aside from Asp201, an enzyme active site residue, Gln239, was
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also found to form H-bond interactions with the side chain amide group of Asn803
whereby it was hypothesized that Gln239 plays a functional role in tuning FIH-1 activity.
Indeed, work from our group showed that this interaction is essential to properly position
the target residue for subsequent hydroxylation[86,88]. Loss of the Gln239 interaction did
not affect the first part of the catalytic cycle, which involves oxidative decarboxylation of
αKG to form succinate and carbon dioxide. This indicates that certain active site
elements are in place to ensure efficient catalysis of FIH-1, which strictly couples αKG
oxidation with native substrate hydroxylation.
Because the regulatory role of FIH-1 in hypoxia sensing lies in its ability to bind
and hydroxylate HIF-1α in an oxygen-dependent manner, it becomes critical for the
enzyme to ensure that αKG oxidation subsequent to HIF-1α binding will effectively
result in HIF-1α hydroxylation. How FIH-1 exactly performs this is the general guiding
question in this research.

1.2.3

Proposed Reaction Mechanism of HIF Hydroxylases
Data from several biophysical studies suggest a common mechanism for the non-

heme Fe(II)/αKG-dependent dioxygenases[89,90,92-94]. Scheme 1.1 shows the proposed
consensus reaction for FIH-1, which follows a sequential ordered mechanism similar to
the PHDs. Initially, the resting six-coordinate Fe(II) center of FIH-1 is bound by the 2histidine-1-carboxylate triad, specifically His199, Asp201 and His279 residues[71], on one
face of the octahedral sphere and three water molecules on the opposite face. Metal
binding is reversible for these enzymes as demonstrated by studies showing activity
inhibition in the presence of iron chelators and cobaltous ions[37,44]. In the case of FIH-1,
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the cosubstrate αKG displaces two of the equatorial water ligands upon binding and
chelates Fe(II) in a bidentate mode via its C2 carbonyl oxygen and one of the C1
carboxylate oxygens[71,89,90,94]. The C2 carbonyl is positioned trans to the facial

Scheme 1.1 Proposed reaction mechanism for FIH-1

triad carboxylate Asp201 residue. The C5 carboxylate oxygen is often found to interact
with a nearby charged or polar residue located in the (R/K)XS motif, which is Lys214
residue in the case of FIH-1[68,71]. Another residue, Thr196, is also found to form H-bond
interactions with the C5 carboxylate end. Additional enzyme interactions with the
uncoordinated C1 carboxylate of αKG form as well, specifically H-bond interactions
with Asn205 and Asn294 residues, which were found to be important for the subsequent
oxidative decarboxylation reaction of FIH-1[86]. Upon binding of the HIF-1α/CTAD
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substrate, the target Asn803 residue does not chelate to the metal directly; instead it is
strategically positioned right on top of the open sixth coordination site of Fe(II) trans to
the distal facial triad His279 residue. Interactions between HIF-1α/CTAD and the facial
triad carboxylate, Asp201, as well as several active site residues such as Gln239 also form
upon binding[68,71]. These interactions ultimately result in the release of the last remaining
axial water ligand, which in turn opens an empty coordination site for O2. Spectroscopic
studies have demonstrated this change in the coordination state of the mononuclear Fe(II)
from hexa- to pentacoordinate in the presence of substrate, which renders it more reactive
to O2[72-74,90,94]. Thus, it seems that dioxygen binding and the subsequent activation is
controlled by loss of the axial water, which in turn is triggered upon substrate binding.
Once O2 is bound, the enzyme is primed for hydroxylation activity[75].
Studies utilizing 18O isotope demonstrated that the hydroxylation reaction
consumes both atoms of molecular oxygen[70,24,122]; one atom gets incorporated into the
succinate product and the other one into the hydroxylated HIF-1α/CTAD substrate. Upon
dioxygen binding to the quaternary (Fe(II)+ αKG)enzyme/substrate complex, the ensuing
dioxygen activation is proposed to occur via electron transfer from Fe(II) to form Fe(III)
superoxide based on the evidence of a radical-based mechanism for another related
enzyme prolyl-4-hydroxylase[76] and the inhibition of prolyl hydroxylase with superoxide
scavengers[121]. This nucleophile can then oxidize the keto-carbon of αKG, which
produces carbon dioxide and succinate as well as a putative iron (IV) oxo (ferryl)
intermediate. Transient and steady-state kinetics as well as spectroscopic studies allowed
for the detection, characterization[95] and identification of this ferryl intermediate as the
species responsible for the subsequent C-H cleavage step[96,97] in the catalytic cycle of the
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related enzyme TauD. Unactivated C-H cleavage is proposed to proceed via hydrogen
atom abstraction of the target residue to form a substrate radical intermediate and a
putative Fe(III) hydroxo species. Finally, oxygen rebound mechanism[93] likely occurs
resulting to primary substrate hydroxylation, specifically at the pro-S position[70] of the βcarbon of Asn803, and the subsequent recovery of the Fe(II) center ready for the next
round of catalysis.
1.3 Summary
A huge wealth of information in the field of hypoxia sensing has been gathered
for more than 12 years since the discovery of the HIFs in the early 90’s[7]. However,
development of drugs specifically targeting the HIF hydroxylases for treatment of a wide
range of hypoxia-related diseases are still considered in its infancy. As the HIF
hydroxylases operate with similar mechanisms but have non-redundant physiological
roles, it is crucial to be able to discriminate and selectively target one from the other.
Studies that will provide any useful information for a more profound understanding of the
structure and function of these enzymes continue to be important.
This dissertation provides additional kinetic and dynamic insights into the
substrate interactions and catalysis of FIH-1 that can potentially be used to improve
future selective targeting studies.
Chapter 2 showed our initial effort in identifying chemical frameworks that might
be useful in the future design of selective inhibitors of HIF hydroxylases.
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Chapters 3 and 4 attempted to address the broad question of how FIH-1
effectively couples substrate binding to turnover, specifically how αKG oxidation
subsequent to substrate binding results to HIF-1α/CTAD hydroxylation. Chapter 3 tells
the investigation of the FIH-1 structural changes observed in the presence of the
cosubstrate, αKG, while chapter 4 describes the characterization of an active site loop
that is hypothesized to play a role in the overall activity of FIH-1.
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1.4 Appendix
1.4.1 Abbreviations
αKG, alpha-ketoglutarate;
ATP, adenosine triphosphate;
ARNT, aryl hydrocarbon acceptor nuclear translocator;
ASB4, Ankyrin repeat and (suppressor of cytokine signaling) SOCS box-containing
protein 4;
ASPP2, ankyrin-repeat-containing, (SRC homology 3) SH3-domain-containing, and
proline-rich-region-containing protein 2;
CBP, (cyclic-AMP response element binding protein) CREB-binding protein;
CTAD, C-terminal trans-activation domain;
CH1, cysteine/histidine-rich domain 1;
DSBH, double-stranded β helix;
EGLN, egg laying nine;
FIH-1, factor inhibiting (hypoxia-inducible factor 1) HIF-1;
HIF, hypoxia-inducible factor;
HIF-P4H, (hypoxia-inducible factor) HIF prolyl 4 hydroxylase;
IκBα, nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor alpha;
NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells;
NTAD, N-terminal trans-activation domain;
PAS, (periodic-aryl hydrocarbon receptor nuclear translocator-single-minded) PerARNT-Sim;
PHD, prolyl hydroxylase domain;
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pVHL, von Hippel-Lindau tumor suppressor protein;
ROX, ribosomal oxygenase;
SRC-1, steroid receptor coactivator 1;
TIF2, transcriptional intermediary factor 2
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CHAPTER 2
SCREENING αKG MIMICS FOR THE SELECTIVE INHIBITION OF FIH-1
This chapter is part of a published paper: Flagg, S.C., Martin, C.B., Taabazuing, C. Y.,
Holmes, B.E., Knapp, M.J. (2012) Screening chelating inhibitors of HIF-prolyl
hydroxylase domain 2 (PHD2) and factor inhibiting HIF (FIH). J Inorg Biochem, 113,
25-30.

2.1 Summary of Contributions to Published Paper
My primary contributions to this paper were the collection of the inhibition
screening data and IC50 values for FIH-1 (Figure 1b and Table 1), a brief description of
the activity assay method, and a very brief analysis of the inhibition results.
We would like to acknowledge Elsevier for allowing us to insert the actual article
as part of this dissertation.
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a b s t r a c t
Two primary O2-sensors for humans are the HIF-hydroxylases, enzymes that hydroxylate speciﬁc residues of
the hypoxia inducible factor-α (HIF). These enzymes are factor inhibiting HIF (FIH) and prolyl hydroxylase-2
(PHD2), each an α-ketoglutarate (αKG) dependent, non-heme Fe(II) dioxygenase. Although the two enzymes
have similar active sites, FIH hydroxylates Asn803 of HIF-1α while PHD2 hydroxylates Pro402 and/or Pro564 of
HIF-1α. The similar structures but unique functions of FIH and PHD2 make them prime targets for selective inhibition leading to regulatory control of diseases such as cancer and stroke. Three classes of iron chelators
were tested as inhibitors for FIH and PHD2: pyridines, hydroxypyrones/hydroxypyridinones and catechols. An
initial screen of the ten small molecule inhibitors at varied [αKG] revealed a non-overlapping set of inhibitors
for PHD2 and FIH. Dose response curves at moderate [αKG] ([αKG] ~ KM) showed that the hydroxypyrones/
hydroxypyridinones were selective inhibitors, with IC50 in the μM range, and that the catechols were generally
strong inhibitors of both FIH and PHD2, with IC50 in the low μM range. As support for binding at the active site
of each enzyme as the mode of inhibition, electron paramagnetic resonance (EPR) spectroscopy were used to
demonstrate inhibitor binding to the metal center of each enzyme. This work shows some selective inhibition
between FIH and PHD2, primarily through the use of simple aromatic or pseudo-aromatic chelators, and suggests
that hydroxypyrones and hydroxypyridones may be promising chelates for FIH or PHD2 inhibition.
© 2012 Elsevier Inc. All rights reserved.

1. Introduction
Cellular oxygen-sensing in metazoans is directly controlled by
non-heme Fe(II) α-ketoglutarate-dependent hydroxylases which hydroxylate the alpha-subunit of the hypoxia inducible factor (HIF1α).[1–3] As these HIF-hydroxylases are key regulators of angiogenesis
and basal metabolism and the progression of diseases such as cancer
and stroke, they are the subject of numerous inhibition studies.[4–6]
A large number of published inhibitors are derived from heteroaromatics such as 8-hydroxyquinoline, or N-oxalyl amino acids, such as
N-oxalylgycine (NOG),[5–7] each of which chelates the active-site Fe(II).
Although much attention has been paid to modifying these frameworks
to improve selectivity, switching focus to the chelating group can augment lead optimization, as shown for MMP [8]. This manuscript describes
our work to identify alternate chelators as leads for selective inhibition of
HIF hydroxylases (Chart 1).
The two best characterized of HIF-hydroxylases are the factor inhibiting HIF (FIH) and prolyl hydroxylase-2 (PHD2),[9–11] which hydroxylate speciﬁc amino acid residues on HIF-1α. Each enzyme uses
αKG to cleave O2, forming succinate, CO2, and a putative high-valent
⁎ Corresponding author at: Department of Chemistry, University of Massachusetts,
Amherst, MA, 01003, United States. Tel.: + 1 413 545 4001; fax: + 1 413 545 4490.
E-mail address: mknapp@chem.umass.edu (M.J. Knapp).
0162-0134/$ – see front matter © 2012 Elsevier Inc. All rights reserved.
doi:10.1016/j.jinorgbio.2012.03.002
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[FeO]2 + oxidant in the ﬁrst half reaction (Scheme 1). Subsequently,
this oxidant inserts the O-atom into a C–H bond to form the hydroxylated
peptide. Despite their common underlying chemistry, PHD2 and FIH
transcriptionally repress HIF by different strategies. PHD2 hydroxylates
residues found in the oxygen-dependent degradation domain (ODDD)
of HIF-1α, Pro402 and/or Pro564, leading to proteasomal degradation of
HIF-1α. FIH hydroxylates Asn803 of HIF-1α, found in the C-terminal transactivation domain (CTAD), which blocks p300 from binding to HIF, thereby repressing transcription.
The metal center of FIH and PHD2 are quite similar, as the Fe(II) is
coordinated by a His2Asp facial triad, bidentate αKG, and an H2O ligand.[12,13] This presents some challenge for inhibitor selectivity,
however selective inhibitors have been identiﬁed for other metalloenzyme families, such as lipoxygenases [14], and the MMPs [15].
In those cases, selectivity likely results from differences in the size
and shape of the closely related active sites. As the αKG-dependent
oxygenase family is large, selectively targeting an individual member
of that family may be challenging. Although both FIH and PHD2 repress
gene expression, their roles in health and disease are not redundant,
and selectively altering the activity of these enzymes is thought necessary for targeted therapeutics. Selectivity between the HIF hydroxylases
may be achievable as the active site pockets differ markedly between FIH
and PHD2. The available volume of the PHD2 active site when peptide is
bound (170 Å3) is similar to that of αKG (130 Å3) [13,16], whereas that
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Fig. 1. a) Initial inhibitor screening for PHD2. Assays included PHD2 (1.5 μM), αKG (10
or 200 μM), Fe(NH4)2SO4 (20 μM), ascorbate (2 mM), ODDD (60 μM) and inhibitor
(100 μM). All components with exception of ODDD were mixed and assays were initiated with ODDD at 37 °C.b) Initial inhibitor screening of FIH. Assays included FIH
(0.5 μM), αKG(10 μM or 500 μM), CTAD (66 μM), ascorbate (2 mM), FeSO4 (500 μM)
and inhibitor (100 μM). All components were mixed except FIH, and assays initiated
with the addition of FIH.

of FIH is signiﬁcantly larger (340 Å3) [12]. Consequently, FIH inhibitors
are often bulkier than αKG, while PHD2 inhibitors tend to be planar aromatic rings [5].
The two coordination sites occupied by αKG are natural targets for
HIF hydroxylase inhibitors, due to the nature of their catalytic cycle
[17], and because metal chelation provides strong binding afﬁnity.
As the C-5 carboxylate of αKG forms a salt-bridge with a buried
basic residue (FIH, Lys 214; PHD2, Arg 383), a pendant anionic group is
a common feature to the metal chelates that inhibit FIH and
PHD2.[5] Other structural distinctions relate to the bulk and polarity
of the amino acid residues lining each active site. The entrance to the
active site differs between PHD2 and FIH, where the C1-carboxylate
of αKG binds, and this may affect inhibitor binding. In FIH the C1carboxylate is stabilized by two hydrogen bonds from Asn205 and
Asn294, which may strictly constrain the width available for bidentate ligands to bind to FIH.[12] In contrast, the C1 carboxylate in PHD2 forms
an indirect hydrogen bond to Asp254 via a water molecule,[13] suggesting that bidentate ligands may bind to PHD2 with an induced-ﬁt in the
plane.
There is currently much effort to develop selective inhibitors for
the HIF hydroxylases as therapeutic agents [5,6] for ischemic and inﬂammatory disorders. Inhibitors that bind as αKG mimics while simultaneously recognizing the active site may be the most promising
for FIH and PHD2, both to minimize side-effects from other αKG-

	
  

Fig. 2. a) X-Band EPR of (CuII)PHD Samples. PHD (0.65 mM), CuSO4 (0.60 mM), bidentate ligand (0.60 mM) in 50 mM HEPES pH 7.50. 9.598 GHz frequency, 5 mW power,
5 G modulation amplitude, 100 GHz modulation frequency, 81 ms time constant at
77 K.b) X-Band EPR of (CuII)FIH Samples. FIH (0.65 mM), CuSO4 (0.60 mM), bidentate ligand (0.60 mM) in 50 mM HEPES pH 7.50. 9.593 GHz frequency, 5 mW
power, 5 G modulation amplitude, 100 GHz modulation frequency, 163 ms time constant at 77 K.

oxygenases, as well as to ensure selectivity toward a speciﬁc HIF hydroxylase. N-oxylylglycine (NOG) and dimethyl N-oxalylglycine
(DMOG) are structurally similar to αKG, and inhibit both PHD2 and
FIH, but their selectivity is poor. More selective inhibitors of FIH
were prepared by synthesizing chiral N-oxalyl amino acids, structural
derivatives of NOG, which are selective for FIH due to the larger active
site of FIH.[7] Quite different compounds have been reported as potent PHD2 inhibitors (IC50 ~ 1 μM) including the heteroaromatic isoquinolines[18,19], benzimidazoles[20], and imidazo[1,2-a]pyridines
[21]. Several of these inhibitors have been shown to bind to the respective active site Fe(II) by X-ray crystallography, showing that a
dominant mechanism of action is metal binding within the active
site.[7,13,20,22,23].
Despite the successes in targeting PHD2 and FIH, most efforts have
focused on a small number of Fe(II) chelating groups. This may limit
therapeutic development, because exploring different metal chelators
can lead to increasingly more effective inhibitors, as shown for other
metalloenzymes.[8] In the present work, we screened a small library
of chelating structures for their ability to inhibit FIH and PHD2, with
particular emphasis on bidentate chelators as structural mimics of
αKG. We were particularly interested in HOP/HOPO structures, as
these chelates seemed to hold promise as HIF-hydroxylase inhibitors
based on their use in other metalloenzyemes, such as matrix metalloproteases [24] and other αKG oxygenases.[25,26].
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Scheme 1. Net reaction for FIH (R-H = Asn) and PHD2 (R-H = Pro).

2.2. Protein expression, puriﬁcation, and activity
Recombinant human PHD2 was expressed and puriﬁed as the catalytic domain (residues 177–426), similar to previous protocols [13].
PHD2 was expressed as an N-terminal GST fusion in E. coli BL21(DE3)
cells, using a pGEX vector (Stratagene). The GST-PHD2 was puriﬁed
using afﬁnity chromatography (GE Bioscience GSTrap), then the GST
removed by thrombin. Puriﬁed protein was then buffer exchanged
into 50 mM HEPES pH 7.00. Protein purity was assessed by SDS-PAGE
gel and mass spectrometry.
Recombinant human FIH-1 was expressed from E. coli with an Nterminal His6 tag, which was removed by thrombin digestion after puriﬁcation, as previously described.[27] Exogenous metal was removed
with EDTA incubation and then size-exclusion chromatography, resulting
in the FIH-1 dimer.
Chart 1. Inhibitor classes tested. CNP (3-Cyano-6-methyl-2(H) pyridinone), NOP (2Hydroxypyridine 1-oxide), DHP (2,3-Dihydroxypyridine), Hop-OH (5-Hydroxy-2hydroxymethyl-4-pyrone), Hop-COOH (5-Hydroxy-4-oxo-4H-pyran-2-carboxylic acid),
Hop-Me (3-Hydroxy-2-methyl-4-pyrone), Hopo (3-Hydroxy-1,2-dimethyl-4(1H)pyridinone, 4NCat (4-Nitrocatechol), MeCat (4-Methylcatechol), BuCat (4-tertButylcatechol).

2. Experimental procedures
2.1. Materials
The prime substrate for FIH was a 39-residue peptide corresponding
to HIF-1α788-826 with a Cys800➔Ala point mutation, which corresponds
to the C-terminal transactivation domain of HIF-1α (CTAD). The CTAD sequence used (Asn803 in bold) was DESGLPQLTSYDAEVNAPIQGSRNLLQGEELLRALDQVN, which was unmodiﬁed at the peptide termini. CTAD
peptide was purchased from EZBiolabs as a desalted product, and was
further puriﬁed by reverse-phase HPLC.
The peptide substrate used for PHD2 was a peptide derived from the
natural sequence of HIF-1α556-574, which is the C-terminal oxygen dependent degradation domain (ODDD) of HIF-1α. The peptide sequence
used (Pro564 in bold) was DLDLEALAPYIPADDDFQL, in which the termini were not modiﬁed, and the natural Met residues were replaced by Ala
at the underlined positions. ODDD was purchased from GL Biochem
(Shanghai) LTD as a 99% purity peptide, and was used as received (dissolved in 50 mM HEPES pH 7.00) for PHD2 activity assays.
Compounds were purchased from commercial sources and used as
receieved. HOP-COOH, HOP-OH, and DHP were purchased from SigmaAldrich; NOP was purchased from Fluka; pyCN, HOP-Me, HOPO, MeCat,
BuCat, NCat were purchased from Acros.
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2.3. Activity assays
PHD2 activity assays were conducted using 1.5 μM PHD, 2 mM
ascorbic acid , 0–500 μM α-ketoglutarate and 20 μM ammonium iron
(II) sulfate in 50 mM HEPES pH 7.00, 37.0 °C. Assays were initiated
by the addition of ODDD and time points were extracted and
quenched in a matrix consisting of 4-α-cyano hydroxycinnamic acid
with a 2:1 ratio of acetonitrile and 0.2% triﬂuoroacetic acid. Samples
were then analyzed on a Bruker Daltonics Omniﬂex MALDI-TOF and
the results were interpreted as a ratio of the parental peak to the hydroxylated peak which exhibits a mass shift of 16 from the parental.
The mole fraction of product (χODDD-OH) was obtained from the resulting spectra by comparing the relative intensities of the peak at
2156 m/z, corresponding to (ODDD+ Na)1 +, to the peak at 2172 m/z,
corresponding to (ODDD+O+Na)1 +. Product formation was calculated
using [ODDDOH] = χ(ODDD-OH) x [ODDD]0, and used to determine initial
rates. Dose response curves were assayed with 1.5 μM PHD2, 2 mM
ascorbic acid , 10 μM αKG and 20 μM ammonium iron (II) sulfate in
50 mM HEPES pH 7.00, 37.0 °C. For each inhibitor concentrations of up
to 1 mM were used to obtain the the dose response curves. Inhibitors
were dissolved in 50 mM HEPES pH 7.00 for working stocks for all assays.
FIH assays were conducted in 50 mM HEPES pH 7.50, at 37.0 °C.
The initial screens included 2 mM ascorbate, 10 μM or 200 μM αKG,
20 μM FeSO4, 80 μM CTAD, 100 μM inhibitor, and 0.5 μM FIH. Assay
components were mixed and incubated in 45 μL at 37 °C for 5 min, before
initiating the reaction with 5 μL of FIH. Dose–response assays were performed under similar conditions, using 10 μM αKG and varying the inhibitor concentration (0–500 μM). Aliquots (5 μL) were quenched in 20 μL of
MALDI matrix (3,5-dimethoxy-4-hydroxycinnamic acid in 75% CH3CN/
H2O containing 0.2% formic acid). FIH mediated hydroxylation of the
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CTAD substrate was monitored by the relative intensities of the substrate
(4255 m/z) and product (4271 m/z) peaks using a Bruker Daltonic
Ominoﬂex MALDI-TOF.
2.4. Electron paramagnetic resonance
The binding constant for Cu2 + binding to FIH was measured by a
ﬂuorescence quenching titration in which 1 mM CuSO4 (50 mM HEPES,
pH 7.50, containing 1 mM citrate) was titrated into a solution of FIH
(20 μM in 50 mM HEPES, pH 7.50, 20 °C) containing αKG (100 μM)
and citrate (1 mM). The method followed was similar to that reported
previously for Co2 + binding to FIH [28], with the exchange of metal
salt. Attempts at measuring Cu2 + binding to PHD2 by ﬂuorescence
quenching were unsuccessful due to a slight turbidity interfering with
the ﬂuorescence readings.
X-Band EPR spectra were recorded on a Bruker Elexsys E-500 ESR
Spectrometer equipped with DM4116 cavity, with samples placed in
a liquid-nitrogen ﬁnger dewar. Samples were prepared by combining
each enzyme with CuSO4 in ratio of 1:0.9 then adding αKG or putative
inhibitor as indicated. In each of the samples, the CuSO4 solution was
slowly added in 0.5 μL increments to prevent protein precipitation.
Spectra were acquired at 5 mW power, 5 G modulation amplitude,
100 GHz modulation frequency.
3. Results and discussion
3.1. Initial screen
An initial screening of all compounds at 100 μM concentration was
performed to identify inhibitors for PHD2 and FIH that were likely to
exhibit IC50 in the micromolar concentration range (Fig. 1). We used a
low-throughput screen in which the initial rate of turnover was measured using a discontinuous MS analysis. Such a labor intensive approach
was necessary in order to accurately measure peptide hydroxylation
kinetics, as we were unable to obtain satisfactory results using the published ﬂuorescence assay for αKG depletion [29]. As the αKG depletion
assay is a subtractive assay, it is difﬁcult to accurately measure initial
rates when the αKG concentration is depleted by less than 10% from initial conditions. A related concern is that the αKG depletion assay does
not directly measure peptide hydroxylation, and therefore measures
the sum of coupled and uncoupled turnovers.
Initial screens were performed at sub-saturating concentrations
([αKG]~ KM) in order to identify inhibitors under non-stringent conditions. The Michaelis constant for αKG indicated stronger αKG afﬁnity
for PHD2 (KM =7±2.5 μM) than for FIH (KM =22±6 μM) [28]. These
screens indicated identiﬁed compounds from each structural class that
would be likely to exhibit IC50 b 100 μM toward PHD2 or FIH. Two compounds from the HOP/HOPO class and two catechols were effective inhibitors of PHD2 at sub-saturating α-KG concentrations. A similar variety of
compounds were effective inhibitors of FIH at sub-saturating αKG. The
non-overlap between inhibitors for FIH and PHD2 strongly suggested
that one or more of these compounds would be selective toward these
enzymes.
A more stringent screen was performed using saturating αKG concentrations ([αKG]>4 KM), as less effective inhibition at elevated [αKG] is a
hallmark for competitive inhibition. Several compounds were less effective inhibitors under stringent conditions, suggesting that the inhibition
mode was competitive for αKG. For FIH, each of the HOP/HOPO compounds (5, 6, 7, 8), as well as two of the catechols (9, 10), exhibited this
pattern. For PHD2, only two of the HOP/HOPO compounds (5 and 7)
and one of the catechols (10) exhibited this competitive pattern.
3.2. Dose response
Full dose–response curves were analyzed for each compound toward FIH and PHD2 using a sub-saturating concentration of αKG,

	
  

with most compounds displaying a simple dose–response indicative
of single-site binding (Table 1). The exceptions are the dose–response
curves for compounds HOPO and BuCat toward PHD2, which indicated
two-binding sites. In general, the dose–response curves were consistent
with the initial screens, as compounds from each structural class inhibited FIH and PHD2 with IC50 b 500 μM.
Most compounds tested were more effective inhibitors of PHD2
than of FIH, likely reﬂecting the structural differences between the active sites. Each dose–response assay used the same sub-saturating
[αKG] / KM(αKG) ratio (~ 1.2), thereby controlling the most important
variable in comparing the IC50. Selectivity likely reﬂects the preference
of aromatic chelators to bind to PHD2, whereas bulky compounds such
as N-derivatized NOG preferentially bind to FIH.
The IC50 trends suggested that these metal chelators distinguished
FIH from PHD2. From the relative trend of IC50 among the catechols, it
appeared that FIH was more tolerant of sterically bulky substitutents
than PHD2, as predicted from the volumes of each active site cavity.
Notably, FIH did not signiﬁcantly discriminate MeCat (9) from BuCat
(10), whereas PHD2 discriminated these compounds by roughly
ten-fold.
Pyridine-based compounds exhibited a wide range of IC50 values,
with NOP and DHP of similar effectiveness toward each enzyme.
The pyCN exhibited no inhibition toward PHD2 nor FIH, suggesting
that bidentate binding as an αKG mimic was necessary for strong inhibition. This may also reﬂect a preference for O-donors over N-donors, as
seen previously.[30]
The HOP/HOPO class of compounds demonstrated a wide range in
inhibitor effectiveness with IC50 values varying by a factor of more
than 100-fold. Both bulk and functional group played a role in inhibition for both FIH and PHD2, consistent with an induced-ﬁt of the inhibitor to the active site. The most effective HOP inhibitor for both
PHD2 and FIH was the HOP-COOH, which structurally resembles a
cis-isomer of αKG. It is likely that HOP-COOH would be able to form
a salt-bridge with the buried basic residue found in both PHD2
(Arg 383) and FIH (Lys 214). The HOP-OH compound exhibited diminished effectiveness toward each enzyme, consistent with the removal
of one part of this salt bridge.
The dimethyl-substituted HOPO was a better inhibitor than the
methyl-substituted HOP-Me for each enzyme. This likely reﬂects the
inherently stronger binding of the HOPO framework to divalent
metals as compared to the HOP framework. Interestingly, HOPO has
been reported as an antiﬁbrotic agent in cell-based screens targeting
the collagen prolyl hydroxylase [25], but no report of its use against
PHD2 has appeared until now.
Several metal chelators bind to the active site of HIF hydroxylases,
as mimics of αKG. Examples include N-oxalylglycine (NOG) and
tricarboxylic acid cycle intermediates,[7,31,32] and isoquinoline derivatives.[18,19] Greater efﬁcacy and selectivity have been achieved
by derivatizing the chelate framework – for example, derivatizing

Table 1
IC50 toward FIH and PHD2.
Compound

1
2
3
4
5
6
7
8
9
10

CNP
NOP
DHP
HOP-OH
HOP-COOH
HOP-Me
HOPO
4NCat
MeCat
BuCat

PHD2

FIH

IC50 (μM)

IC50 (μM)

> 1000
3
5
400
30
1000*
40
6
4
30*

> 1000
10
75
170
50
70
30
10
50
120

*For HOP-Me the concentration to achieve exactly half the maximal rate is 16 μM, for
BuCat it is 1 μM, the values in the table are reﬂective of the second inhibitory event.
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the NOG backbone with canonical amino acid sidechains revealed
that D-isomers were selective inhibitors of FIH, with N-oxalyl-Dphenylalanine (KI = 90 μM) the most effective inhibitor from that
study [7]. Similarly, elaborated isoquinolines [18,19] are potent inhibitors of PHD2. These reports, and scattered reports of other chelators as
HIF hydroxylase inhibitors, indicate that targeting both the metal center
and the active site can enhance selectivity [21,30]. These studies underscore the promise of a dual-targeting approach to inhibitor design.
3.3. EPR spectra of PHD2 and FIH
EPR was used to monitor ligand binding to the active site of both
PHD2 and FIH (Fig. 2). As the native metal is unsuited for X-band perpendicular mode EPR (Fe(II) likely has S=2), enzymes were constituted with
Cu(II), a d9 metal that is spectroscopically observable by conventional EPR
methods and which binds tightly to FIH (KD =5.8×10− 12 M). Each enzyme was constituted with a representative inhibitor from each class,
DHP (3), HOPO (7) and 4NCat (8) (Table 2). With Cu(II), the magnitude
of gII and AII are the most telling parameters as they are very sensitive
to the geometry and identity of the ligands in the XY plane of type-2
copper centers such as those found in Cu-constituted αKG-dependent
hydroxylases [33].
The spectrum of (Cu)PHD2 exhibited moderate g-anisotropy (g⊥ =
2.06, gII = 2.29), and large hyperﬁne coupling (A|| = 148 G), due to coordination by the His2Asp facial triad as well as likely by 3 waters. The line
widths were rather broad, consistent with some disorder of the metal
center due to the water ligands. With the formation of (Cu + αKG)
PHD2, g-anisotropy increased (g⊥ = 2.07, gII = 2.35) and the Cu(II) hyperﬁne coupling constant decreased (A|| = 142 G), consistent with an
N/O-rich coordination sphere with anionic ligands.[33]
The spectral features for (Cu)FIH and (Cu + αKG)FIH were very
similar to the those observed for the analogous PHD2 samples
(Table 2), as seen previously for FIH and related αKG-dependent oxygenases.[28,34] Additionally, binding of either αKG or any of the inhibitors led to a sharper line shape and the appearance of additional
ﬁne structure near g = 2.07 for both PHD2 and FIH, consistent with
the expulsion of waters form the coordination sphere, and a more ordered metal center.
The EPR data indicated that the representative inhibitors bound to
the metal center in both PHD2 and FIH as an αKG mimic. This is consistent with the moderate level of inhibition observed toward both
enzymes. A notable difference between PHD2 and FIH is the spread
in the magnitude of A||, as a decrease in this parameter indicates that
the four ligands in the XY plane are distorted away from a planar arrangement. The hyperﬁne splitting was relatively invariant for all
(Cu + ligand)PHD2 samples (A|| = 142 – 148 G), indicating that the
geometry about the Cu(II) center was relatively insensitive to replacement of αKG for 2 H2O or any of the representative inhibitors. In

Table 2
EPR Spectral Parameters for (Cu)FIH and (Cu)PHD2 Samples. Parameters were determined using Spincount.
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contrast, the hyperﬁne splitting for FIH varied widely (A|| = 134 –
152 G) upon similar ligand replacement, indicating that Cu(II) in the
FIH active site was subject to greater geometric distortion than in
PHD2. This may arise from sterics within the active site of PHD2 limiting the orientation of the metal ligands, whereas there are fewer such
clashes within the larger FIH active site.
4. Conclusions
This work identiﬁed simple aromatic or pseudo-aromatic chelators
as effective inhibitors of PHD2 and FIH, thereby expanding the number
of chelate structures used for therapeutic development. Since both
PHD2 and FIH share a similar Fe(II) binding site containing a His2Asp facial triad, inhibitor selectivity likely reﬂects secondary contacts within
the active site. For example, EPR of Cu(II) forms of the enzyme indicated
that the PHD2 active sited permitted less variation in ligand planarity
than FIH. This more deﬁned active site in PHD2 led to greater variation
in IC50 than observed for FIH.
Selectivity toward PHD2 was enhanced by the presence of polar
functional groups on the chelate ring, suggesting a direction for further reﬁnement of selective and potent PHD2 inhibitors. In particular,
the HOP/HOPO class of chelates may be promising for further elaboration
of selective inhibitors toward FIH or PHD2, due to their wide variation in
IC50 in response to functional group polarity and bulk. Inasmuch as HOP/
HOPO-based structures have been used as the foundation for metalloenzyme inhibitors and medicinal inorganic compounds,[24,35] basing
further inhibitors on the HOP(O) framework may lead to increasingly selective inhibitors of PHD2, and/or FIH.
Abbreviations
4NCat
4-nitrocatechol
BuCat
4-tert-butylcatechol
CNP
3-cyano-6-methyl-2(H) pyridinone
CTAD
C-terminal transactivation domain of HIF-1α;
DHP
2,3-dihydroxypyridine
ESI-MS electrospray ionization mass spectrometry;
FIH-1
the factor inhibiting HIF;
HEPES
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid;
HIF
Hypoxia Inducible Factor;
Hop-COOH 5-hydroxy-4-oxo-4H-pyran-2-carboxylic acid
Hop-Me 3-hydroxy-2-methyl-4-pyrone
Hop-OH 5-hydroxy-2-hydroxymethyl-4-pyrone
HOP
hydroxypyridone
HOPO
3-hydroxy-1,2-dimethyl-4(1H)-pyridinone
HOPO
hydroxypyridinone
MeCat
4-methylcatechol
MMP
matrix metalloprotease
NOP
2-hydroxypyridine 1-oxide
PHD2
prolyl Hydroxylase domain 2
αKG
alpha-ketoglutarate

EPR Parameters

	
  

gII

g⊥

AII (G)

(Cu)PHD
(Cu + αKG)PHD
(Cu + DHP)PHD
(Cu + HOPO)PHD
(Cu + 4Ncat)PHD
(Cu)FIH
(Cu + αKG)FIH
(Cu + DHP)FIH

2.06
2.07
2.07
2.07
2.07
2.06
2.07
2.07

(Cu + HOPO)FIH
(Cu + 4Ncat)FIH

2.07
2.07

2.29
2.34
2.31
2.31
2.31
2.30
2.35
2.32
2.33
2.33
2.32
2.27

152
143
145
147
147
143
136
137
130
137
141
131
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2.2.2 Supplemental

Figure 2.1 Dose-response assay curves for FIH-1 fitted to a one-component binding
equation in OriginPro. The reaction mix contained the following components: 0.5 µM
enzyme, 20 µM FeSO4, 2 mM ascorbate, 10 µM αKG, 80 µM HIF-1α/CTAD, and 0-500
µM inhibitor. All assays were done in 50 mM HEPES pH 7.50 at 37°C.
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CHAPTER 3
αKG-INDUCED CONFORMATIONAL CHANGES IN FIH-1: IMPLICATIONS
FOR SUBSTRATE BINDING, CATALYSIS, AND REGULATION

3.1 Introduction
Factor inhibiting hypoxia-inducible factor-1 (FIH-1) is an Fe(II)/α-ketoglutaratedependent dioxygenase that modulates hypoxia-inducible factor-1 (HIF-1) in an oxygendependent manner via hydroxylation of Asn803 in the C-terminal trans-activation domain
(CTAD) of the HIF-1α subunit[26,33]. This single amino acid modification leads to
transcriptional repression of HIF-1 under normal oxygen conditions[1,2]. The fact that
FIH-1 modulates HIF-1 makes it an attractive drug target for the treatment of hypoxiarelated diseases such as anemia, stroke, heart disease and cancer. However, the presence
of other related oxygenases in the cells necessitates selective therapeutic targeting, which
is challenging given the exquisite similarity of the active sites. Thus, studies that will
probe the molecular details of the substrate interactions of FIH-1 can potentially uncover
subtle differences that can be exploited for the future development of highly selective
drugs.
The nature of substrate binding for FIH-1 is thought to follow a sequential
binding order, which is based on the consensus reaction mechanism proposed for the nonheme iron dioxygenases (Scheme 1.1)[48-52]. A recent study in the lab supported this
binding order for FIH-1[42] wherein the essential cofactor αKG binds directly to Fe(II)
prior to HIF-1α/CTAD substrate. The substrate does not chelate the metal directly but
binds right on top of Fe(II), which triggers aquo ligand release from the sixth
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coordination site trans to the distal facial triad His279 residue. O2 then binds in the vacant
site and gets activated at an appreciable rate as observed for the related enzymes TauD,
CS2, and SyrB2[46,57,58].
In an effort to uncover the unique substrate interactions of FIH-1 for future
therapeutic investigations, the available crystal structures were closely inspected.
Superposition of the crystal structures for the apo (1IZ3, 2.80 Å)[47] and various ligandbound enzyme forms – αKG-bound (1MZF, 2.40 Å; 1H2N, 2.84 Å)[6,7] and αKG/CTADbound (1H2L, 2.25 Å)[7] – did not reveal large-scale displacements in the protein
backbone structure of FIH-1 but only showed sidechain reorientations within the active
site. Except for a few others like CurA[59], no significant conformational changes in the
protein backbone were also observed upon Fe(II) or αKG binding as seen in the crystal
structures of PHD2 and several of the αKG dioxygenases[56,20,14]. Nonetheless, it has been
shown via NMR, at least for PHD2 and AlkB, that binding of αKG results in a
significantly more rigid structure[9,10,15]. Moreover, it has been noted by several groups
that the presence of αKG or an αKG mimic like N-oxalylglycine (NOG) facilitated the
formation of crystals which is attributed to its stabilizing effect on the protein fold[6,7,11].
Despite the lack of crystallographic evidence, a molecular dynamics study of FIH-1
revealed substantial structure stabilization in the presence of αKG[53]. In our lab, we have
observed the drastic quenching of the intrinsic fluorescence intensity of FIH-1 upon αKG
addition, which is a clear indication that some αKG-dependent conformational changes,
at least within the environment of the reporter tryptophan residues, are happening to the
enzyme. A similar observation was also noted for the related enzymes, TfdA and
XanA[43,62]. The authors have, in fact, utilized the observed significant Trp quenching to
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probe αKG binding. Based on all these studies, we postulated that αKG binding induces
conformational changes within the active site of FIH-1, which likely results to structural
stabilization.
When FIH-1 was first identified as a protein that interacts with HIF-1 from yeast
two-hybrid assays, Mahon and co-workers[32] made the interesting observation that in
vitro, the 41-mer HIF-1α/CTAD 786-826 did not bind FIH-1 under the GST pull-down
assay conditions which do not include any cofactor, and that it will only bind sufficiently
if the extra residues 576-785 (which comprises the inhibitory domain of HIF-1α) are
included. However, it was found in later studies that even without the inhibitory domain,
the 39-mer HIF-1α/CTAD 788-826 peptide is a satisfactory stand-alone substrate for
FIH-1 activity assays provided the cofactors Fe(II) and αKG are included. The group of
Lando et al.[33] also made the important observation that in addition to preventing p300
binding to HIF-1α/CTAD via hydroxylation, FIH-1 itself could physically block the
association. The caveat however, is that FIH-1 could not directly compete with p300 for
HIF-1α/CTAD binding unless the cofactors Fe(II) and αKG are present. These
observations strongly imply that the binding of αKG to metal-bound FIH-1 is a
prerequisite to HIF-1α/CTAD binding. A quite similar implication was also hinted at
when Zhou et al.[57] observed the lack of spectroscopic changes at the metal center of the
related enzyme clavaminate synthase 2 (CS2) upon addition of the native substrate in the
absence of αKG. They implied, however, that the results do not rule out substrate binding
as it can also mean that the bound substrate simply did not affect the metal center[57].
Nevertheless, the hypothesis that αKG is required for optimal substrate binding to FIH-1
is not implausible. Our hypothesis then is that αKG binding induces conformational
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changes within the active site resulting to FIH-1 stabilization and that this stabilization is
optimal for HIF-1α/CTAD binding. The postulated model will potentially support and
provide a structural basis for the sequential ordered binding mechanism thought to
operate for this enzyme.
To test this hypothesis, we used thermal shift assays, global hydrogen/ deuterium
exchange, intrinsic protein fluorescence experiments and limited proteolysis coupled to
mass spectrometry. Here, we show evidence of αKG-induced conformational changes in
FIH-1. We demonstrate that the presence of αKG stabilizes the enzyme, which has
important ramifications on the nature of substrate binding, on catalysis, potentially on
enzyme regulation as well as on the design of future selective inhibitors for FIH-1.

3.2 Experimental Procedure
3.2.1 Materials
The substrate used for FIH-1 is a 39-mer peptide corresponding to human HIF-1α
788-826 C-terminal activation domain (CTAD). The sequence used (Asn803 in bold and
underlined) was DESGLPQLTSYDAEVNAPIQGSRNLLQGEELLRALDQVN with the
termini kept unmodified. It was obtained from EZBiolab (Carmel, IN) as a desalted
product. The synthetic peptide contained a Cys à Ala mutation that still preserves the
hydrophobic character but eliminates any unwanted side-chain interaction with the thiol
group. The peptide was purified prior to use by RP-HPLC. It was dissolved in 25%
acetonitrile (CH3CN)/0.2% trifluoroacetic acid (TFA) and purified to at least 95% purity.
The concentration of the peptide is determined by monitoring the absorbance of Tyr
residue at 293 nm (ε = 2400 M-1cm-1) in 0.1 M NaOH[38].
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Iron (II) sulfate (FeSO4), manganese sulfate (MnSO4), and 3,5-dimethoxy-4hydroxycinammate (sinapinic acid) were purchased from Acros Organics (Morris Plains,
NJ). The rest of the chemicals and the snakeskin dialysis membrane were obtained from
Fisher Scientific (Fair Lawn, NJ). Molecular weight cutoff filters (MWCO) were
obtained from Millipore (Burlington, MA) and Vivaspin20 ultrafiltration tubes were from
Vivascience Sartorius (Gottingen, Germany).
3.2.2 FIH-1 Expression and Purification
BL21-DE3 E. coli cells containing the wild-type FIH-1/pET28a plasmid were
grown in Luria-Bertani broth (25 g/L) supplemented with 30 µg/mL kanamycin at 37°C
with constant shaking. The cells were induced with 0.5 mM isopropyl β-D-1thiogalactopyranoside (IPTG) when the OD600 reached 0.5-0.7 and then further incubated
at 37°C for 5 h before harvesting the cells by centrifugation. Cell lysis was facilitated by
the use of lysozyme (1 mg/mL) and sonication on ice for 30 mins with 30 secs break
between each burst cycle. Cell debris was removed by centrifugation at 15000 rpm
(26786g), 4°C for 45 mins. The crude cell lysate was dialyzed against 10 mM Tris, pH
8.0 at 4°C and then clarified by centrifugation at 15000 rpm (26786g), 4°C for 10 mins.
Purification of the His-tagged enzyme was carried out by Ni-affinity chromatography
using the BioRad BioLogic LP pump system. The enzyme was eluted out using 250 mM
imidazole/50 mM NaH2PO4/300 mM NaCl, pH 8.04 buffer at a flow rate of 3 mL/min.
The enzyme eluate was buffer-exchanged against 10 mM Tris, pH 8.0 at 4°C to reduce
the imidazole concentration. The concentration of the protein was estimated by UV
absorbance at 280 nm using ε280 = 1.22 mL mg-1cm-1 [37]. The His-tag attached to the
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N-terminus was then removed by incubation of the enzyme with thrombin (0.5 U/mg
protein) for 36 h at 4°C. The cleaved enzyme was obtained by affinity chromatography
and was incubated with 50 mM ethylenediaminetetraacetic acid (EDTA), pH 8.0 at 4°C
overnight. The protein sample was then concentrated at 4°C using the Amicon pressure
concentrator fitted with a 30kDa MWCO filter and finally with the Vivaspin20
ultrafiltration tube before it was loaded into the Sephadex G75 resin column to obtain the
FIH-1 dimer. The purity of the enzyme was checked by SDS-PAGE.
3.2.3 Activity Assays
FIH-1 activity was assayed by following the formation of the hydroxylated CTAD
peptide substrate over a specified period of time using the MicroFlex MALDI-TOF MS
(Brucker Daltonics, Billerica, MA). Unless otherwise specified, steady state assays were
done under ambient O2 concentrations at 37.0°C in 50 mM HEPES (pH 7.02) maintained
at a total ionic strength of 100 mM using NaCl. The reaction buffer contained 500 µM
αKG, 2 mM ascorbate, and 50 µM FeSO4. All the buffer constituents were mixed and
initially incubated at 37.0°C for 3 mins, after which the reaction was initiated by adding
enzyme to a final concentration of 0.5 µM. The reaction was quenched by addition to
20 µL of 75% CH3CN/0.2% TFA saturated with the MALDI matrix, 3,5- dimethoxy-4hydroxy-cinnamate, at various time points ranging from 20-120 secs. To determine the
amount of hydroxylated CTAD, the product of the total CTAD concentration and the
ratio of the peak intensity for the hydroxylated product relative to the overall peak
intensities (combined intensities of the parent and hydroxylated peaks) was calculated.
The amount of hydroxylated CTAD was plotted versus time and the initial rate was
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determined from the slope of the plot.
3.2.4 Fluorescence Quenching Experiments
The samples in the cuvette for fluorescence experiments contained one or two or
all of the following components: 2 µM FIH-1, 50 µM MnSO4, 500 µM αKG, 200 µM
HIF-1α/CTAD in 50 mM HEPES pH 7.0 with the total ionic strength maintained at 100
mM using NaCl. All samples were mixed thoroughly and then incubated at room
temperature (~23°C) for at least 3 mins prior to fluorescence measurement with a Photon
Technology International Quantamaster-4 SE fluorimeter. Tryptophan fluorescence
emission scan was done at the wavelength range of 300-375 nm using excitation and
emission slit widths of 0.1 mm and 2.5 mm respectively. The excitation wavelength used
was 295 nm and the emission intensity at 330 nm was monitored.
For binding experiments, the same samples were prepared without HIF-1α/CTAD
substrate. The titrant solution contained 2.8 mM HIF-1α/CTAD, 2 µM FIH-1, 50 µM
MnSO4, 500 µM αKG in 50 mM HEPES pH 7.0 with the total ionic strength maintained
at 100 mM using NaCl. The emission spectra generated were baseline-corrected with the
buffer blank and were smoothed using the adjacent-averaging method in OriginPro. The
titration data were obtained by recording the magnitude of emission intensity at 330 nm.
The binding data was fitted to a modified form of the Hill plot equation where n and Vmax
are fixed at unity and K is the binding affinity:
𝑦 =   
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3.2.5 Thermal Shift Experiments
Samples for the melt curve experiments contained one or two or all of the
following components: 5 µM FIH-1, 50 µM MnSO4 and 500 µM αKG in 50 mM HEPES
pH 7.0. For each sample, 45 µL of the master mix was distributed to each well in the 96well qPCR microplate and 5 µL of freshly prepared 5X SYPRO Orange (Sigma-Aldrich,
5000X stock diluted in dimethylsulfoxide) was thoroughly mixed in. The microplate was
sealed with a Microseal adhesive film, briefly spun and immediately loaded onto a BioRad CFX Connect RT-PCR machine and the samples were heated at a rate of 1°C/min
from 20°C to 90°C. The fluorescence intensity (excitation wavelength: 450-490 nm;
emission wavelength: 560-580 nm) was monitored as a function of temperature. The Tm
was determined using the positive first derivative plot of the data points generated.
3.2.6

Global Hydrogen/Deuterium Exchange with Mass Spectrometry
For the HDX-MS experiments, a portable icebox equipped with an injection port

and a C4 RP column was used. It was connected to the HPLC pump on one end and the
ESI-TOF MS instrument on the other. All samples were initially prepared on ice prior to
incubation at room temperature (26°C). The different samples contained one or two or
all of the components upon final dilution into ammonium acetate buffer: 20 µM FIH-1,
50 µM MnSO4, 500 µM αKG, 200 µM CTAD in 50 mM HEPES pH 7.0 with the total
ionic strength maintained at 100 mM with NaCl. A master mix for each of the different
samples were initially prepared, out of which 2 µL were taken out for each time point and
incubated for 3 mins at RT. Ammonium acetate buffer (10 mM) in H2O (pH 7.1) (for the
m0 control) or in D2O (pD 7.4) was then added to a final volume of 20 µL to initiate the
H/D exchange. Samples were quenched at varying time points by injection into the LC
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lines that had been equilibrated with 0.1 % formic acid and kept on ice. A quick gradient
of 0.1% aqueous formic acid/0.1% formic acid in acetonitrile was immediately ran
through the column at a constant flow rate of 200 µL/min but was initially disconnected
from the MS instrument until after 3 mins of the total run has elapsed to allow salt
removal. The LC line was then connected and ESI-MS data was acquired in positive
mode using the QStar XL quadrupole TOF-MS fitted with a TurboIon spray source.
To account for the back-exchange during data acquisition, a non-deuterated
control (m0) and a full-deuterated control (m100) were obtained. The full-deuterated
control was prepared by incubation of the protein in D2O at 37°C for 16 hours and then 5
minutes at 90°C prior to injection. The relative deuterium uptake (D) was calculated
using the equation below[8]:
(𝒎

!  𝒎 )

𝐃 =    (𝒎𝒐𝒃𝒔  !  𝒎 𝟎)
𝟏𝟎𝟎

𝟎

Equation 3.2

The data points were fitted to a tri-exponential equation where y0 is the actual number of
exchangeable amide protons at a given condition (%D multiplied by N where N is the
theoretical number of exchangeable amide protons; N = total amino acid residues – Pro
residues – 1 for the N-terminus; for FIH-1, N = 324), A, B, and C correspond to the slow,
medium and fast exchangers with assigned average rate constants k1 (0.05 min-1),
k2 (1 min-1), and k3 (20 min-1) respectively[36]:
𝑦   =    𝑦! − 𝐴𝑒 !!! ! − 𝐵𝑒 !!! ! − 𝐶𝑒 !!! !

Equation 3.3

3.2.7 Limited Proteolysis with Mass Spectrometry
Proteolysis experiments were carried out at 37°C with 150 µg FIH-1 in 50 mM
Tris pH 7.5 in the presence or absence of 100 µM MnSO4 and 500 µM αKG. Samples
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were initially incubated on ice for 10 mins and then at 37°C for a minute prior to addition
of 0.5 mg/mL trypsin to a protease/substrate weight ratio of 1:300. Nine microliter
aliquots were quenched at varying time points into 1 µL of 10 mM AEBSF and stored at
-80°C until use. The samples were analyzed as soon as possible. For SDS-PAGE analysis
in 12% gel, 1.5 µL of the quenched sample was mixed with 6 µL 2X gel loading buffer
(GLB) and diluted to a total volume of 10 µL with 50 mM Tris pH 7.5. For MALDI-MS
analysis, 3 µL of the quenched sample was mixed with 15 µL of 10 mg/mL sinapinic acid
in 70% CH3CN/0.03% TFA. To verify the protein terminal sequence using MALDI in
source decay, the samples were mixed in a 1:1 ratio with 10 mg/mL sinapinic acid in
30% CH3CN/0.1% TFA. The air-dried spotted samples were briefly rinsed with cold
water to remove excess salt and then air-dried again before analysis. MS Data was
acquired with Bruker Microflex (Billerica, MA) using at least 50% laser power and 5%
frequency in linear mode.
3.2.8 Circular Dichroism Spectroscopy
Protein samples for CD measurements were prepared in 10 mM KH2PO4 (pH
7.04) with 500 µM αKG and 50 µM MnSO4. Protein concentrations used ranged from
0.2-0.4 mg mL-1 as measured by UV absorbance at 280 nm (ε280 = 1.22 mL mg-1cm-1).
The spectra were collected over the wavelength range of 190-250 nm at 37°C using a
high-transparency quartz cell with pathlength of 0.1 cm on a Jasco J-1500 CD
spectrometer. The instrument was blanked with the buffer solution containing all
constituents except the protein. All measurements were collected at least three times to
ensure that the signal is for that of a sample at equilibrium. The average of these
measurements were taken and used to generate the CD spectra.
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3.2.9 Determination of Solvent –Accessible Surface Area (SASA)
Solvent accessibility was calculated using the online open software
GETAREA[39]. The PDB structures 1H2L and 1IZ3 were used for the αKG-bound and
apo FIH-1 respectively. A water probe radius of 1.4 angstroms was selected for all
calculations. The values for each amino acid were expressed in % ratios, which represent
the relative side-chain area to “random coil” value per residue. The “random coil” value
is assigned as the average SASA of each residue represented as X in the tripeptide GlyX-Gly in a set of 30 random conformations.[17]
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3.3 Results and Discussion
3.3.1 Intrinsic Fluorescence Quenching Indicates αKG-induced Structural Changes in
FIH-1
The significant reduction in the intrinsic fluorescence intensity of αKG-bound
FIH-1 as initially observed in our lab (Figure 3.1) led us to further investigate the effect
of αKG binding on the enzyme structure, because this is a clear indication that some

Figure 3.1 Trp fluorescence emission spectra of FIH-1 in the absence and presence of
αKG. Samples contained one or two or all of the following components: 2 µM FIH-1,
50 µM MnSO4, 500 µM αKG in 50 mM HEPES pH 7.0 at RT (~23°C). The experiment
was done in duplicate.
conformational changes are occurring in the enzyme, at least within the vicinity of the
reporter Trp residues. The intrinsic protein fluorescence is predominantly due to
tryptophan (Trp) emissions, the emission wavelength of which varies from 300 to 350 nm
depending on the polarity of the protein environment. Hence, Trp fluorescence is a good
probe for protein structural changes.[41] Intrinsic protein fluorescence quenching
experiments are commonly employed in our lab to monitor ligand binding to FIH-1. The
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isosteric Mn+2 was used to replace Fe+2 for all the experiments except the activity assays
to prevent complicating reactions due to αKG oxidation. The divalent metal cations are
chemically similar in terms of their preference for the same coordination environment but
Mn+2 does not support FIH-1 activity[27]. CoCl2 is often used to replace the active site
metal in Trp quenching assays but in this particular study, MnSO4 was used instead to
ensure consistency all throughout. The protein concentrations were maintained constant
during the titration process.
FIH-1 has eight Trp flourophores and several of them are in the vicinity of the
active site (Figure 3.2). Binding of Mn2+ only induced a slight decrease in the
fluorescence intensity as seen in Figure 3.1. This can be attributed to minor
reorganizations within the active site upon metal binding, which slightly modified the
surroundings of the reporter Trp. The most likely residue responsible for the fluorescence

Figure 3.2 FIH-1dimer structure (1H2L) with the eight Trp residues indicated in black
sticks. Encircled in red are the Trp residues that most likely contribute to the quenching
effect seen in the presence of αKG. Trp296 is identified. The cupin barrel core of the
enzyme is shaded in violet for both monomer units while the red sphere near Trp296
represents Fe(II) in the active site.
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signal is Trp296 as it is closest to the metal binding site. The crystal structures revealed a
very slight movement for this residue as well as the rest of the tryptophans in the
presence of metal. Upon addition of αKG, the fluorescence signal was significantly
quenched to more than half of the original intensity implying substantial conformational
changes within the environment of the Trp residues[35]. The emission maximum appears
to be slightly blue-shifted in the presence of αKG, which may indicate that the reporter
tryptophan residues became buried during these structural changes[35]. A close inspection
of the structures[6,47] revealed that, in the presence of αKG, the indole sidechain of Trp296
is flipped about the Cβ-Cγ bond such that the indole nitrogen was positioned away – from
5Å to 7Å, relative to Fe(II). This could possibly account for most of the quenching effect
observed. A few of the Trp residues are found to be within a sulfur-bearing amino acid,
which was shown to be an effective quencher of Trp fluorescence[41]. For example, Trp27
is within 11 Å of Cys216 while a methionine residue (Met275) is within 7 Å of Trp179.
Several of the Trp residues are found to be within the acidic side chains of Asp and Glu,
which were also shown to quench Trp fluorescence[41]. Trp76 is within 4Å of Asp161 while
Trp277 is about 5Å away from the carboxylate of Glu60. There were no observed changes
in the proximity of the reporter and “quencher” residues upon αKG binding based on the
available crystal structures. However, this does not completely rule out the likely
contributions of one or several of the residues mentioned to the observed quenching
effect. The preliminary fluorescence data clearly implies that some structural changes are
happening to the enzyme in the presence of αKG.
To test whether the observed fluorescence results are due to changes in the
secondary structures of FIH-1 upon αKG binding, circular dichroism spectra of the apo,
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metal-bound and αKG-bound enzyme forms were obtained at pH 7.11. The spectra as
shown in Figure 3.3 has two negative features at around 210 nm and 219 nm and a
positive feature at 191 nm, which is indicative of a mixed α-helix/β-strand structure
known for FIH-1. The data plainly shows that the structural changes implied by the
fluorescence data is not due to some large-scale perturbations in the secondary structures
of FIH-1.

Figure 3.3 Far-UV CD spectra of wild type FIH-1 with and without cofactors. Samples
contained 50 µM MnSO4, 500 µM αKG and 0.2-0.4 mg/mL enzyme in 10 mM KH2PO4
pH 7.11 and were analyzed at 37°C. The experiment was done in duplicate.

3.3.2 Thermal Stability and Solvent Accessibility Supports αKG-induced Structural
Changes in FIH-1
Binding of αKG to FIH-1 could conceivably affect the structural flexibility of the
enzyme core and so to probe for this effect, we determined the susceptibility of the
protein to thermal denaturation and solvent exchange. Protein stability in the presence of
the cofactor αKG was determined by thermal shift assays using RT-PCR. This assay is
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based on the increase of fluorescence intensity of the hydrophobic dye SYPRO Orange
upon binding to the hydrophobic regions of the protein that gets exposed during thermal
denaturation[40].

Figure 3.4 Thermal shift curves showing the effect of αKG on the thermal stability of
FIH-1. The inset is the derivative plot to facilitate apparent melting point determination.
The thermal shift of the assay mix containing one or two or all of the components: 5 µM
FIH-1, 50 µM MnSO4, 500 µM αKG in 50 mM HEPES pH 7.0, was monitored using
SYPRO Orange dye with an RT-PCR machine. The experiment was done in triplicate.

The method utilizes the melt as well as the real-time detection capabilities of RT-PCR
machines. Addition of metal to apo FIH-1 did not significantly changed the thermal melt
curve whereas addition of αKG increased the apparent melting temperature from 47°C to
52°C (Figure 3.4). This 5°C increase in the enzyme’s thermal stability tells two things –
(1) that αKG is bound to the active site metal and more importantly, (2) that αKG
addition resulted in a more tightly folded structure of the protein. A strikingly similar
observation of the stabilizing effect of αKG was also seen for the other HIF hydroxylase,
PHD2, using NMR[10] and mass spectrometry[9,36].
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The notion of a more rigid FIH-1 structure upon αKG binding is further supported
by the data from global hydrogen/deuterium exchange experiments coupled to
mass spectrometry (HDX-MS) (Figure 3.5), which indicate that αKG-bound FIH-1 had
less solvent-accessible regions than the apo or metal-bound forms of the enzyme as seen
by the decreased deuterium uptake of the former. A similar observation using the same
experiment was also noted in our lab for the other HIF hydroxylase, PHD2[36]. The fitted
parameters summarized in Table 3.1 clearly show the decrease in the total number of
actual exchangeable sites (y0) in the enzyme upon αKG binding, which implies that
certain residues became inaccessible.

Figure 3.5 Global deuterium uptake plots showing the effect of αKG on the backbone
amide solvent accessibility of FIH-1. The data were fitted to a tri-exponential equation
(equation 3.3) (see Table 3.1 below for the summary of the fitted parameters). H/D
exchange was initiated by diluting samples in 10 mM ammonium acetate buffer pD 7.4 to
give a final concentration of 20 µM FIH-1, 50 µM MnSO4 and 500 µM αKG. Samples
were quenched at various time points upon injection into the C4 column equilibrated with
0.1% formic acid at ~0°C and then analyzed using ESI/TOF mass spectrometry. The
HDX experiments were done in duplicate.
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Table 3.1 Summary of the fitted parameters y0 (total exchangers), A (slow exchangers), B
(medium exchangers), and C (fast exchangers) generated upon non-linear regression
analysis of the global HDX data using equation 3.3. The HDX experiments were done in
duplicate.
Apo FIH-1a, b

(Mn)FIH-1a, b

(Mn+αKG)FIH-1a, b

y0

186 ± 1

199 ± 5

157 ± 2

Aslow

47 ± 2

60 ± 8

55 ± 4

Bmedium

55 ± 3

50 ± 11

51 ± 6

Cfast

84 ± 3

89 ± 10

51 ± 6

a

The corresponding average rate constants were fixed accordingly during the fitting: k1
(0.05 min-1), k2 (1 min-1), and k3 (20 min-1)[36]. The initial parameters obtained were
relative values; the number of exchangeable amides reported above was calculated by
multiplying the relative values by N (N = 324).
b
Errors are associated with the derivation of the parameters using equation 3.3.

Because αKG binds to the metal within the enzyme core, the observed solvent
protection is likely not due to some covered binding interface but rather due to residues
that became buried upon rigidification of the enzyme. In H/D exchange, a more
structured protein will exchange with the solvent less frequently due to fewer solventexposed sites and thus will exhibit less deuterium uptake. The results imply then that the
αKG-bound form of the enzyme is a more compact protein, which is consistent with the
observed greater thermal stability of this enzyme species.
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3.3.3 αKG Binding Stabilizes the FIH-1 Cupin Barrel Core Against Trypsin Degradation
To obtain structural insight into the observed αKG-induced conformational
changes in FIH-1, limited proteolysis coupled to MALDI-TOF mass spectrometry was
performed. This technique (without gel electrophoresis) has been successfully used to
monitor the protein-ligand interactions of the related enzyme PHD2 with αKG and αKG
mimics[15]. Limited proteolysis is widely used for studies of protein dynamics and it relies
on the fact that exposed regions of the proteins are more prone to proteolytic
degradation[16]. Conformational changes induced by ligand binding causes certain regions
of the protein to open up and be more solvent accessible which affects the rate and/or
nature of proteolysis[16]. In our experiments, trypsin was used as the protease because its
high specificity (cleavage at the carboxy side of Arg and Lys residues) will enable us to
predict the potential cleavage sites in FIH-1. This will facilitate downstream
identification of the generated proteolytic fragments, which will in turn give further
structural information about the protein regions that were stabilized upon αKG binding.
Trypsin reactions are typically supplemented with Ca2+ but in our experiments, it was left
out to prevent precipitation issues, which was observed in our initial studies. All samples
were quenched in a 1 mM solution of the broad-spectrum serine protease inhibitor
AEBSF to ensure stoppage of the trypsin reaction as well as to allow for parallel analysis
of samples using SDS-PAGE and MALDI/TOF-MS.
The SDS-PAGE data (Figures 3.6A and B) revealed immediate cleavage of both
apo and αKG-bound FIH-1 after 2 mins of incubation. A total of four major tryptic bands
were observed for both enzyme forms. The first band corresponded to the intact protein
(~41 kDa), which was successively degraded as the proteolysis reaction progressed.
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Figure 3.6 Limited proteolysis of FIH-1 in the absence and presence of αKG as analyzed
via SDS-PAGE. N stands for negative control which is (Mn+αKG)FIH-1 without trypsin
incubated for 4 hours (240 mins) at 37°C. M stands for MW marker. Samples were
analyzed in 12% gel. (A) Protein samples (150 µg FIH-1, 100 µM MnSO4, 500 µM αKG
in 50 mM Tris pH 7.5) were incubated with 0.5 mg/mL trypsin in a 1:300
protease/substrate ratio for the indicated time points at 37°C and then quenched in 1 mM
AEBSF. The sample loading volume used was 1 µL per well corresponding to about 2 µg
of protein. (B) A second replicate sample was performed as in A but the sample loading
volume used this time was 3 µL to make band 2 more visible. (C) A third replicate
sample was prepared as in A but the incubation time was extended to 24 hours (1440
mins). Arrow indicates the ~34 kDa fragment assigned as band 4.
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Trypsin cleavage of the intact apo protein appeared to occur more rapidly compared to
the αKG-bound FIH-1. For the apo enzyme, a second very faint transient band at ~40
kDa (band 2) was observed after 5 mins, which rapidly disappeared just around 30 mins.
Figure 3.6B shows the same experiment (but performed on a different day) with three
times the loading volume to make this particular band more visible. A third ~ 36 kDa
fragment (band 3) appeared just after 2 mins of proteolysis and remained until after 30
mins when it began to diminish and became barely detectable after 4 hours (240 mins).
Although the band 3 species eventually got cleaved after longer periods of incubation,
this fragment is the most prominent band for the proteolysis reaction with apo enzyme. A
slightly less prominent fourth ~34 kDa band (band 4) simultaneously appeared at the 15min time point which intensified with time but then became less visible after 4 hours and
was completely degraded upon prolonged incubation (1440 mins or 24 hours) as shown
in Figure 3.6C. The band 4 fragment was initially assigned as the stable enzyme core
species on the basis of it being the only observable band after longer periods of
incubation (at least 240 mins or 4 hours) for both apo and αKG-bound FIH-1.
Protein fragments of similar sizes were also generated for the αKG-bound
enzyme upon trypsinolysis. Although the fragmentation patterns were similar as seen in
Figure 3.6A, the rates of protein cleavage were clearly different. Firstly, the αKG-bound
intact protein (band 1) was not as rapidly cleaved as the apo one. Secondly, a more
visible ~40 kDa fragment (band 2) was observed to appear after 2 mins, which though
vague at first eventually intensified and then got cleaved after an hour whereas in the apo
enzyme this fragment is barely visible and was rapidly cleaved after a few minutes.
Thirdly, the ~36 kDa band (band 3) which also appeared after 2 mins was cleaved after
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just an hour of incubation unlike in the apo enzyme where band 3 is still detectable up to
4 hours. It seems that addition of αKG accelerated the trypsin cleavage of this particular
fragment. Lastly, the rate of proteolysis of the ~34 kDa fragment (band 4) which was
previously assigned as the stable core decreased significantly in the presence of αKG. In
fact, the intensity of this core fragment remained strong after 4 hours and was still intact
even after 24 hours of proteolytic treatment whereas it completely disappeared for the
apo enzyme under longer incubation periods (Figure 3.6C).
To summarize the gel results, it was found that for the αKG-bound enzyme (i) the
intact ~41 kDa protein (band 1) was more resistant to trypsin degradation, (ii) the ~40
kDa fragment (band 2) which appeared after 2 mins was more intense and slightly more
resistant to degradation, (iii) the ~36 kDa fragment (band 3) which also appeared after 2
mins was more rapidly degraded and (iv) the ~34 kDa core fragment (band 4) which
appeared after 15 mins was much more intense and much more resistant to trypsin
degradation. Together, the limited proteolysis data implicates the generation of a more
stable and more structured protein core in the presence of αKG, which is consistent with
the previous thermal shift and H/D exchange data.
To gain further structural insight on the effect of αKG on FIH-1 flexibility,
parallel analyses of the same samples used for electrophoresis were performed using
MALDI-TOF mass spectrometry. The MS data (Figure 3.7 and Table 3.2) largely
corroborated the gel results for the αKG-bound enzyme but not so much for the apo
form. For example, the gel data indicates that the intact enzyme (band 1) is mostly
cleaved after 30 mins whereas it is still clearly present based on the MS data. This may be
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Figure 3.7 Analysis of the limited proteolysis data of FIH-1 by MALDI/TOF mass
spectrometry in linear mode. The same quenched samples (150 µg FIH-1, 100 µM
MnSO4, 500 µM αKG in 50 mM Tris pH 7.5) used in SDS-PAGE analysis were mixed
with 10 mg/mL sinapinic acid in 70% CH3CN/0.03% TFA in a 1:5 sample/matrix ratio.

Table 3.2 Summary of the average observed masses for the four major tryptic fragments
determined after MALDI/TOF-MS analysis.
Observed MWa

Calculated MWb

Band 1 (intact FIH-1)

41186 ± 635

40567

Band 2

39601 ± 489

40076/38728

Band 3

36654 ± 585

36349/36178

Band 4

34904 ± 609

34931/34897

Protein Species

a

The errors represent the FWHM values generated after fitting the peaks to a Gaussian
function.
b
The calculated MW are the masses of FIH-1 trypsin fragments that are consistent with
the corresponding observed MW.
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partly attributed to sample loading errors. The transient, least intense band 2 species
corresponding to the ~40 kDa fragment was barely detected by MALDI under the
conditions used for apo enzyme but the rest of the gel bands were accounted for.
In an effort to identify the observed trypsin fragments, the FIH-1 amino acid
sequence together with the crystal structure was manually inspected for the solventexposed Arg and Lys residues. The solvent-accessible surface areas (SASA) of these
basic residues were also calculated for both apo and αKG-bound FIH-1 using the
respective crystal structures (1IZ3 and 1H2L). Residues with SASA ratio values greater
than 30% are generally considered to be solvent exposed[19]. A simplified diagram of the
primary structure of FIH-1 (Figure 3.8) was created to illustrate the proposed cleavage
sites that can possibly account for the observed masses of the protein fragments
generated. While both termini of FIH-1 revealed potential trypsin cleavage sites upon
inspection of the structure as well as from SASA calculations, attention was initially
focused on those basic residues at the N-terminus because of the involvement of the
C-terminus in FIH-1 dimerization. All the reactions were done in buffer at physiological
pH (7.0) and temperature (37°C) so the enzyme is most likely in the dimeric form.
Notable likely exceptions to this are the C-terminal residues Lys301 and Lys314, which are
situated within or at the end of a loop excluded from the buried regions of the Cterminus. Cleavage at any of these residues will generate a ~34 kDa and a ~36 kDa
fragment respectively (Figure 3.8B). The C-terminal residue Lys348 is another potential
cleavage site, which is located at the end-most exposed region of the dimer interface.
Cleavage at the carboxyl side of this residue will generate a ~40 kDa fragment.
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At the N-terminus of FIH-1 are three likely cleavage sites as well – Arg20, Arg43,
and Arg54. There is a likelihood that the successive trypsin cleavage of the protein at
these sites, which is dictated by the solvent accessibility of the residues, is responsible for
the observed trypsin fragmentation pattern. Using the simplified diagram in Figure 3.8B,
one is tempted to predict that the (i) cleavage of the intact protein at Arg20 which

Figure 3.8 (A) Primary structure of FIH-1 showing all the possible predicted trypsin
cleavage sites located at the carboxyl side of basic amino acids marked in red.
Highlighted in grey are the amino acids involved in the enzyme dimer interface. (B)
Diagram of intact FIH-1 showing the likely cleavage sites upon trypsin digestion. The
molecular masses of the resultant trypsin fragments are shown. Only those sites with
calculated SASA values exceeding 30% and whose predicted fragment masses
corroborates with the available limited proteolysis data are shown.
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generates a ~39 kDa fragment will give rise to band 2 in the gel, (ii) a second cleavage at
Arg43 which generates a ~36 kDa fragment will give rise to band 3 and (iii) a third
cleavage at Arg54 which generates a ~34 kDa fragment will give rise to band 4. However,
analysis of the actual masses of the four major protein fragments by MALDI/TOF-MS,
which are summarized in Table 3.2, revealed that the predicted mass upon cleavage at the
carboxyl side of Arg20 (MW = 38728) is not within the error of the observed mass for the
band 2 species. On the other hand, the predicted fragment mass for that of the C-terminal
residue Lys348 (MW = 40076) is within the error and might therefore likely account for
the observed mass. Using a similar argument, the band 3 species can be satisfactorily
accounted for either by cleavage of intact FIH-1 at the N-terminal residue Arg43 (MW =
36178) or at the C-terminal residue Lys314 (MW = 36349). Notably, Lys314 residue is
located at the beginning of the helix region of the enzyme dimer interface so the
probability of cleavage relative to Arg43 is lower, though the possibility cannot be entirely
ruled out. Similarly, the band 4 species can also be accounted for either by cleavage of
intact FIH-1 at the N-terminal residue Arg54 (MW = 34931) or at the C-terminal residue
Lys301 (MW = 34897).
As mentioned previously, band 4 (~34 kDa fragment) was initially assigned as the
stable enzyme core species due to the observed stability of this fragment during trypsin
degradation. To support this assignment as well as to identify the actual protein fragment
of band 4, sequencing data was obtained via in-source decay (ISD) using MALDI-TOF
mass spectrometry (Figure 3.9). MALDI-ISD is a useful tool for top-down sequencing to
verify the end termini of intact known proteins[29,30]. The fragmentation process during
ISD occurs via a radical pathway and so the major fragment ions expected to form
	
  

62	
  

Figure 3.9 Top-down sequence verification of the ~34 kDa tryptic fragment (band 4) of
FIH-1 using in-source decay (ISD) coupled to MALDI/TOF-MS. The sample quenched
after 4 hours of protease incubation was used for the analysis. It was mixed with 10
mg/mL sinapinic acid in 30% CH3CN/0.1% TFA in a 1:1 ratio. (A) Spectrum showing
the c-, (zn+2)- and a few y-ions identified for the m/z range lower than 2000. Also shown
are the verified N- and C-terminal sequences of FIH-1. (B) Spectrum for the m/z range
higher than 2000.
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Table 3.3 Summary of the observed c- and z-ions for the 34 kDa fragment (band 4)
generated during ISD-MALDI/TOF-MS. The regions of the N- and C-termini identified
from sequence analysis were highlighted in gray.
N-terminus: AEELIENEEPVVLTDTNLVYPALKWDLEYLQE
C-terminus: MRNIEKMLGEALGNPQEVGPLLNTMIKGRYN

A
Sequence

Observed

Calculated

Sequence

Observed

Calculated

(N-terminus)

(c-ions)

(c-ions)

(C-terminus)

(z-ions)

(z-ions)

V

1270

1271

G

2028

2028

V

1369

1370

N

1915

1915

L

1484

1483

P

1819

1818

T

--

1584

Q

1689

1689

D

--

1699

E

--

1560

T

1799

1800

V

1461

1461

N

1915

1914

G

--

1404

L

2028

2027

P

1308

1307

Sequence

Observed

Calculated

Sequence

Observed

Calculated

(N-terminus)

(c-ions)

(c-ions)

(C-terminus)

(z-ions)

(z-ions)

K

2699

2698

N

3186

3185

W

2885

2884

I

3070

3071

D

3001

3000

E

2959

2958

L

--

3113

K

--

2828

E

3242

3242

M

2701

2700

B
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are the cn and (zn+2) ions[31]. Peaks corresponding to the ladder of (zn+2)-ions as well as
some c-ions generated at 60% laser power were observed and identified for the parallel
sample ((Mn+αKG)FIH-1) quenched after 4 hours of trypsin incubation. This particular
sample was chosen based on SDS-PAGE and MS results which showed that the dominant
protein species present at the specified timepoint is the ~34 kDa fragment (Figures 3.6
and 3.7). A few y-ions were also observed, which is unusual but not impossible[29,31]. The
identified fragment ions were summarized in Table 3.3. This analysis verified parts of the
N-terminal sequence of the fragment. More importantly, parts of the C-terminal sequence
involved in FIH-1 dimerization were also identified, ruling out the cleavage at the Cterminal residue Lys301 (MW = 34897) as the event that generated band 4. The sequence
data unambiguously identified the band 4 species as the protein fragment generated upon
trypsin cleavage at the N-terminal residue Arg54 (MW = 34931).
The observed difference in the rates of trypsin proteolysis for apo versus αKGbound FIH-1 is consistent with the idea of the existence of at least two distinct
conformational states of the enzyme, which is dependent on the cofactor present. Each
enzyme form conceivably represents a different conformational state.
3.3.4 αKG Binding is a Prerequisite for Optimal HIF-1α/CTAD Substrate Binding
Based on early observations mentioned previously that imply the requirement of
cofactors for sufficient HIF-1α/CTAD binding[32,33], we further postulated that the
substrate only binds optimally to the αKG-bound form of the enzyme. To initially test
this hypothesis, we turned again to intrinsic fluorescence quenching experiments. As with
the previous Trp quenching experiments, the protein concentrations were kept constant
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all throughout. Addition of HIF-1α/CTAD substrate to apo or metal-bound FIH-1 did
not cause a significant change in the quenching intensity (as indicated by the filled data
points in Figure 3.10) implying that either the substrate did not bind the enzyme or its
binding did not drastically perturb the environment of the reporter tryptophan residues.
The former case is the most likely event, i.e. the substrate did not bind, because upon
addition of HIF-1α/CTAD to the αKG-bound form of the enzyme, the signal was
quenched to some extent, which was taken as an indication of a binding process. The

Figure 3.10 Trp fluorescence emission spectra of FIH-1 in the presence of HIF-1α/
CTAD substrate. Samples contained one or two or all of the following components: 2 µM
FIH-1, 50 µM MnSO4, 500 µM αKG in 50 mM HEPES pH 7.0 at RT (~23°C). Empty
data points – spectra in the absence of CTAD; filled data points – spectra in the presence
of 200 µM HIF-1α/CTAD.

preliminary data suggests that optimal HIF-1α/CTAD binding requires the prior presence
of αKG in the active site of FIH-1. This will support the sequential ordered binding
mechanism proposed for this enzyme[19]. Inspection of the structures with bound substrate

	
  

66	
  

showed sidechain reorientations of two Trp residues, Trp27 and Trp296, which possibly
accounts for the observed quenching effect. Altogether, the available data suggest that,
despite the lack of crystallographic evidence, FIH-1 undergoes substantial structural
changes prior to HIF-1α/CTAD binding, which are very likely relevant to the enzyme’s
hydroxylase function. The conformational perturbations possibly occur on a binding or
catalytic timescale.
To lend more experimental support to the proposed model that HIF-1α/CTAD
only binds optimally to αKG-bound FIH-1, preliminary binding experiments were
performed by monitoring the changes in the intrinsic protein fluorescence intensity upon
substrate addition. Figure 3.11 shows HIF-1α/CTAD binding data obtained for FIH-1 in
the presence and absence of αKG. One can deduce from the data that the substrate
apparently does not even bind when αKG is absent or if it does, binds with an extremely
low affinity that cannot be determined from the available data points and possibly in a
different non-optimal binding orientation as a trend of slight fluorescence enhancement
was generally observed instead of fluorescence quenching (supplemental Figure 3.16).
On the other hand, it clearly binds when αKG is present as seen in Figure 3.11. Nonlinear
curve-fitting of the plot for the αKG-bound FIH-1 gave a KD value of 92 ± 9 µM which
is well within the range of the KD, CTAD values (~90 µM) for FIH-1 previously observed
(supplemental Figure 3.17) in our lab as well as the reported KM, CTAD (~79 µM)[5]. The
results clearly indicate that the affinity of the substrate depends on the cofactor bound to
FIH-1, suggesting distinct conformational states for the apo/metal- and αKG-bound
enzyme forms.
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Figure 3.11 Binding of HIF-1α/ CTAD substrate to FIH-1 in the absence ((Mn)FIH-1:
open circles, apo FIH-1: filled triangles) and presence (filled circles) of αKG. Samples
contained one or two or all of the following components: 2 µM FIH-1, 50 µM MnSO4,
500 µM αKG in 50 mM HEPES pH 7.0 at RT (~23°C). The experiment was performed
in duplicate at an excitation λ of 295 nm and the intrinsic fluorescence quenching was
monitored between 300 to 375 nm. Nonlinear regression analysis of the plot for the
αKG-bound enzyme using equation 3.1 gave a KD value of 92 ± 9 µM.

3.3.5 αKG-induced Conformational Changes in FIH-1: Implications for Substrate
Binding, Product Release, Regulation and Selective Inhibition of FIH-1
The available results clearly demonstrated that the ternary metal-αKG/FIH-1
complex assumes a more compact structure, which rendered FIH-1 more resistant to
thermal denaturation, deuterium exchange and protease attack compared to apo enzyme.
These are clear indications of a conformational change induced by αKG despite the
absence of crystallographic evidence. In light of this, the B-factors were analyzed using
the available crystal structures. As shown in Figure 3.12, the outer rims of the enzyme
barrel core consisting of alpha-helices and loops were mostly flexible in the absence of
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αKG. The presence of these flexible regions in the apo enzyme indicates a more loosely
structured protein, which is consistent with the observed greater susceptibility of the apo
form of FIH-1 to thermal denaturation, deuterium exchange, and protease attack. As
demonstrated by the available thermal stability and solvent exchange data, the presence

Figure 3.12 Comparison of the B-factors mapped onto the 3-D surface for apo (1IZ3)
and αKG-bound (1H2N) FIH-1.

of the metal did not significantly changed the profile of the enzyme relative to the apo
form indicating that metal-bound FIH-1 exhibited a similar open structure as apo FIH-1.
On the other hand, the presence of αKG induced conformational changes that rendered
the enzyme more thermally stable and less accessible to solvent as well as protease
attack, which is indicative of a more tightly structured protein.
The binding of αKG to FIH-1 greatly stabilized the enzyme core (~34 kDa
protein fragment corresponding to band 4 in the gel), which was shown to comprise the
eight-stranded β-barrel (or cupin barrel) without the enzyme region opposite the substrate
binding site (shaded in green in Figure 3.13). This conclusion was based on the available
limited proteolysis data coupled to mass spectrometry and MALDI-ISD sequencing data.
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The observed substantial stabilization of αKG-bound FIH-1 jives very well with the
molecular dynamics results of an earlier study[53].
The cupin barrel core is conserved among the αKG-dependent oxygenase
superfamily[24]. It serves as a common platform where the active site pocket is enclosed
and where a combination of loops, alpha helices and additional beta strands extends out
from the core to form the substrate contacts unique for each enzyme[5]. It can be seen in
Figure 3.13 that removal of the protein region, which gets cleaved off by trypsin (shaded

Figure 3.13 (A) FIH-1 primary structure showing the trypsin cleavage at Arg54 (indicated
by the arrow) to generate the 34 kDa core monomer fragment. Shaded in green is the
protein region that gets cleaved off from the enzyme core species. (B) Front and flipped
backside view of FIH-1 dimer structure showing the location of the green region. The
cupin barrel core is shaded in purple. The red sphere is Fe(II) in the active site.
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in green) to generate the ~34 kDa species, will still leave the active site within the barrel
core as well as the dimer interface intact. We predict then that the ~34 kDa protein
fragment should still exhibit residual hydroxylation activity.
The available data allowed for the conception of a simple equilibrium model
(Figure 3.14) for FIH-1. The salient features of the model are as follows: (1) the enzyme
dimer exists in at least two conformational states: the loose, more flexible state and the
tight, more stable state, (2) the population of each conformational state depends on the
presence of cofactors, (3) the tight, more stable conformer represented by the αKGbound enzyme species is more suited for optimal substrate binding (Scheme 3.1). The
cupin barrel core of FIH-1 allowed for a more compact restructuring of the enzyme in the
presence of cofactors.

Figure 3.14 Proposed model for the different conformational states of FIH-1. The
population of these states depends on the presence of cofactors. Binding of the metal to
apo enzyme does not induce significant structural changes whereas binding of αKG to
the metal-bound form of the enzyme induces stabilizing changes within the active site
core that results to pre-formation of the substrate-binding site.

The observed structural changes in the presence of αKG are likely connected with
the subsequent step, which is substrate binding. These changes are possibly localized in
the vicinity of the active site within the cupin barrel core but do not involve major
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perturbations in the secondary structures as supported by CD spectroscopy. Rather, the
changes likely involve the “inward packing” of the cupin barrel core itself, which resulted
in the “clamping” together of mobile elements protruding out of the core to better define
the substrate-binding site. The proposed changes are conceivable given that αKG
interacts with both sides of the β-barrel when coordinated to the metal center. On one side
of the barrel are the residues Asn205 and Asn294, which form H-bond interactions with the
C1 carboxylate of αKG; while on the other side of the barrel are the residues Lys214 and
Thr196, which form interactions at the C5 carboxylate end. One can imagine the inward
pulling effect that the enzyme core experiences upon αKG binding resulting to FIH-1
stabilization as consistently implied by the available data. Since the conformational
changes are proposed to involve the same structural elements that just got packed tighter,
such subtle structural information will have been lost in the ensemble-averaged view of
crystal structures. Thus, quite ironically, the proposed inward packing model can also
potentially explain the observed lack of crystallographic evidence for the proposed αKGinduced structural changes. This is in contrast with CurA, an enzyme from the same
superfamily, which was shown via crystallography to have distinct αKG-dependent open
and closed conformations[59].
The idea of a more rigid, stable structure for priming the enzyme towards optimal
substrate binding seems counterintuitive if the induced-fit model is invoked[28,34].
However, as implied before, it can also mean that the more rigid protein core allowed for
the flexible elements to come together to properly pre-define the substrate-binding
groove. The induced-fit model still applies for FIH-1 as further sidechain reorientations
are clearly happening upon the actual substrate binding event based on the crystal
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structures[7]. A pre-formed substrate binding site would make sense for FIH-1 given that
(1) the HIF-1α/CTAD substrate is mostly unstructured in solution prior to binding[54] and
that (2) the substrate can adopt different structures when bound depending on the nature
of the binding partner[7,54] (Figure 3.15). For example, when bound to FIH-1, the crystal
structures revealed two sites of interaction for HIF-1α/CTAD substrate: site 1 or the
hydroxylation site (-LTSYDCEVN803API-) in which the susbstrate is mostly in the coil
conformation extending to a single tight turn that projects the target Asn803 residue into
the active site pocket and, site 2 or the C-terminal site (-LQGEELLRAL-) in which the
substrate adopts a short helical structure[7]. A manual inspection of the tight turn formed
by the FIH-1-bound substrate revealed that it is an inverse γ-turn consisting of three site 1
residues (-VN803A-) and which have an H-bond formed between the backbone carbonyl
oxygen of Val802 residue and the amide group of Ala804 residue. On the other hand, when
HIF-1α/CTAD is bound to the trans-coactivator p300/CBP, the same two sites of
interactions were also observed but parts of the site 1 region (-SYDCEVN803-) was

Figure 3.15 Different conformations adopted by 788-826 HIF-1α/CTAD depending on
its binding status. Highlighted in gray are the two sites of interaction. The target Asn803
residue is located on site 1. The straight line indicates unstructured coil conformation.
Also indicated is the tight γ-turn (spanning -VN803A- residues) formed upon binding to
FIH-1.
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shown to adopt a helical structure instead of the extended coil conformation. One can
imagine then how a pre-formed binding site will allow for the selection of a particular
binding orientation that will be optimal for the ensuing molecular process. The relatively
more polar environment of the FIH-1 binding site interacting with site 1 of HIF-1α/
CTAD substrate favored the formation of the inverse γ-turn. This binding environment
does not require as much enthalpic stabilization as when the binding site is mostly
hydrophobic like in the case of p300/CBP[54] wherein the hydrophobic interactions can be
energetically satisfied by the more extensive intrapeptide H-bonding in an α-helix. The
entropic penalty that must be paid to form the critical γ-turn upon binding to FIH-1 is
more than compensated by the observed enzyme stabilization of αKG-bound FIH-1 as
well as the intraturn H-bond formed and the favorable substrate interactions that lock the
target HIF-1α/CTAD-Asn803 in place. The pre-formed binding site also limits the
conformational space of the substrate and thus, selectively favors the optimal binding of
HIF-1α/CTAD. The absence of a pre-formed binding site can possibly explain the
observed extremely low affinity of the substrate for the apo or metal-bound enzyme
forms. This active site feature of FIH-1 is not seen in the other HIF hydroxylase, the
PHDs, which employ a lid domain in the form of the β2β3 loop to recognize and bind
substrates[36,55]. Therefore, the unique pre-formed substrate-binding site of FIH-1 in the
presence of αKG has the potential to become a selective therapeutic target. In fact, an
early study based on crystal structures of FIH-1 had recognized this precise structural
constraint of the enzyme as a possible target for future inhibitor design[7]. Perhaps this
same structural constraint within the active site is the basis for the substrate selectivity of
FIH-1. One can speculate that any unstructured protein sequences which can form a
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γ-turn or possibly any tight turn and which contain a properly placed Asn residue or a
similar-sized one with a β-methylene group are potential substrates.
Pre-organization of the substrate binding site has been observed by several groups
for the αKG dioxygenases[11-14], although the significance in the context of the proposed
sequential binding order was not realized then. Conceivably, the model shown in Figure
3.14 provides a structural basis for the proposed sequential ordered mechanism of FIH-1.
The cofactor αKG binds to Fe(II) in the active site, which induces the enzyme to undergo
structural rearrangements possibly via core packing, resulting in a more stable enzyme
form that favors optimal substrate binding. Hence, αKG has to necessarily bind first
before the substrate. Unprecedented support for the proposed model comes from early
studies that initially established the involvement of FIH-1 to hypoxia sensing[32,33].
According to those studies, one implication is that HIF-1α/CTAD does not sufficiently
bind to FIH-1 unless the cofactors are included. The proposed model satisfactorily
explained these earlier observations. Only when the cofactors are bound will the proper
substrate binding site form, allowing HIF-1α/CTAD to assume the inverse γ-turn needed
to properly project the target residue towards the metal center.
The available data also allowed for the conception of a mechanistic model
(Scheme 3.1) consistent with the proposed conformational state model for FIH-1.

Scheme 3.1 Mechanistic model showing the probable basis for the sequential ordered
mechanism proposed for FIH-1.
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Productive substrate binding only occurs when both metal and αKG are bound to the
enzyme. The substrate has a very low affinity for the apo enzyme as supported by the
binding assays; if ever binding does occur, it can unfavorably block the binding of
cofactors giving rise to an unproductive enzyme complex. Thus, in order to form a
productive enzyme complex, the binding of the cofactors has to necessarily happen prior
to substrate binding. This provides additional mechanistic support for the proposed
sequential binding mechanism of FIH-1.
As subtly illustrated in Figure 3.14, the enzyme assumes a more open structure
without αKG. This can potentially provide a structural mechanism for product release
whereby the products are released upon equilibrium shift to the more loosely structured
and therefore more open metal-bound enzyme form, which occurs as αKG is being
consumed. However, for productive reactions, it becomes necessary that the rate at which
this proposed shift happens is slower than the rate of coupling between αKG oxidation
and substrate hydroxylation.
At the risk of sounding highly speculative, we also realized the potential insight
that our proposed model might provide regarding FIH-1 regulation. It can, for example,
provide a mechanistic strategy through which FIH-1 is potentially regulated and readily
made available when the need arises. Referring to Scheme 3.1, one can imagine that
binding of a suitable ligand to the apo enzyme under hypoxia can reversibly lock the
enzyme in a conformational state that is not amenable for productive turnover. This will
decrease the available pool of enzymes until conditions return to normal, i.e. normoxia,
whereby the enzyme will be made available again by reversible ligand dissociation.
Again, we cannot emphasize enough that the idea is highly speculative at this point of the
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study but it is not too far-fetched and can be further explored to shed light in a critical
area that is largely unknown for this enzyme superfamily.

3.4 Conclusions and Future Directions
In this chapter, the effect of αKG binding on the structure of FIH-1 was
investigated in an effort to explore the subtle differences in the enzyme-substrate
interactions that might prove useful for future selective therapy. The available data
allowed for the conception of a simple equilibrium model for FIH-1, wherein the enzyme
dimer exists in at least two conformational states, the population of which is αKGdependent. The binding of αKG shifts the equilibrium towards the more tightly folded
and stabilized enzyme state as strongly indicated by the results showing the decreased
susceptibility of αKG-bound FIH-1 to thermal denaturation, solvent exchange and
protease attack. The stabilization effect of αKG on FIH-1 is likely due to the “inward
packing” of the cupin barrel core upon formation of interactions with enzyme core
residues on both sides of the barrel. One way to test the model is to disrupt these
interactions via single-point mutations of residues shown to interact with αKG on either
side of the barrel such as Asn205 and Thr196 and to compare the stabilization effect of
αKG on these variants relative to wildtype FIH-1.
The more stabilized enzyme state of αKG-bound FIH-1 due to “inward packing”
is proposed to promote optimal substrate binding via pre-formation of the substratebinding site. The available results support this as a greater affinity of the HIF-1α/CTAD
substrate for the αKG-bound enzyme form was observed. This would be the first time
such a model was proposed for FIH-1 or for any Fe(II)/αKG-dependent dioxygenase. To
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be clear, the premises of the model are (1) that FIH-1 exists in at least two
conformational states, the population of which is αKG-dependent, (2) that αKG binding
induces stabilizing conformational changes in FIH-1 which leads to pre-formation of the
optimal substrate binding site and, (3) that stabilization of FIH-1 upon αKG binding as
well as the intraturn H-bond and the optimal interactions formed upon substrate binding
more than compensates for the entropic penalty required by HIF-1α/CTAD substrate to
form the tight γ-turn. For future studies, a more robust binding experiment than the
intrinsic fluorescence quenching assay will have to be performed in order to provide
unambiguous support to the notion that the substrate only binds optimally to the αKGbound enzyme form. Isothermal titration calorimetry is an ideal tool for this purpose as it
has the added benefit of providing a complete thermodynamic profile of the binding
process. However, this method is easier said than done especially for a dimer enzyme like
FIH-1, which requires cofactors and whose substrate is a potentially sticky peptide.
For future investigations, computational studies using methods that are based on
recent MD simulations coupled to computational analyses such as quasi-anharmonic
analysis (QAA)[60] as well as the traditional quasi-harmonic approximation[61] can be
done to further probe the proposed conformational states of FIH-1 and their relevance to
enzyme function. Experimental studies using NMR spectroscopy would be a very useful
tool to correlate the enzyme conformational dynamics to enzyme function in solution.
However, the size of the FIH-1 dimer (~80 kDa) as well as the need for huge amounts of
enzyme and substrate might be serious limitations. An alternative tool that will still allow
for the study of the enzyme under turnover conditions albeit with lower resolution would
be small angle x-ray scattering. Unlike NMR though, any structural information obtained
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from this method would have to be coupled to kinetic data obtained from other means to
enable the correlation of enzyme dynamics to activity. Another useful low-resolution tool
for this purpose is single molecule fluorescence. It has the added benefit of providing
information about the different conformational states of the enzyme without requiring
huge amounts of the protein.
The model being proposed in this study definitely warrants further rigorous
testing as it has great potential to provide for several unprecedented insights into the
nature of substrate binding, product release, and possibly regulation of FIH-1. Equally
important is the great potential to selectively target FIH-1 via its proposed pre-formed
γ-turn binding site, which to our knowledge is a unique feature of the enzyme.
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3.5 Appendix
3.5.1 Abbreviations
HDX, hydrogen deuterium exchange;
MALDI, matrix assisted laser desorption ionization;
NMR, nuclear magnetic resonance;
TOF, time-of-flight;
SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis;
SASA, solvent accessible surface area;
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3.5.2 Supplemental
3.5.2.1 Binding of HIF-1α/CTAD to different enzyme forms of FIH-1

Figure 3.16 Representative fluorescence emission spectra of (Mn+αKG)FIH-1,
(Mn)FIH-1, and apo FIH-1 in the presence of HIF-1α/CTAD substrate. Samples
contained one or two or all of the following components: 2 µM FIH-1, 50 µM MnSO4,
500 µM αKG in 50 mM HEPES pH 7.0 at RT (~23°C). The experiment was performed
at an excitation λ of 295 nm and the emission was monitored between 300 to 375 nm.
The data curves shown were unsmoothed. The arrows show the general trend of change
in intrinsic fluorescence intensity as the titration progresses.

	
  

81	
  

3.5.2.2 Binding of HIF-1α/CTAD to (Co+αKG)FIH-1

Figure 3.17 Binding of HIF-1α/CTAD substrate to (Co+αKG)FIH-1. CoCl2 was used to
replace Fe(II) in the active site. The sample contained 2 µM FIH-1, 25 µM CoCl2, and
500 µM αKG in 50 mM HEPES pH 7.0 at RT (~23°C). The experiment was performed
in triplicate at an excitation λ of 295 nm and the fluorescence quenching monitored
between 300 to 375 nm. The inset figure shows a sample of the fluorescence emission
spectra generated. The trend as shown by the arrow is decreasing intensity with
increasing amounts of the substrate. Curve-fitting using equation 3.1 gave a KD value of
91 ± 5 µM for the αKG-bound enzyme.
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CHAPTER 4
100s LOOP OF FIH-1: LINK BETWEEN SUBSTRATE BINDING AND
CATALYSIS

4.1 Introduction
A defining characteristic of O2 sensing by the non-heme Fe(II)/αKG-dependent
dioxygenase, FIH-1, is that O2 activation must occur with high fidelity to transduce the
signal in the form of hydroxylation at HIF-1α/CTAD-Asn803, requiring the tight coupling
between HIF-1α substrate binding and O2 activation. How exactly the enzyme performs
this is yet to be resolved and would potentially provide useful insights about its substrate
selectivity for selective targeting as well as future enzyme engineering studies. One
conclusion that is apparent from all the mechanistic studies done for FIH-1[17,22,23,25-27] is
that, in order to achieve efficient oxygen activation, the native substrate must be able to
effectively displace the water ligand occupying the sixth coordination site of Fe(II). This
is part of the so-called substrate triggering mechanism wherein oxygen activation only
occurs at an appreciable rate when native substrate is present[14,38]. This phenomenon has
been empirically observed for other members of the nonheme iron dioxygenase
superfamily such as clavaminate synthase and phenylalanine hydroxylase[17,18,28,29]. While
there is still no known similar evidence for FIH-1, the very slow reactivity of the enzyme
with oxygen in the absence of substrate to form the autohydroxylated species[4] is indirect
support for the substrate-induced O2 activation phenomenon.
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In the proposed mechanism for FIH-1 (Scheme 1.1), binding of the substrate
triggers O2 binding to αKG-bound Fe(II). This was proposed to occur via disruption of
the H-bond interaction between the unbound oxygen of the facial triad carboxylate Asp201
residue and the axial water ligand, thus facilitating aquo release and creating an empty
coordination site for O2 binding[14,21-23,27]. The disruption results in a new H-bond
interaction between Asp201 and the backbone amide of HIF-1α/CTAD-Asn803. Upon
binding to the vacant coordination site, O2 is subsequently activated to the superoxide
nucleophile, which can then attack the keto-carbon of αKG to generate succinate, CO2
and the proposed ferryl (FeIVO) oxidant species. These steps can be thought to comprise
the first half of the catalytic cycle, which will be referred to as αKG oxidation or
succinate production. The second half comprises the insertion of oxygen into the
unactivated beta C-H of HIF-1α/CTAD-Asn803 to produce the hydroxylated substrate,
which will be referred to as HIF-1α/CTAD hydroxylation. At the point of the cycle
where the putative ferryl species is formed (i.e. upon succinate production), the reaction
can be uncoupled, meaning no hydroxylated substrate is produced afterwards. Insofar as
FIH-1 is concerned, this uncoupling has only been observed in (1) certain enzyme
variants in the presence of native substrate[16] or (2) wild-type enzyme in the presence of
poor substrate variants[23,26] but not with wild-type enzyme and native substrate together
under turnover conditions[5,16]. The mechanism of the observed uncoupling still remains
to be established though there are strong hints that proper substrate positioning plays a
key role[16,24]. So far, there is no direct evidence of what exactly happens to the putative
ferryl species during uncoupling; it is very likely that the reactive species exchanges with
a solvent molecule[3,4] and subsequently hydroxylates some nearby properly oriented
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oxidizable residue within the active site. Indeed, our group has shown spectroscopic
evidence of this event also known as autohydroxylation (or self-hydroxylation)[4]. The
production of reactive oxygen species (ROS) was ruled out as an alternate route for the
putative ferryl oxidant in FIH-1 as there was none observed[5]. It becomes apparent then
that the second half of the catalytic cycle for FIH-1, which results in HIF-1α/CTADAsn803 hydroxylation, will only proceed and thus be coupled to the first half when the
generated reactive iron oxidant species is sufficiently juxtaposed with the target residue
of the substrate.
The exact mechanism by which FIH-1 achieves tight coupling of the first half
(αKG oxidation) to the second half of the catalytic cycle (HIF-1α/CTAD hydroxylation)
remains unresolved, although there have been several proposed models[16,24,35]. One
model, based on spectroscopic studies with the related enzyme clavaminate synthase 2,
describes the conversion of the coordination geometry of the active site Fe(II) from sixcoordinate (6C) to five-coordinate (5C), which requires the binding of both the
cosubstrate αKG, and native substrate[35]. The premise is that only upon binding of the
substrate will the metal coordination switch happen making iron more reactive to O2.
Hence, dioxygen activation leading to αKG oxidation will only occur once the substrate
is in proximity, which ensures tight coupling. Support for the model came from
spectroscopic-based observations of the metal coordination switch noted for the other
related enzymes[28,29]. While the metal coordination switch model holds true for FIH-1 as
previously shown by MCD studies[25], it cannot sufficiently account for the observation
that certain FIH-1 variants, such as the facial triad Asp201 mutants[36] and mutants of
Gln239 residue[16,31], significantly uncouple even in the presence of the enzyme’s native
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substrate. Indeed, enhanced αKG oxidation was observed for the Asp201 variants as
evidenced by the greater [14C]CO2 production compared to wild-type FIH-1[36].
Nonetheless, the same study provided mechanistic support to the model as the
decarboxylation of αKG was observed to be 10-fold lower in the absence of substrate.
Clearly though, the enzyme employs additional mechanisms to ensure that αKG
oxidation will efficiently proceed to HIF-1α/CTAD hydroxylation.
An extension of the earlier model, this time based on data using TauD[24],
describes the involvement of H-bond interactions between the facial triad carboxylate
Asp201 and the axial sixth water ligand previously seen in crystal structures[30]. The
premise is that only upon binding of the native substrate will the H-bond get disrupted,
which provides the trigger for the release of the last water ligand. Aquo release results to
conversion of the iron coordination geometry from 6-coordinate to 5-coordinate creating
a vacant site for O2 binding. Thus, O2 binding and the subsequent activation will only
occur once the substrate binds, ensuring tight coupling of αKG oxidation to HIF-1α/
CTAD hydroxylation. Unlike the earlier model, the aquo ligand release model was able
to account for the observed uncoupling of the facial triad carboxylate Asp201 mutants[36].
Our group further postulated a variation of the model, which not only describes the
involvement of H-bond interactions between the first sphere residues but also between
residues surrounding the active site like Gln239 and the target Asn803 residue of HIF-1α/
CTAD substrate. The presumptions are that (1) the interactions involving the first sphere
residues facilitate dioxygen activation via removal of the water ligand as well as
transition state stabilization of αKG while (2) the interactions involving Gln239 residue
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help position HIF-1α/CTAD-Asn803 in the proper orientation relative to the generated
iron oxidant species, which ensure tight coupling.[16]
Collectively, the previous studies strongly indicate the presence of structural
elements within the active site of FIH-1, which ensure that the optimal interaction
between the target HIF-1α/CTAD-Asn803 residue and the iron oxidant species will occur
for efficient catalysis. To investigate this further, we took a closer inspection of the FIH-1
structure. Superposition of the crystal structures for the apo (1IZ3, 2.80 Å) and various
ligand-bound enzyme forms -- αKG-bound (1MZF, 2.40 Å; 1H2N, 2.84 Å) and
αKG/CTAD-bound (1H2L, 2.25 Å) -- did not reveal significant changes in the protein
backbone structure of the enzyme as seen before[3,30] but only showed sidechain
reorientations within the active site. A molecular dynamics study by Park and coworkers[1] using the apo and αKG-bound structures of FIH-1 suggests that αKG binding
decreases the flexibility of a certain loop region (we termed the 100s loop) (Figure 4.1A),
which is in close proximity to the active site. Using the aforementioned FIH-1 structures,
our initial attempt at online protein dynamics analysis based on the Gaussian network
model[2], predicted the same loop region to be less flexible in the presence of αKG
(Figure 4.2). This prediction corroborated with the empirical B-factors, which led us to
postulate that the 100s loop plays a functional role in the substrate interactions and
catalysis of FIH-1. As mentioned before, the available crystal structures of FIH-1
revealed several sidechain reorientations within the active site in the presence of
substrate[3,30]. The most substantial of these changes is the side chain rotation of Tyr102,
which incidentally is in the 100s loop (Figure 4.1B). A movement of roughly 10Å
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Figure 4.1 (A) Dimer structure of FIH-1 showing the location of the 100s loop. The
cupin barrel core where the active site is located is shaded in purple. The red sphere is
Fe(II). (B) Image of the aligned FIH-1/100s loop structures (a: 1MZF, blue, without
substrate; b: 1H2L, gray, with substrate) showing the reorientation of Tyr102 in the
presence of HIF-1α/CTAD substrate (gray) which stacks the phenol group on top of
Asn803 residue. The rest of the enzyme and substrate structures were removed for clarity.

Figure 4.2 Comparison of the experimental and theoretical B-factors of apo (1IZ3) and
αKG-bound FIH-1 (1H2N) mapped onto the structure. The 100s loop region is encircled.
The theoretical B-factors were calculated using the Gaussian network model algorithm.
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repositioned the phenol sidechain of Tyr102 and stacked it right on top of the target
HIF-1α/CTAD-Asn803 residue as if securing it in place. It also formed H-bond
interactions with the substrate via the amide nitrogen of Gln807 residue. We predicted then
that Tyr102 will play a particularly important role in the substrate interactions of FIH-1.
In this chapter, we report our findings for the role of the 100s loop of FIH-1.
Using a combination of steady state kinetic analysis of site-directed loop mutants,
spectroscopy and mass spectrometry, we show the unprecedented involvement of the
loop, particularly Tyr102, in the efficient turnover of the HIF-1α/CTAD substrate via
precise substrate positioning of the target HIF-1α/CTAD-Asn803 residue. Based on the
available data, we propose a modified version of the model for the coupling mechanism
in FIH-1.

4.2 Experimental Procedure
4.2.1 Materials
The 39-mer peptide corresponding to human HIF-1α 788-826 CTAD
(DESGLPQLTSYDAEVNAPIQGSRNLLQGEELLRALDQVN) was obtained from
EZBiolab (Carmel, IN) and was used as the substrate in all activity assays. The synthetic
peptide contained a Cys à Ala mutation that still preserves the hydrophobic character
but eliminates any unwanted side-chain interaction with the thiol group. The peptide was
purified prior to use by RP-HPLC. It was dissolved in 25% acetonitrile/0.2%
trifluoroacetic acid and purified to at least 95% purity. The concentration of the peptide is
determined by monitoring the absorbance of Tyr at 293 nm (ε = 2400 M-1cm-1) in 0.1 M
NaOH[28].
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Iron (II) sulfate (FeSO4), manganese sulfate (MnSO4), and 3,5-dimethoxy-4hydroxycinammate were purchased from Acros Organics (Morris Plains, NJ). The rest of
the chemicals and the snakeskin dialysis membrane were obtained from Fisher Scientific
(Fair Lawn, NJ). Molecular weight cutoff filters (MWCO) were obtained from Millipore
(Burlington, MA) and Vivaspin20 ultrafiltration tubes were from Vivascience Sartorius
(Gottingen, Germany). Primers used for site-directed mutagenesis were designed using
the Quickchange primer design software of Stratagene (La Jolla, CA) and purchased
( >90% purity by HPLC) from Integrated DNA Technologies (Coralville, IA). DNA
sequencing was done by Genewiz, Inc (South Plainfield, NJ). Plasmid purification was
done using the Qiagen (Hilden, Germany) miniprep kit.
4.2.2 Site-Directed Mutagenesis
The FIH-1 loop mutant plasmids (pET28a) were generated by PCR amplification
using forward and reverse primers (see Table 4.1) that introduced the site-directed

Table 4.1 Primers used in generating the FIH-1 100s loop mutants
Mutation

Primer DNA sequencea

Tyr102àPhe

5’-AGCACCCACAAGTTCTTGTTCTATGATGAGAAGAAGATG-3’

Tyr102àAla

5’-CCAGCACCCACAAGTTCTTGGCCTATGATGAGAAGAAGATGG-3’

Lys107àAla

5’-CAAGTTCTTGTACTATGATGAGAAGGCGATGGCCAATTTCCAGAACTTTAA-3’

a

The underlined codon corresponds to the modified amino acid

`
mutations. Figure 4.3 shows the location of the mutated residues relative to the metal
center and the substrate. Removal of the parental plasmid DNA was facilitated by
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digestion with the restriction enzyme Dpn1. The mutant plasmids were transformed into
supercompetent XLI-Blue E. coli cells using the heat shock method. The single mutations
were confirmed by DNA sequencing of the plasmid purified from the transformants. The
plasmids were then transformed into supercompetent BL21-DE3 E. coli cells.

Figure 4.3 Active site of FIH-1 showing the loop residues (blue) targeted for
mutagenenesis. Lys107 makes indirect contact with the substrate residue Glu801 (not
shown) via water molecules. Also shown is the substrate target residue HIF-1α/CTADAsn803 (gray).
4.2.3 FIH-1 Expression and Purification
BL21-DE3 E. coli cells containing the wild-type FIH-1/ pET28a plasmid were
grown in Luria-Bertani broth (25 g/L) supplemented with 30 µg/mL kanamycin at 37°C
with constant shaking. The cells were induced with 0.5 mM IPTG when the OD600
reached 0.5-0.7 and then further incubated at 37°C for 5 h before harvesting the cells by
centrifugation. Cell lysis was facilitated by the use of lysozyme (1 mg/mL) and
sonication on ice for 30 mins with 30 secs break between each burst cycle. Cell debris
was removed by centrifugation at 15000 rpm (26786g), 4°C for 45 mins. The crude cell
lysate was dialyzed against 10 mM Tris, pH 8.0 at 4°C and then clarified by
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centrifugation at 15000 rpm (26786g), 4°C for 10 mins. Purification of the His-tagged
enzyme was carried out by Ni-affinity chromatography using the BioRad BioLogic LP
pump system. The enzyme was eluted out using 250 mM imidazole/50 mM
NaH2PO4/300 mM NaCl, pH 8.04 buffer at a flow rate of 3 mL/min. The enzyme eluate
was buffer-exchanged against 10 mM Tris, pH 8.0 at 4°C to reduce the imidazole
concentration. The concentration of the protein was estimated by UV absorbance at 280
nm using ε280 = 1.22 mL mg-1cm-1 [32]. The His-tag attached to the N-terminus was then
removed by incubation with thrombin (0.5 U/mg protein) for 24 h at 4°C. The cleaved
enzyme was obtained by affinity chromatography and was incubated with 50 mM EDTA,
pH 8.0 at 4°C overnight. The protein sample was then concentrated at 4°C using the
Amicon pressure concentrator fitted with 30kDa MWCO filter and finally with the
Vivaspin20 ultrafiltration tube before it was loaded into the Sephadex G75 resin column
to obtain the FIH-1 dimer. The purity of the enzyme was checked by SDS-PAGE.
LC/ESI-MS was also performed to check the molecular masses of the enzyme variants.
4.2.4 Steady-State Activity Assays
FIH-1 activity was assayed by following the formation of the hydroxylated
HIF-1α/CTAD peptide substrate using the MicroFlex MALDI-TOF MS (Brucker
Daltonics, Billerica, MA). Unless otherwise specified, steady state assays were done
under ambient O2 concentrations at 37.0°C in 50 mM HEPES (pH 7.02) maintained at a
total ionic strength of 100 mM using NaCl. The reaction buffer contained 500 µM αKG,
2 mM ascorbate, and 50 µM FeSO4. All the buffer constituents were mixed and initially
incubated at 37.0°C for 3 mins, after which the reaction was initiated by adding enzyme
to a final concentration of 0.5 µM. The reaction was quenched into 20 µL of 75%
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CH3CN/0.2% TFA saturated with the MALDI matrix, 3,5- dimethoxy-4hydroxycinnamate, at various time points ranging from 20-240 secs. To determine the
amount of hydroxylated HIF-1α/CTAD, the product of the total CTAD concentration and
the ratio of the peak intensity for the hydroxylated product relative to the overall peak
intensities (parent peak and hydroxylated peak intensities) was calculated. The amount of
hydroxylated HIF-1α/CTAD was plotted versus time and the initial rate was determined
from the slope of the plot. Steady state kinetics plots were generated by plotting the initial
rate normalized to enzyme concentration and the substrate concentration. The plots were
fitted to the Michaelis-Menten equation (equation 4.1):
𝑣/𝐸 =   

!!"#   ×  [!]
!! ![!]

Equation 4.1

4.2.5 Circular Dichroism Spectroscopy
Protein samples for CD measurements were prepared in 10 mM KH2PO4 (pH
7.04) with 500 µM αKG and 50 µM MnSO4. Protein concentrations used ranged from
0.2-0.4 mg mL-1 as measured by UV absorbance at 280 nm (ε280 = 1.22 mL mg-1cm-1).
The spectra were collected over the wavelength range of 190-250 nm at 37°C using a
high-transparency quartz cell with pathlength of 0.1 cm on a Jasco J-715 CD
spectrometer. The instrument was blanked with the buffer solution containing all
constituents except the protein. All measurements were collected at least three times to
ensure that the signal is for that of a sample at equilibrium. The average of these
measurements were taken and used to generate the CD spectra.
4.2.6 Thermal Shift Experiments
Samples for the melt curve run were prepared containing one or two or all of the
following components: 5 µM FIH-1, 5 µM MnSO4 and 500 µM αKG in 50 mM HEPES
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pH 7.0. For each sample, 45 µL of the master mix was distributed to each well in the 96well qPCR microplate and 5 µL of freshly prepared 5X SYPRO Orange (Sigma-Aldrich,
5000X stock diluted in dimethylsulfoxide) was thoroughly mixed in. The microplate was
sealed with a Microseal adhesive film, briefly spun and immediately loaded onto a BioRad CFX Connect RT-PCR machine and the samples were heated at a rate of 1°C/min
from 20°C to 90°C. The fluorescence intensity (excitation wavelength: 450-490 nm;
emission wavelength: 560-580 nm) was monitored as a function of temperature.
4.2.7 UV/visible Spectroscopy
Autohydroxylation monitored by UV/vis spectroscopy was done as previously
described[5] with minor modifications. Anaerobically prepared protein samples contained
225 µM FeSO4, 1 mM αKG and 230 µM FIH-1 in 50 mM HEPES pH 7.0. For samples
with substrate, HIF-1α/CTAD was added to a final concentration of 125 µM. The
samples were incubated for 30 mins inside the glovebox prior to addition of airequilibrated buffer to initiate autohydroxylation. The reaction was monitored at 583 nm
for at least 6 hours at room temperature (~23°C).
4.2.8

Electron Paramagnetic Resonance Spectroscopy
Protein samples for X-band EPR measurements were prepared as previously

described[5] except that the samples were anaerobically reconstituted with FeSO4 instead
of CuSO4. Stocks of FIH-1, αKG, and HEPES buffer were sealed with rubber septa and
degassed with argon gas, and brought into a glovebox. FeSO4 and DEANO were brought
into the glovebox as solids and prepared using degassed H2O and 10 mM NaOH
respectively. The DEANO concentration was verified by the characteristic UV
absorbance at 250 nm (ɛ250 = 6500 M-1cm-1)[10,15]. Anaerobic EPR samples containing
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FIH-1/ Tyr102àAla (0.2 mM), FeSO4, (0.18 mM), αKG (1 mM), HIF-1α/CTAD (0.6
mM), and DEANO (0.50 mM) in 50 mM Hepes pH 7.00 were prepared and aged
anaerobically at 23°C for 20 minutes to allow NO release from DEANO. The samples
were capped and flash frozen in liquid nitrogen (LN2) immediately upon removal from
the glovebox. X-Band EPR data was recorded using a Bruker Elexsys E-500 EPR
equipped with a DM4116 cavity and a Bruker ER 4118CF-O LHe/LN2 cryostat at 9.624
GHz frequency, 6.0 mW power, 10 G modulation amplitude, 100 GHz modulation
frequency, 163 ms time constant at 4K.
4.2.9 Succinate Coupling Assays
Coupling of αKG decarboxylation and HIF-1α/CTAD hydroxylation was
determined by LC separation and UV detection at room temperature (25°C). Succinate
produced from quenched-steady state reactions of FIH-1 was detected at 210 nm using a
Hamilton PRP-X300 anion exclusion column. A linear gradient of 2% acetonitrile and
0.5 mM H2SO4 was ran through the column at a flow rate of 2 mL/min. Calibration was
done using serially-diluted fresh succinate stocks in 50 mM Tris with concentrations
ranging from 65 µM to 520 µM. The steady state assays were done in 50 mM Tris (pH
7.08 at 37°C) under ambient O2 conditions. HEPES was not used this time because of the
huge salt peak it produces during LC quantitation, which complicates subsequent
succinate peak analysis. Ascorbate was also left out of the reaction mix for the same
reason. Wild type enzyme was used as the control to ensure that the conditions used still
support coupled enzymatic activity. The reaction components included 1 µM for all
enzyme concentrations except for Tyr102àAla mutant (25 µM), 50 µM FeSO4, 500 µM
αKG and 200 µM HIF-1α/ CTAD. The hydroxylated HIF-1α/CTAD (CTAD-OH) was
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monitored using MALDI-MS as described above. The coupling ratio (C) is defined as the
ratio of the rate of succinate production (as given by the slope of the line) over the rate of
CTAD-OH production.

4.3 Results and Discussion
4.3.1 The 100s Loop Mutations Affected Substrate Binding and Catalysis of FIH-1
The molecular masses of the generated FIH-1 loop variants were determined by
LC/ESI-TOF mass spectrometry (supplemental Figure 4.11). The observed masses
correspond well with the expected masses for each enzyme species: wild type FIH-1
(observed mass 40567.3 Da; expected mass 40566.7 Da), Tyr102àPhe/FIH-1 or Y102F
(observed mass, 40551.4 Da; expected mass, 40550.7 Da), Tyr102àAla/FIH-1 or Y102A
(observed mass, 40474.5 Da; expected mass, 40474.6 Da) and Lys107àAla/FIH-1 or
K107A (observed mass, 40510.5 Da; expected mass, 40509.6 Da). Steady state kinetic
assays of the variants were conducted to test the role of the 100s loop in substrate binding
and catalysis of FIH-1 (Figure 4.4). The kinetic parameters were measured at pH 7.02,
37.0°C in 50 mM HEPES, with the total ionic strength fixed at 100 mM using NaCl.
Fixed concentrations of FeSO4, αKG, and O2 were used while the HIF-1α/CTAD
substrate concentration was varied. As the Fe2+ and αKG concentrations were saturating,
but the O2 concentration was fixed at the ambient level (ca. 217 µM), the reported rate
constants summarized in Table 4.2 are apparent.
The data shown in Figure 4.4 clearly indicate that the Ala mutations of the loop
residues affected FIH-1 activity to different extents whereas the variant with the
conservative Phe mutation at position 102 exhibited wild type-like activity. Wild type
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FIH-1 exhibited steady-state rate constants that were in good agreement with those
previously reported, with kcat = 39 ± 1 min-1 and kcat/KM = 0.49 ± 0.03 min-1 µM-1. The
conservative Tyr102àPhe mutant exhibited modest effects on enzyme activity, as kcat
(42 ± 2 min-1) was indistinguishable from that of WT-FIH-1 while kcat/KM (0.15 ± 0.01
min-1 µM-1) was decreased by a factor of 3. This may be due to some minor changes in
electrostatics upon loss of the hydroxyl group, which is shown in crystal structures to
form an H-bond with the substrate via the amide group of Gln807 residue. In contrast, the
Tyr102àAla mutant drastically affected steps throughout the catalytic cycle, as it
exhibited greatly reduced kinetic constants relative to wild type FIH-1, with more than
150-fold reduction in kcat (< 0.2 min-1) and a 3000-fold reduction in kcat/KM (1.3 × 10-4
min-1 µM-1). Because both kinetic parameters were significantly reduced, the apparent

Figure 4.4 Steady state kinetics plots for wild type FIH-1 and the loop variants. The data
were fitted using the Michaelis-Menten equation. The reaction was done at 37°C in
50 mM HEPES pH 7.02 containing 50 µM FeSO4, 500 µM αKG, 2 mM ascorbate,
0.5 µM enzyme for WT and Y102F, 1 µM enzyme for K107A, 20 µM enzyme for
Y102A, and 0-450 µM HIF-1α/CTAD. The assay experiments were at least done in
triplicate.
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Table 4.2 Summary of the parameters generated from the fit of the Michaelis-Menten
plots for wild type FIH-1 and the loop variants. KD for HIF-1α/CTAD was also included
for comparison to the KM for HIF-1α/CTAD.
kcat (min-1) KM (µM)

KM (µM) kcat/KM ( min-1 µM-1) KD (µM)b

HIF-1α/CTAD

αKG

HIF-1α/CTAD

2-O

HIF-1α/CTAD

WT FIH-1

39 ± 1

79 ± 6

17 ± 2

0.49 ± 0.03

91 ± 5

Tyr102àPhe

42 ± 2

288 ± 30

10 ± 3

0.15 ± 0.01

204 ± 8

Tyr102àAla

< 0.2

> 500

9 ± 1a

0.00013 ± 0.00001

> 500

Lys107àAla

27 ± 2

> 500

8±3

0.06 ± 0.002

> 500

a

Value determined by fitting the the uninhibited part of the steady-state kinetics plot
using the Michelis-Menten equation (equation 4.1).
b

Values determined by monitoring intrinsic fluorescence quenching (or Trp quenching)
assays (supplemental Figure 4.13).

implication is that the Ala mutation at residue 102 affected a common kinetic step, which
according to the proposed mechanism for FIH-1 (Scheme 1.1), corresponds to the oxygen
activation step. Overall, the kinetics data strongly suggest a very important role for the
bulk of Tyr102 residue on FIH-1 activity. The Lys107àAla mutant principally affected
steps involved in substrate binding, as there was only a slight decrease in kcat
(27 ± 2 min-1) and an 8-fold decrease in kcat/KM (0.06 ± 0.002 min-1 µM-1) relative to wild
type FIH-1. The substrate binding affinity of the mutant was apparently reduced at least
5-fold. This might be due to some minor substrate contact alterations. In the crystal
structures, Lys107 residue is shown to form indirect interactions with Glu801 of HIF-1α/
CTAD via water molecules.
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The KM values for αKG (see supplemental Figure 4.12 for the steady state assay
plots) were essentially unchanged or at the most, only slightly slower relative to wildtype FIH-1 except for the slow Tyr102àAla variant, which apparently exhibited strong
partial substrate inhibition at concentrations above 50 µM αKG. Lys107àAla mutant
seemed to exhibit some inhibition at really high αKG concentrations (> 500 µM) but not
as dramatic as the slow variant. The steady state kinetics data for Tyr102àAla variant
(supplemental Figure 4.12) fitted well to a partial uncompetitive inhibition model[41,43]
(supplemetal Equation 4.3) wherein excess αKG binds like an inhibitor to an already
αKG-bound enzyme form. The model may or may not describe what is actually
happening at high αKG levels but it can be a good start to account for the observation.
The apparent KM for αKG upon curve-fitting to equation 4.3 is greater (52 ± 39 µM) than
wild type. On the other hand, fitting of the non-inhibited data points using the MichaelisMenten equation gave a KM value (9 ± 1 µM) that is reasonably close to that of wild type
enzyme. This apparent partial substrate inhibition is bewildering and interesting at the
same time as Tyr102 residue is quite far from the metal center (at least 9 Å away) and
thus, is not expected to be directly involved in αKG binding. Indeed, this notion is
supported by two independent binding assays based on intrinsic fluorescence quenching
(or Trp quenching) assay as well as absorbance change at 490-500 nm monitored by UVvis spectroscopy (supplemental Figures 4.14 and 4.15). The KD values obtained were
essentially similar for both wild type (35 ± 2 µM; 32 ± 9 µM) and mutant enzyme
(22 ± 2 µM; 25 ± 10 µM). Cu-EPR spectroscopy data (supplemental Figure 4.16) also
provided support, as the spectral lineshapes were very similar relative to wild type under
conditions of low and high αKG concentrations, indicating that the metal coordination
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geometry was not altered by the mutation. Loss of the bulk at position 102 could have
resulted in a more open and thus more solvent accessible active site. This raises the
possibility of two αKG molecules binding to the active site metal, which results to
inhibition. However, the initial Cu-EPR data did not support this hypothesis. Global
HDX data (supplemental Figure 4.17; Tables 4.10A and B) did not reveal any large-scale
structural changes at high αKG concentrations that could have affected activity. The slow
variant appears to be slightly more solvent accessible than wild type which is expected
given the removal of the bulk at position 102. Both wild type and the slow variant
showed a slightly higher number of exchangeable protons at low αKG concentrations
suggesting a few small-scale changes. So far, the only plausible explanation we can
arrive at is that removal of the bulk of Tyr102 induced some αKG-dependent, localized
structural rearrangements that negatively affected the activity possibly via disruption of
substrate binding but not to such an extent as to completely abolish enzyme activity. This
is reminiscent of homotropic allostery to some extent[42]. The proposed αKG-dependent,
localized structural rearrangements likely contribute to the observed slight reduction in
the thermal stability of this slow variant relative to wild type upon αKG binding as noted
from thermal shift data (Figure 4.6; Table 4.3). Initial binding experiments seem to
support this hypothesis of an αKG-dependent disruption of substrate binding
(supplemental Figure 4.18) though much still needs to be done to wrap up this part of the
study. Nevertheless, it is quite clear at this point that the residue at position 102 has a
critical role on FIH-1 activity.
Because of the drastic effect of a single residue mutation on enzyme activity as
observed for the Tyr102àAla mutant, we wanted to know if the effect was due to some
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widespread perturbations in the enzyme structure. To test for these, the CD spectra for
wild type FIH-1 and the loop mutants were measured at pH 7.04 in 10 mM KH2PO4
buffer. To prevent untoward oxidation reactions, Mn2+ was used in place of Fe2+ for all
samples. Wild type FIH-1 exhibited two negative CD features (Figure 4.5) near 208 nm
and 222 nm, with a tailing positive feature below 200 nm, as expected for the mixed α/β
secondary structure observed crystallographically[3,30]. Each of the loop mutants exhibited
a CD spectrum that was similar to that of wild type FIH-1, indicating that the overall
protein structure was unaffected by point mutations. This was further supported by
thermal stability data obtained through monitoring of protein unfolding using a

Figure 4.5 Far-UV CD spectra of wild type FIH-1 and the loop variants. Samples
contained 50 µM MnSO4, 500 µM αKG and 0.2-0.4 mg/mL enzyme in 10 mM KH2PO4
pH 7.04 and were analyzed at 37°C.

hydrophobic fluorescent dye and RT-PCR. Similar to wild type, the apparent melting
temperatures for all the variants were elevated by at least 3°C in the presence of αKG
(Figure 4.6; apparent melting temperatures summarized in Table 4.3). Both Tyr102àAla
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Figure 4.6 Comparison of the apparent melting temperatures determined from thermal
shift assays for wild type FIH-1 and the loop variants in the presence of αKG. The
thermal stability of the assay mix containing one or all of the components: 5 µM FIH-1,
50 µM MnSO4, 500 µM αKG in 50 mM HEPES pH 7.0, was monitored using SYPRO
Orange dye with an RT-PCR machine.

Table 4.3 Apparent melting points of FIH-1 loop variants determined from thermal shift
assays.

a

	
  

Tm, app (°C)a

Tm, app (°C)a

Apo FIH-1

(Mn+αKG)FIH-1

WT FIH-1

47 ± 0.3

52.5 ± 0.5

Tyr102àPhe

48 ± 0.5

52 ± 0.1

Tyr102àAla

46 ± 0.6

49.5 ± 0.5

Lys107àAla

45 ± 0.3

49 ± 0.5

The reported values are the average of three replicate samples.
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and Lys107àAla mutants exhibited a slight reduction (about 3°C difference) in thermal
stability compared to wild type upon αKG binding, which might mean that the flexibility
associated with these residues have some role in enzyme function, most likely on
substrate binding. The decrease might be due to some small-scale structural
rearrangements upon mutation. Nevertheless, the general trend of increasing thermal
stability in the presence of αKG for all the loop variants tested points to an essentially
similar folded structure that is still capable of binding αKG. Collectively, these data
supported the notion that for the loop mutants, any drastic effect on enzyme activity is
likely not due to large-scale changes in the protein structure.
4.3.2 Loss of Bulk in the Loop Residue, Tyr102, Did Not Affect Oxygen Activation
The very low enzyme activity exhibited by Tyr102àAla mutant prompted the
question of whether dioxygen activation was compromised in this variant. An indirect
measurable indication of dioxygen activation is the amount of succinate produced as a
result of αKG oxidation. During uncoupling events, O2 activation proceeds to produce
succinate but does not proceed further to produce an equimolar amount of hydroxylated
substrate. Consequently, less hydroxylated product does not automatically indicate less
succinate, or reduced ability to activate O2.
To indirectly monitor O2 activation, succinate quantitation assays combined with
UV-vis and {FeNO}7 EPR spectroscopy were conducted. UV-vis spectroscopy was used
to monitor the autohydroxylation of FIH-1, which is dependent on the presence of iron,
αKG, and O2[4,32] and which is also indicative of oxygen activation albeit at a
significantly reduced rate. Anaerobic preparation of the (Fe+αKG)FIH-1 complex
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initially resulted in a light violet-colored solution with an absorption peak centered at 500
nm (supplemental Figure 4.19) similar to that observed for the related enzyme TauD[6].
This absorption arises from the metal to ligand charge transfer between the T2g(π) orbitals
of Fe(II) and the empty low-lying π* orbitals of αKG[13]. Wild-type and the conservative
mutant Tyr102àPhe formed the purple autohydroxylated species at comparable rates
(Figure 4.7A; Table 4.4) while Tyr102àAla mutant formed the chromophore species at a
slightly reduced rate, which indicates that this slow enzyme variant is still capable of O2
activation. The purple chromophore species was previously identified to be the Fe(III)-OTrp296 protein species in wild type FIH-1[32] and is assumed to be the same chromophore
species for the loop variants given that the λmax values are reasonably similar. The
corresponding broad absorption peak for the generated autohydroxylation species of the
slow mutant was centered at around 570 nm (Figure 4.7B), which is slightly blue-shifted
compared to wild type (583 nm) and Tyr102àPhe (580 nm) (supplemental Figure 4.20).
This may be due to perturbations in the steric crowding within the active site upon loss of
the bulk of Tyr102 residue.
Results from end point succinate assays further supported the observation that
Tyr102àAla mutant can still activate oxygen as it was observed to produce succinate
although at an apparently slower rate than wild type and the other two loop mutants
(Table 4.5). Together with the previous kinetic and autohydroxylation data, this
observation of reduced succinate production hinted at a slower rate of O2 activation,
which points to a possible indirect role of Tyr102 residue on oxygen activation. Its role is
likely structural in nature. Close inspection of the FIH-1 structure revealed Tyr102 as one
of the residues lining the enzyme’s proposed solvent channel (supplemental Figure 4.21),
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Figure 4.7 FIH-1 autohydroxylation monitored by UV-vis spectroscopy. (A) Autohydroxylation timecourse plots for wild-type FIH-1 and the Tyr102 variants monitored at
583 nm. (B) Autohydroxylation spectra for the loop variant Tyr102àAla. The arrow
indicates the increase in the absorption signal of the chromophore with a λmax at 570 nm.
The spectra was obtained over a period of several hours after air exposure at RT (~23°C)
of the anaerobically prepared samples (230 µM enzyme, 225 µM FeSO4, 1 mM αKG) in
50 mM HEPES pH 7.0.

Table 4.4 Summary of the autohydroxylation rates for wild-type and the Tyr102 variants.
Autohydroxylation Ratea
(µM min-1)
WT FIH-1

1.51 ± 0.35

Tyr102àPhe

0.91 ± 0.13

Tyr102àAla

0.66 ± 0.10

Lys107àAla

N.D.

a

The reported values were determined from the slope of the line generated using the early
time points up to 15 mins.
N.D., not determined.
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Table 4.5 Comparison of the amounts of succinate and hydroxylated HIF-1α/CTAD
produced after 15 mins using 1 µM enzyme for all enzymes except Y102A (25 µM) with
50 µM FeSO4, 500 µM αKG,	
  and	
  200 µM HIF-1α/CTAD in 50 mM Tris pH 7.08 at
37°C. Negative controls contained all components except αKG,	
  which	
  was	
  replaced	
  by	
  
NOG.	
  	
  	
  
	
  

a

[Succinate]a

[CTAD-OH]b

µM

µM

WT FIH-1

59.4 ± 0.5

46.5 ± 0.05

Tyr102àPhe

52.2 ± 0.1

46.3 ± 0.03

Tyr102àAla

18.4 ± 0.3c

4.8 ± 0.08c

Lys107àAla

51.8 ± 0.3

46.4 ± 0.06

[Succinate] was determined by HPLC quantitation.

b

[CTAD-OH] was obtained using MALDI/TOF-MS as described in the experimental
procedure.
c

Reaction mix was further incubated for 3 hours at 37°C. The following are the results
obtained after 3 hours incubation: [succinate] = 50.4 ± 0.09 µM; [CTAD-OH] = 11.5 ±
0.07 µM.

which overlaps with site 1 of the substrate binding groove[3]. The said channel, which has
never been formally identified in FIH-1, is most likely a transient one that really only
comes into shape upon substrate binding. The substrate-induced structural changes
possibly impose active site accessibility of O2, limiting the binding configurations it can
assume. A more open channel, as when the bulk at position 102 is removed, will
conceivably result to O2 having more freedom to sample different non-productive binding
configurations, which can in turn slow down O2 activation.
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To demonstrate the intact ability of Tyr102àAla mutant to productively bind
oxygen, {FeNO}7 EPR spectroscopy analysis was performed. Nitric oxide (NO) was used
as the O2 mimic. NO binds to Fe2+ in non-heme O2 activating enzymes with similar
geometry to that of bound O2 to form a spectroscopically accessible S = 3/2 metal
center[7-9]. The EPR lineshape and the rhombic zero-field splitting parameter (E/D) of
{FeNO}7 centers in Fe2+ enzymes are sensitive reports on the geometry of the {FeNO)7
center.[7,8,11] As the EPR line shape and E/D ratio are dominated by large zero field
splitting, the effective g-values (geff) are centered near g = 4. As the S = 3/2 electronic
structures were axial (E/D < 0.1), the observed geff values (gx, gy,) were related to zerofield splitting (E/D) using the relationship in equation 4.2[12].
G! , g ! =    g ! [  2 −   3/2

! !
!

±

!!
!

]

Equation 4.2

Anaerobic addition of NO to (Fe+αKG) Tyr102àAla and (Fe+αKG+CTAD) Tyr102àAla
complexes resulted to a yellow colored-solution and complex EPR line-shape near g = 4
(Figure 4.8; parameters summarized in Table 4.6). The EPR spectrum of (Fe+αKG+NO)
Tyr102àAla sample was highly heterogeneous and exhibited several S = 3/2 species at
geff = 4.29, 3.75 (E/D = 0.047), 4.11, 3.93 (E/D = 0.015), and 4.06, 4.00 (E/D = 0.005). In
comparison, the spectrum for wild type (Fe+αKG+NO)FIH-1] sample displayed a lineshape arising from a single S = 3/2 species with geff = 4.11, 3.92 (E/D = 0.016). In the
presence of substrate, the spectrum of (Fe+αKG+NO+CTAD) Tyr102àAla complex
displayed only one S = 3/2 species with geff = 4.06 and 3.99 (E/D = 0.005), suggesting
that there was one dominant geometry for bound gas, likely arising from steric constraints
provided by the target asparagine residue. Because the spectra of Tyr102àAla mutant and
wild type FIH-1 upon HIF-1α/ CTAD binding are similar, it suggests that the slow
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Figure 4.8 X-band EPR spectra for Tyr102àAla mutant (Y102A). The sample contained
200 µM enzyme, 180 µM FeSO4, 1 mM αKG, and 500 µM DEANO in 50 mM HEPES
pH 7.00 and aged anaerobically at 23°C for 20 minutes to allow NO release from
DEANO in the presence or absence of 600 µM HIF-1α/CTAD.
Table 4.6 Comparison of the X-band EPR parameters for NO complexes of wild type
FIH-1 versus Tyr102àAla mutant (Y102A).
gX, gY

E/D

values
(Fe+αKG+NO)WT

4.11, 3.92

0.016

(Fe+αKG+NO+CTAD)WT

4.06, 4.00

0.005

4.13, 3.91

0.017

4.29, 3.75

0.047

4.11, 3.93

0.015

4.06, 4.00

0.005

4.06, 3.99

0.005

(Fe+αKG+NO)Y102A

(Fe+αKG+NO+CTAD)Y102A
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mutant is still able to form the proper gas binding environment which leads to turnover.
Together with the results from the auto-hydroxylation experiment, the data indicates that
the Tyr102àAla mutation did not significantly impair the first part of the catalytic cycle
in the proposed mechanism, which involves oxygen activation and the subsequent
succinate production.
4.3.3 Loss of Bulk in the Loop Residue, Tyr102, Affected Coupling
To account for the drastically reduced activity of the Tyr102àAla variant despite
retaining the ability to activate oxygen, we turned to steady state assays to check for
coupling by comparing the amount of succinate produced to the amount of hydroxylated
substrate. Under tight coupling conditions, equimolar amounts of succinate and
hydroxylated HIF-1α/CTAD will be observed to give a coupling ratio (C) close to unity.
Uncoupling will result to higher C values. Succinate quantitation experiments revealed
that Tyr102àAla mutant could still produce succinate albeit at a slower rate (Table 4.5;
coupling ratios summarized in Table 4.7). Nevertheless, it was able to produce as much
succinate as wild type and the other two mutants upon longer incubation (~3 hours) in
agreement with the previous autohydroxylation data, which indicates that oxygen
activation still occurs for this slow variant. The C value was significantly elevated (C =
4.1 ± 0.35) for Tyr102àAla mutant whereas wild type was tightly coupled (C = 0.97 ±
0.05) as previously observed[5]. The other two loop variants, Tyr102àPhe (C = 0.93 ±
0.08) and Lys107àAla (C = 1.17 ± 0.2) were also similarly coupled. This data indicates
that Tyr102àAla mutant uncouples appreciably which would explain the observed
reduced hydroxylated product yield. In fact, endpoint assay results (Table 4.7) show that
even with 50 µM enzyme, this variant only produced less than 25% of hydroyxlated
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Table 4.7 Summary of the coupling ratios and yield of hydroxylated CTAD for FIH-1
loop variants.

a

Ca

% yieldb

WT FIH-1

0.97 ± 0.05

99

Tyr102àPhe

0.93 ± 0.08

94

Tyr102àAla

4.1 ± 0.35

21

Lys107àAla

1.17 ± 0.2

96

C = [succinate]/[CTAD-OH]; determined under steady state conditions

b

end-point assay conditions: 50 µM enzyme, 100 µM FeSO4, 2 mM ascorbate, 500 µM
αKG, 99 µM HIF-1α/CTAD, 50 mM HEPES pH 7.0 (total ionic strength maintained at
100 mM with NaCl); incubated for 3 hours at 37°C; samples were taken and quenched at
the following time points: 2, 5, 10, 30, 60, 180 mins; values reported were based on
samples quenched after 3 hours; % yield is calculated based on the fraction of
conversion to CTAD-OH, i.e. 99% yield means [CTAD-OH] = 98 µM.

HIF-1α/CTAD after 3 hours of incubation whereas wild type and the other two loop
variants achieved almost complete conversion of the substrate in less than 10 mins.
The elevated coupling ratio observed for the Tyr102àAla mutant points to an
unprecedented role of this residue on enzyme turnover via substrate positioning. A
similar observation in our lab was previously seen for the slow Asn variant of Gln239
residue[16,31], which like Tyr102àAla mutant also uncoupled considerably. Based on the
crystal structures, the sidechain of Gln239 gets reoriented upon substrate binding to form
two H-bond interactions with the amide group of HIF-1α/CTAD-Asn803, which ensures
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that the target residue is properly positioned for efficient iron oxidant attack. In a similar
manner, the significant sidechain displacement of Tyr102, which stacks it right on top of
HIF-1α/CTAD-Asn803 (Figure 4.1B), is also crucial in positioning the target residue as
strongly implied by the coupling data. The steric stacking interaction appears to be CH/π
in nature as the aromatic plane of the phenol side chain is stacked close (~4Å) (Figure
4.9A) to the β-carbon of Asn803 residue[19,20]. Based on the crystal structures, the target
Asn residue is positioned such that the pro-R hydrogen atom is ideally pointed towards
the aromatic ring of Tyr102 residue. The use of steric interactions by FIH-1 to position the
substrate is reminiscent of the observation previously made on the related enzyme TauD
regarding a Phe residue, which like Tyr102, also lies on the other side of the substrate
directly opposite the iron metal[40]. Comparison of the placement of both residues in each
case relative to the substrate and the iron metal show striking similarities (Figure 4.9).
The Ala mutation in both cases resulted in enhanced uncoupling.

Figure 4.9 Comparison of the steric placement relative to the substrate in (A) FIH-1
versus (B) TauD.
The significant effect of the Tyr102àAla mutation on FIH-1 activity, prompted us
to search the literature to determine whether Tyr102 residue is conserved across species.
Indeed, after BLAST alignment of FIH-1 sequences from representative samples
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Table 4.8 BLAST protein sequence alignment of the 100s loop segment of FIH-1 from
five representative species. The Tyr102 residue is in bold and underlined.
Species

FIH-1 100s loop sequence

H. sapiens

KFLYYDEKKMGN

M. muculus

KFLYYDEKKMGN

C. crassius

KFLYYDEKKMAN

H. occelatum

KFLYYDEKKMVN

D. melanogaster

NP--YADGLATQN

obtained from UniProt, we found Tyr102 to be conserved across species from fish to
mammals and even insects (Table 4.8) although the sequence of the latter must be
regarded with caution as it is evidently divergent. Nonetheless, this finding supported a
critical role for Tyr102 residue in FIH-1 activity.
4.3.4 Precise Substrate Positioning is Key to Tight Coupling of αKG Oxidation and
Substrate Hydroxylation in FIH-1
It appears that efficient catalysis in the form of hydoxylated HIF-1α/CTAD relies
heavily on the precise positioning of the target residue as the reactive iron oxidant species
must be sufficiently juxtaposed to effectively promote hydrogen atom abstraction from an
unactivated carbon and the subsequent hydroxyl radical rebound. Single mutations of
Tyr102 and Gln239 residues independently resulted to a significantly reduced enzyme
activity, which in both cases were attributed to impaired substrate positioning. Thus, it
becomes apparent that the enzyme utilizes a combination of electrostatic and steric
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Figure 4.10 Image of aligned FIH-1 structures (1MZF, blue (without substrate); 1H2L,
light grey (with substrate)) showing the rotation of Tyr102 and the downward movement
of the amide sidechain of Gln239 in the presence of HIF-1α/CTAD (in dark grey) to
properly position the target residue Asn803 via steric and H-bond interactions respectively.
The iron is shown as a red sphere coordinated to the facial triad motif and αKG (green).
Also shown is Asp201 forming an H-bond interaction with the backbone amide of Asn803
residue.

interactions just to position the target Asn803 residue correctly (Figure 4.10). Our group
previously alluded[16] that the interaction between substrate and enzyme residues within
the active site of FIH-1 might be the link between αKG oxidation and substrate
hydroxylation. Combining the previous published data from the lab with observations
made in this study enables us to be more specific about that important link in FIH-1. The
precise substrate positioning afforded by both Tyr102 and Gln239 is the key link to ensure
that αKG oxidation subsequent to substrate binding is efficiently coupled to HIF-1α/
CTAD hydroxylation. Apparently, neither one of these residues can independently
secure the target Asn803 residue in a productive orientation as mutation of one is enough
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to cause uncoupling. It might well be that these residues comprise a structural element of
the enzyme, the sole purpose of which is to precisely position the substrate for efficient
hydrogen abstraction by the iron oxidant species. Inspection of the crystal structures
would seem to include the primary sphere residue Asp201 in this group as it forms a
hydrogen bond with the amide backbone of HIF-1α/CTAD-Asn803 (Figure 4.10). The
need to precisely position the substrate points to a distance-dependent orientation
requirement of the hydrogen abstraction event, which is likely critical to the ability of the
putative ferryl species to form the O-H bond[39,40].
To lend structural support to the proposed substrate positioning model, we
attempted to obtain the crystal structures of the Tyr102àAla mutant with and without
substrate. Unfortunately, the supposedly substrate-bound structure (2.7Å; already
submitted to the PDB bank by Cornelius Taabazuing) showed no density where the
substrate is expected to be located, meaning it had no substrate occupancy. This is
probably because of the very low substrate affinity of this mutant. Nonetheless, the
protein backbones (wild type vs Tyr102àAla mutant) were found to be superimposable
and so just based on this information, the best conclusion we can arrive at is that the
observed drastic effect on enzyme activity can be ascribed to the loss of the phenol side
chain group of Tyr102 residue.
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4.4 Conclusions and Future Directions
The loop region in FIH-1 termed the 100s loop was investigated in relation to its
role in substrate interactions and catalysis. Precedent for the study came from a previous
computational work demonstrating reduced loop flexibility upon αKG binding[1]. Steady
state kinetic data strongly indicate that the 100s loop is important for substrate binding
and catalysis. The results particularly revealed a critical role for the bulk at position 102
as the Tyr102àAla mutation drastically reduced enzyme activity whereas the conservative
Tyr102àPhe exhibited wild type-like behavior. The slow variant exhibited reduced
thermal stability relative to wild type in the presence of αKG as shown by thermal shift
data, which suggests that the flexibility associated with this residue or loop region is
important for enzyme activity. Other experiments can be done such as thermal unfolding
by CD spectroscopy or differential scanning calorimetry to provide further data on the
effect of Tyr102àAla mutation on conformational stability. The slow variant also
apparently exhibited an unexpected partial substrate inhibition with αKG, which might
have something to do with its observed reduced thermal stability. At least two hypotheses
have been proposed for the mechanism of partial inhibition: (1) inhibition is due to two
αKG molecules bound to the active site or (2) inhibition is due to αKG-dependent local
conformational effects, with the latter hypothesis being considered the most plausible in
the current study. The mutation induced negligible effects on global structure relative to
wild type as noted from CD spectroscopy and global HDX-MS data. However, the
possibility still remains that the mutation somehow altered loop dynamics; removal of the
bulk of Tyr102 likely induced some αKG-dependent, localized structural rearrangements
that negatively impacted the already reduced activity via disruption of substrate binding
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at high αKG levels. The disruption being referred to here is probably in addition to the
substrate positioning effect of Tyr102 residue. Initial substrate binding experiments at low
and high αKG seem to support this hypothesis but much work still needs to be done to
prove or disprove it. For one, additional binding experiments have to be done to ensure
robustness of the initial data. The proposed αKG-dependent, small-scale rearrangements
in the slow variant might be uncovered by low-resolution tools like limited proteolysis,
which can then be compared and contrasted to that of wild type enzyme. On a much
grander scale, the rate of conformational exchange for the loop residues of wild type
versus Tyr102àAla mutant can be measured either by NMR or local HDX-MS to probe
any alterations in the loop dynamics that somehow affected αKG interactions and
ultimately substrate binding. Additionally, the αKG ligand stoichiometry of wild type
and Tyr102àAla mutant can be measured by UV-vis spectroscopy using the method of
continuous variations to prove or disprove the first hypothesis that the inhibition is due to
two αKG molecules bound to the active site. So far, initial Cu-EPR data did not support
this hypothesis but was not completely ruled out.
Further kinetic and biophysical characterization of the slow loop variant revealed
an unprecedented role for Tyr102 in enzyme activity via substrate positioning. The
Tyr102àAla mutation did not significantly impair the first part of the catalytic cycle
which leads to αKG oxidation but drastically affected and thus uncoupled the second part
which leads to HIF-1α/CTAD hydroxylation. Although the mutant did not lose its ability
to activate dioxygen, it did so at an apparently slower rate as suggested by kinetic,
spectroscopic and coupling data so one cannot entirely rule out the possible involvement
of Tyr102 residue in oxygen activation. Its involvement is probably linked to its structural
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placement within the proposed solvent channel of FIH-1, which is being speculated in
this study as the enzyme’s O2 gate that limits the gas to bind predominantly in a
productive orientation upon substrate-induced rearrangements. Molecular dynamics
simulations might be able to formally identify this proposed O2 pathway in FIH-1. As no
single residue in the proposed channel seems to act like the lone guard of the “gate”
based on the structures, use of double (i.e. Tyr103àTrp/Glu105àGln) or triple residue
mutations that will limit accessibility is probably the way to test this for O2 kinetics
should the computational studies give favorable results. Currently, there are only indirect
evidences but no direct ones to demonstrate that substrate binding in FIH-1 causes O2
activation to happen at an appreciable rate as observed for the other dioxygenases. This is
another area of FIH-1 research that can be done for future studies to provide unequivocal
support of the enzyme’s substrate triggering phenomenon. It would also pave the way to
tackle the question of whether the substrate triggering mechanism in FIH-1 is dependent
on substrate positioning.
That Tyr102 residue is found to be sterically involved in substrate positioning is
consistent with the initial observation from crystal structures, which showed significant
rearrangement for this residue upon substrate binding. In the presence of HIF-1α/CTAD,
the phenol side chain of Tyr102 is shown to be stacked against HIF-1α/CTAD-Asn803 as if
securing the target residue in the proper orientation for efficient oxidation by the iron
oxidant species. This steric stacking interaction is most likely CH/π in character. It might
be possible to characterize this interaction in FIH-1 using a combination of quantum
chemical calculations and molecular dynamics simulations if only crystal structures of
the Tyr102àPhe and Tyr102àAla variants bound to substrate are available. Based on the
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available data, we postulated that proper substrate positioning afforded by FIH-1 residues
within the active site including Tyr102 ensures tight coupling between αKG oxidation and
HIF-1α/CTAD hydroxylation. This corroborates as well as extends the substrate
positioning model previously implied in our lab, which identified Gln239 residue to
contribute via H-bond interactions[16]. The original premise of the model is that tight
coupling of αKG oxidation to substrate hydroxylation is ensured via proper substrate
positioning of HIF-1α/CTAD-Asn803 by Gln239 residue relative to the iron oxidant
species. The data obtained in this study allowed for a slight modification in the proposed
model; that FIH-1 maintains tight coupling by employing structural elements within the
active site, which not only provide electrostatic (Gln239 and possibly Asp201) but steric
(Tyr102) interactions as well, to precisely position the substrate relative to the iron oxidant
species. One way to further test the steric role of Tyr102 in substrate positioning is to
generate variants at this position that will replace Tyr with hydrophobic residues
intermediate in size between Ala and Phe residues as was done in an earlier work on
TauD[40]. A strikingly similar observation as that for Tyr102 was noted for Phe159 residue
of TauD, which showed increasing trend of uncoupling with decreasing bulk at this
position[40]. Use of a substrate specifically deuterated at the target Asn residue position
would give very informative kinetic isotope results but generation of such a peptide
substrate is extremely difficult though not impossible.
The requirement of the enzyme for both electrostatic and steric interactions to
secure HIF-1α/CTAD-Asn803 residue in place makes sense given the relative flexibility
of the extended conformation assumed by this region (site 1) of the substrate as discussed
in the previous chapter. Enzyme uncoupling due to impairment of the productive binding
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orientation of the target residue might conceivably result in the increased residence time
of the generated iron oxidant species although for Tyr102àAla variant, loss of the bulk
probably enhanced solvent accessibility of the active site and so the reactive species
could just as easily get hydrolyzed by solvent molecules. However, using deuterated
solvent might slow the rate of hydrolysis and possibly enable the detection of the elusive
iron oxidant species in FIH-1 by stopped flow UV-vis spectroscopy. Fortunately, the
slow variant did not lose its ability to activate dioxygen and thus can still generate the
reactive iron species. It might even prove advantageous that the mutant can do so at an
apparently slower rate than wild type as suggested by kinetic, spectroscopic and coupling
data.
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4.5 Appendix
4.5.1 Abbreviations
BLAST, basic local alignment search tool;
EPR, electron paramagnetic resonance;
DEANO, diethylamine nitric oxide;
NO, nitric oxide;
Tris, tris(hydroxymethyl)aminomethane;
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4.5.2 Supplemental
4.5.2.1 LC/ESI-TOF mass spectrometry to determine molecular mass of FIH-1

Figure 4.11 ESI/TOF mass spectra of wild type FIH-1 and loop mutants. LC-MS
samples were prepared by dilution in 10 mM ammonium acetate buffer pH 7.4 to give a
final concentration of 20 µM FIH-1 and then injected into the RP-C4 column equilibrated
with 0.1% formic acid at RT (~23°C). Quick gradient elution was performed with
acetonitrile/0.1% formic acid solvent for 10 mins. The masses were analyzed using the
Qstar XL hybrid ESI/TOF instrument fitted with TurboIon spray source.
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4.5.2.2 Steady-state kinetic assays of FIH-1 to determine the KM for αKG

Figure 4.12 Steady state kinetics plots for wild type FIH-1 and the loop variants. The
data were fitted using the Michaelis-Menten equation giving apparent KM values of
17 ± 2 µM for wild type, 10 ± 3 µM for Y102F, and 8 ± 3 µM for K107A. For Y102A,
the plot was fitted to a partial uncompetitive inhibition equation[41,43] where kcat and ki
correspond to the catalytic constants of the uninhibited and inhibited steps respectively,
KM and Ki are the constants for the first (uninhibitory) and second (inhibitory) αKG
association events respectively, nH is the Hill coefficient (fixed at 1), x is the second Hill
coefficient (fixed at 2) that takes into account the cooperativity of the inhibitory event:
𝑣/𝐸 =   

!!"# !  !!   ×  ( ! ! /!! ! )

!  !  

! ! !!
[!]!!

  !  ( ! ! /!! ! )

Equation 4.3

The apparent KM from this fit is 52 ± 39 µM while Ki is 21 ± 9 µM. Fitting of the data
points in the uninhibited region of the plot using the Michaelis-Menten equation (inset)
gave an apparent KM value of 9 ± 1 µM. The reactions were performed at 37°C in 50 mM
HEPES pH 7.02 containing 50 µM FeSO4, 2 mM ascorbate, 900 µM HIF-1α/CTAD,
0.5 µM enzyme for WT and Y102F, 1 µM enzyme for K107A, 20 µM enzyme for
Y102A, and 0-1000 µM αKG.
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4.5.2.3 Intrinsic fluorescence quenching (or Trp quenching) assays to determine the
binding affinity of HIF-1α/CTAD to (Co+αKG)FIH-1

Figure 4.13 Binding of HIF-1α/CTAD to (Co+αKG)FIH-1 by monitoring the intrinsic
protein fluorescence quenching at 330 nm. The fitted curves using the modified Hill
equation (equation 3.1) gave KD values of 91 ± 5 µM for wild type, 204 ± 8 µM for
Y102F, and greater than 500 µM for both Y102A and K107A. CoCl2 was used to replace
Fe(II) in the active site. FIH-1 (2 µM) was equilibrated at RT (~25°C) with 25 µM CoCl2
and 500 µM αKG in 50 mM HEPES pH 7.0 for about 3 mins and then titrated with
HIF-1α/CTAD. The experiment was at least done in duplicate. The inset figure shows a
sample of the raw fluorescence emission spectra generated. The arrow shows the trend of
decreasing intensity with increasing amounts of HIF-1α/CTAD.
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4.5.2.4 Binding of αKG to wild type versus Tyr102àAla FIH-1

Figure 4.14 Binding of αKG to (Co)FIH-1 by monitoring the intrinsic protein
fluorescence quenching at 330 nm. The fitted curves using the modified Hill equation
(equation 3.1) gave a KD value of 35 ± 2 µM for wild type and 22 ± 2 µM for Y102A.
CoCl2 was used to replace Fe(II) in the active site. FIH-1 (0.5 µM) was equilibrated at RT
(~25°C) with 25 µM CoCl2 in 50 mM HEPES pH 7.0 for about 3 mins and then titrated
with αKG. The experiment was done in triplicate. The inset figure shows a sample of the
raw fluorescence emission spectra generated. The arrow shows the trend of decreasing
intensity with increasing amounts of αKG.

Figure 4.15 Binding of αKG to (Fe)FIH-1 by monitoring the change in absorbance at
λmax of 490-500 nm. The fitted curves using the modified Hill equation (equation 3.1)
gave a KD value of 32 ± 9 µM for wild type and 25 ± 10 µM for Y102A. FIH-1 (200 µM)
was anaerobically equilibrated inside the glovebox at RT (~25°C) with 198 µM FeSO4 in
50 mM HEPES pH 7.0 for about 3 mins and then titrated with αKG. The experiment was
at least done in duplicate. The inset figure shows a sample of the unsmoothed absorbance
spectra generated. The arrow shows the trend of increasing magnitude of absorbance with
increasing amounts of αKG.
	
  

130	
  

4.5.2.5 Cu-EPR spectroscopy of wild type versus Tyr102àAla FIH-1 at low and high
αKG

Figure 4.16 Cu-EPR spectra of wild type and Tyr102àAla (Y102A) FIH-1 at low and
high αKG levels. FIH-1 (275 µM) was equilibrated at RT (~25°C) with 250 µM CuSO4
and 300 or 900 µM αKG in 50 mM HEPES pH 7.0 for about 5 mins and then transferred
to EPR tubes.
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4.5.2.6 Global HDX-MS of wild type versus Tyr102àAla FIH-1 at low and high αKG

Figure 4.17 Global deuterium uptake plots showing the effect of low and high αKG on
the backbone amide solvent accessibility of wild type versus Tyr102àAla FIH-1. The
relative deuterium uptake (D) was calculated using the equation below[44]:
(𝒎
!  𝒎 )
𝐃 =    (𝒎𝒐𝒃𝒔  !  𝒎 𝟎)
Equation 4.4
𝟏𝟎𝟎

𝟎

The data were fitted to a tri-exponential equation (equation 4.5) (see Table 4.10A below
for the summary of the fitted parameters). H/D exchange was initiated by diluting
samples in 10 mM ammonium acetate buffer pD 7.4 to give a final concentration of
20 µM FIH-1, 50 µM MnSO4 and 500 µM (high) αKG. Samples were quenched at
various time points upon injection into the C4 column equilibrated with 0.1% formic acid
at ~0°C and then analyzed using ESI/TOF mass spectrometry.
Table 4.9A Comparison of the fitted parameters y0 (total exchangers), A (slow
exchangers), B (medium exchangers), and C (fast exchangers) generated upon non-linear
regression analysis of the global HDX data of wild type versus Tyr102àAla FIH-1 using
equation 4.5.

	
  

Apo FIH-1a, b

(Mn)FIH-1a, b

Apo Y102Aa, b

(Mn)Y102Aa, b

y0

186 ± 1

199 ± 5

192 ± 2

200 ± 3

Aslow

47 ± 2

60 ± 8

47 ± 3

52 ± 5

Bmedium

55 ± 3

50 ± 11

51 ± 5

56 ± 8

Cfast

84 ± 3

89 ± 10

94 ± 4

92 ± 7

132	
  

Table 4.9B Comparison of the fitted parameters for wild type versus Tyr102àAla FIH-1
at low and high αKG.
(Mn+αKG)FIH-1a, b

(Mn+αKG)Y102Aa, b

High αKG

Low αKG

High αKG

Low αKG

y0

157 ± 2

167 ± 1

160 ± 2

173 ± 1

Aslow

55 ± 4

51 ± 2

59 ± 3

53 ± 2

Bmedium 51 ± 6

50 ± 3

49 ± 5

45 ± 4

Cfast

66 ± 2

52 ± 5

75 ± 4

51 ± 6

a

The corresponding average rate constants were fixed accordingly during the fitting:
k1 (0.05 min-1), k2 (1 min-1), and k3 (20 min-1)[45]. The initial parameters obtained were
relative values; the number of exchangeable amides reported above was calculated by
multiplying the relative values by N (N = 324).
b
Errors are associated with the derivation of the parameters using equation 4.5 where y0 is
the actual number of exchangeable amide protons at a given condition (%D multiplied by
N where N is the theoretical number of exchangeable amide protons; N = total amino
acid residues – Pro residues – 1 for the N-terminus; for FIH-1, N = 324), A, B, and C
correspond to the slow, medium and fast exchangers with assigned average rate constants
k1 (0.05 min-1), k2 (1 min-1), and k3 (20 min-1) respectively:
𝑦   =    𝑦! − 𝐴𝑒 !!! ! − 𝐵𝑒 !!! ! − 𝐶𝑒 !!! !
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Equation 4.5

4.5.2.7 Binding affinity of HIF-1α/CTAD to Tyr102àAla FIH-1 at low and high αKG

Figure 4.18 Binding of HIF-1α/CTAD to (Co+αKG)Y102A at low and high αKG by
monitoring the intrinsic protein fluorescence quenching at 330 nm. The fitted curves
using the modified Hill equation (equation 3.1) gave KD values of 132 ± 6 µM at low
(50 µM) αKG and greater than 500 µM at high (500 µM) αKG. CoCl2 was used to
replace Fe(II) in the active site. FIH-1 (2 µM) was equilibrated at RT (~25°C) with
25 µM CoCl2 in 50 mM HEPES pH 7.0 for about 3 mins and then titrated with 6.1 mM
HIF-1α/CTAD. The experiment was at least done in duplicate. The inset figure shows a
sample of the raw fluorescence emission spectra generated. The arrow shows the trend of
decreasing intensity with increasing amounts of HIF-1α/CTAD.
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4.5.2.8 UV-vis spectrosocopy of wildtype FIH-1 in the presence of cofactors and
substrate

Figure 4.19 UV-vis spectra of wildtype FIH-1 (300 µM) in 50 mM HEPES pH 7.0 which
was anaerobically equilibrated inside the glovebox at RT (~25°C) with one or two or all
of the following components for at least 5 mins: 280 µM FeSO4, 600 µM αKG, 300 µM
HIF-1α/CTAD.
4.5.2.9 Autohydroxylation of wildtype FIH-1 and Tyr102àPhe as monitored by UV-vis
spectroscopy

Figure 4.20 Autohydroxylation spectra for wild type and the loop variant Tyr102àPhe.
The arrow indicates the increase in the absorption signal of the chromophore with a λmax
at 583 nm and 580 nm respectively. The spectra were obtained over a period of several
hours after air exposure at RT (~23°C) of the anaerobically prepared samples (230 µM
enzyme, 225 µM FeSO4, 1 mM αKG) in 50 mM HEPES pH 7.0.
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4.5.2.10 Proposed solvent channel of FIH-1 in the absence and presence of substrate

Figure 4.21 Configuration of the proposed solvent channel residues (grey spheres) in the
absence and presence of substrate (orange spheres). Tyr102 residue was highlighted in
cyan (behind and to the left of Tyr103 residue) while the red sphere is the iron center.
αKG (not shown) is coordinated to the left of the red sphere.

	
  

136	
  

4.6 References
1. Park, H., Ko, S., Ho Jeon, Y. (2010) Force field design and molecular dynamic
simulations of factor-inhibiting HIF-1 and its complex with known inhibitors:
implications for rational inhibitor design. J Mol. Graphics Modelling, 29, 221-228.
2. Yang, L.W., Xiong Liu, Christopher Jon Jursa, Mark Holliman, A.J. Rader, Hassan
Karimi, Ivet Bahar. (2005) iGNM: a database of protein functional motions based on
gaussian network model. Bioinformatics, 21, 2978-2987.
3. Elkins, J.M., Hewitson, K.S., McNeill, L.A., Seibel, J.F., Schlemminger, I., Pugh,
C.W., Schofield, C.J. (2003). Structure of factor-inhibiting hypoxia-inducible factor
(HIF) reveals mechanism of oxidative modification of HIF-1α. Journal of Biological
Chemistry, 278:3, 1802-1806.
4. Chen, Y.H., Comeaux, L.M., Herbst, R.W., Saban, E., Kennedy, D.C., Maroney,
M.J., Knapp, M.J. (2008) Coordination changes and auto-hydroxylation of FIH-1:
uncoupled O2 activation in a human hypoxia sensor. J Inorg. Biochem., 102:12, 21202129.
5. Saban, E., Flagg, S.C., Knapp, M.J. (2011) Uncoupled O2-activation in the human
HIF-asparaginyl hydroxylase, FIH, does not produce reactive oxygen species. J
Inogr. Biochem., 105, 630-636.
6. Ryle, M. J., Padmakumar, R., & Hausinger, R. P. (1999). Stopped-flow kinetic
analysis of Escherichia coli taurine/alpha-detoglutarate dioxygenase: interactions
with alpha-ketoglutarate, taurine, and oxygen. Biochemistry, 38:46, 15278-15286.
7. Brown, C. A., Pavlosky, M. A., Westre, T. E., Zhang, Y., Hedman, B., Hodgson, K.
O., Solomon, E. I. (1995) Spectroscopic and theoretical description of the electronic
structure of S = 3/2 iron-nitrosyl complexes and their relation to O2 activation by nonheme iron enzyme active sites. J. Am. Chem. Soc., 117, 715–732.
8. Han, A. Y., Lee, A. Q., Abu-Omar, M. M. (2006) EPR and UV-vis studies of the
nitric oxide adducts of bacterial phenylalanine hydroxylase: effects of cofactor and
substrate on the iron environment. Inorg. Chem., 45, 4277–4283.
9. Ye, S., Price, J. C., Barr, E. W., Green, M. T., Bollinger Jr., J. M., Krebs, C., Neese,
F. (2010) Cryoreduction of the NO-adduct of taurine:alpha-ketoglutarate dioxygenase
(TauD) yields an elusive {FeNO}(8) species. J. Am. Chem. Soc., 132, 4739–4751.
10. Maragos, C. M., Morley, D., Wink, D. A., Dunams, T. M., Saavedra, J. E., Hoffman,
A., Bove, A. A., Isaac, L., Hrabie, J. A., Keefer, L. K. (1991) Complexes of NO with
nucleophiles as agents for the controlled biological release of nitric-oxidevasorelaxant effects. J. Med. Chem., 34, 3242–3247.

	
  

137	
  

11. Diebold, A. R., Brown-Marshall, C. D., Neidig, M. L., Brownlee, J. M., Moran, G.
R., Solomon, E. I. (2011) Activation of alpha-keto acid-dependent dioxygenases:
application of an {FeNO}(7)/{FeO2}(8) methodology for characterizing the initial
steps of O-2 activation. J. Am. Chem. Soc., 133, 18148–18160.
12. Arciero, D. M., Orville, A. M., Lipscomb, J. D. (1985) [17O]Water and nitric oxide
binding by protocatechuate 4,5-dioxygenase and catechol 2,3-dioxygenase. Evidence
for binding of exogenous ligands to the active site Fe2+ of extradiol dioxygenases.
J. Biol. Chem., 260, 14035–14044.
13. Pavel, E.G., Zhou, J., Busby, R.W., Gunsior, M., Townsend, C.A., Solomon, E.I.
(1998) Circular dichroism and magnetic circular dichroism spectroscopic studies of
the non-heme ferrous active site in clavaminate synthase and its interaction with
alpha-ketoglutarate cosubstrate. J Am. Chem. Soc., 120, 743-753.
14. Hausinger, R. P. (2004). Fe(II)/α-ketoglutarate-dependent hydroxylases and related
enzymes. Crit. Rev. Biochem. Mol. Biol., 39, 21-68.
15. Keefer, L. K., Nims, R. W., Davies, K. M., Wink, D. A. (1996) NONOates’' (1substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide
dosage forms. Meth. Enzym., 268, 281–293.
16. Saban, E., Chen, Y.H., Hangasky, J., Taabazuing, C., Holmes, B.E., Knapp, M.J.
(2011) The second coordination sphere of FIH controls hydroxylation. Biochemistry,
50:21, 4733-4740.
17. Zhou, J., Gunsior, M., Bachmann, B., Townsend, C.A., Solomon, E.I. (1998)
Substrate binding to the α-ketoglutarate-dependent non-haem iron enzyme
clavaminate synthase 2: coupling mechanism of oxidative decarboxylation and
hydroxylation. J Am. Chem. Soc., 120, 13539-13540.
18. Zhang, Z.H., Ren, J., Stammers, D.K., Baldwin, J.E., Harlos, K., Schofield, C.J.
(2000) Structural origins of the selectivity of the trifunctional oxygenase clavaminic
acid synthase. Nat. Struct. Biol., 7, 127-133.
19. Tsuzuki, S., Honda, K., Uchimaru, T., Mikami, M., Tanabe, K. (2000) The magnitude
of the CH/π interaction between benzene and some model hydrocarbons. J Am.
Chem. Soc., 122, 3746-3753.
20. Tsuzuki, S., Honda, K., Uchimaru, T., Mikami, M., Tanabe, K. (2000) Origin of the
attraction and directionality of the NH/π interaction: comparison with OH/π and
CH/π. J Am. Chem. Soc., 122, 11450-11458.

	
  

138	
  

21. Diebold, A.R., Straganz, G.D., Solomon, E.I. (2011) Spectroscopic and
computational studies of alpha-keto acid binding to Dke1: understanding the role of
the facial triad and the reactivity of beta-diketones. J Am. Chem. Soc., 133, 1597911991.
22. Abu-Omar, M.M., Loaiza, A., Hontzeas, N. (2005). Reaction mechanisms of
mononuclear non-heme iron oxygenases. Chem. Rev., 105, 2227–2252.
23. Hangasky, J.A., Saban, E., Knapp, M. J. (2013). Inverse solvent isotope effects
arising from substrate triggering in the factor inhibiting hypoxia inducible factor.
Biochemistry, 52:9, 1594–602.
24. Neidig, M.L., Brown, C.D., Light, K.M., Fujimori, D.G., Nolan, E.M., Price, J.C.,
Barr, E.W., Bollinger Jr, J.M., Krebs, C., Walsh, C.T., Solomon, E.I. (2007) CD and
MCD of CytC3 and taurine dioxygenase: role of the facial triad in α-KG-dependent
oxygenases. J Am. Chem. Soc., 129:46, 14224-14231.
25. Light, K.M., Hangasky, J.A., Knapp, M.J., Solomon, E.I. (2013) Spectroscopic
studies of the mononuclear non-heme Fe(II) enzyme FIH: second-sphere
contributions to reactivity. J Am. Chem. Soc., 135:26, 9665-9674.
26. Ho, R.Y.N., Mehn, M.P., Hegg, E.L., Liu, A., Ryle, M.J., Hausinger, R.P., Que Jr., L.
(2001) Resonance raman studies of the iron (II)-α-keto acid chromophore in model
and enzyme complexes. J Am. Chem. Soc., 123, 5022-5029.
27. Solomon, E.I., Brunold, T.C., Davis, M.I., Kemsley, J.N., Lee, S.K., Lehnert, N.,
Neese, F., Skulan, A.J., Yang, Y.S., Zhou, J. (2000) Geometric and electronic
structure/function correlations in non-heme iron enzymes. Chem. Rev., 100, 235-249.
28. Kemsley, J.N., Mitic, N., Zaleski, K.L., Caradonna, J.P., Solomon, E.I. (1999)
Circular dichroism and magnetic circular dichroism spectroscopy of the catalytically
competent ferrous active site of phenylalanine hydroxylase and its interactions with
pterin cofactor. J Am. Chem. Soc., 121, 1528-1536.
29. Pavel, E.G., Martins, L.J., Ellis Jr, W.R., Solomon, E.I. (1994) Magnetic circular
dichroism studies of exogenous ligand and substrate binding to the non-heme ferrous
active site in phthalate dioxygenase. Chem. Biol., 1:3, 173-183.
30. Dann, C. E., Bruick, R. K., Deisenhofer, J. (2002). Structure of factor-inhibiting
hypoxia-inducible factor 1: An asparaginyl hydroxylase involved in the hypoxic
response pathway. Proceedings of the National Academy of Sciences of the United
States of America, 99:24, 15351–15356.

	
  

139	
  

31. Hangasky, J., Ivison, G., Knapp, M.J. (2014) Substrate positioning by Gln(239)
stimulates turnover in factor inhibiting HIF, an αKG-dependent hydroxylase.
Biochemistry, 53:36, 5750-5758.
32. Chen, Y.H., Comeaux, L.M., Eyles, S.J., Knapp, M.J. (2008) Auto-hydroxylation of
FIH-1, an Fe(II) , α-ketoglutarate dependent human hypoxia sensor. Chem. Commun.,
4768-4770.
33. Conejo-Garcia, A., McDonough, M.A., Loenarz, C., McNeill, L.A., Hewitson, K.S.,
Ge, W., Lienard, B.M., Schofield, C.J., Clifton, I.J. (2010) Structural basis for
binding of cyclic 2-oxoglutarate analogues to factor inhibiting hypoxia-inducible
factor. Bioorg. Med. Chem. Lett., 20:20, 6125-6128.
34. http://www.ezbiolab.com/peptide_tech.html
35. Zhou, J., Gunsior, M., Bachmann, B., Townsend, C.A., Solomon, E.I. (1998)
Substrate binding to the α-ketoglutarate-dependent non-haem iron enzyme
clavaminate synthase 2: coupling mechanism of oxidative decarboxylation and
hydroxylation. J Am. Chem. Soc., 120, 13539-13540.
36. Hewitson, KS., Holmes, S.L., Ehrismann, D., Hardy, A.P., Chowdhury, R., Schofield,
C.J., McDonough, M.A. (2008) Evidence that two enzyme-derived histidine ligands
are sufficient for iron binding and catalysis by factor inhibiting HIF (FIH). J Biol.
Chem., 283:38, 25971-25978.
37. Taabazuing, C.T., Fermann, J., Garman, S., Knapp, M.J. (2016) Substrate promotes
productive gas binding in the α-ketoglutarate-dependent dioxygenase FIH.
Biochemistry, 55:2, 277-286.
38. Klinman, J.P. (2001) Life as aerobes: are there simple rules for activation of dioxygen
by enzymes? J Biol Inorg Chem, 6, 1-13.
39. Muthukumaran, R.B., Grzyska, P.K., Hausinger, R.P., McCracken, J. (2007) Probing
the iron-substrate orientation for taurine/alpha-ketoglutarate dioxygenase using
deuterium electron spin echo envelope modulation spectroscopy. Biochemistry, 46,
5951-5959.
40. McCusker, K.P. and Klinman, J.P. (2009) Modular behavior of tauD provides insight
into the origin of specificity in α-ketoglutarate-dependent nonheme iron oxygenases.
Proceedings of the National Academy of Sciences of the United States of America,
106:47, 19791-19795.
41. Pastra-Landis, S.C., Evans, D.R., Lipscomb, W.N. (1978) The effect of pH on the
cooperative behavior of aspartate transcarbamylase from Escherichia coli. J Biol
Chem, 253, 4624-2630.
	
  

140	
  

42. Monod, J., Wyman, J., Changeux, J.P. (1965) On the nature of allosteric transitions: a
plausible model. J Mol Biol, 12, 88-118.
43. Licata, V.J. and Allewell, N.M. (1997) Is substrate inhibition a consequence of
allostery in aspartate transcarbamylase? Biophysical Chemistry, 64, 225-234.
44. Liu, Y.H. and Konermann, L. (2006). Enzyme conformational dynamics during
catalysis and in the resting state monitored by hydrogen/deuterium exchange mass
spectrometry. FEBS Letters, 580, 5137-5142.
45. Pektas, S. and Knapp, M.J. (2013) Substrate preference of the HIF-prolyl
hydroxylase-2 (PHD2) and substrate-induced conformational change. J Inorg.
Biochem., 126, 55-60.

	
  

	
  

141	
  

BIBLIOGRAPHY
Abu-Omar, M.M., Loaiza, A., Hontzeas, N. (2005). Reaction mechanisms of
mononuclear non-heme iron oxygenases. Chem. Rev., 105, 2227–2252.
Arany, Z., Huang, L.E., Eckner, R., Bhattacharya, S., Jiang, C., Goldberg, M.A., Bunn,
H.F., Livingston, D.M. (1996) An essential role for p300/CBP in the cellular response to
hypoxia. Proc. Natl. Acad. Sci. USA, 93, 12969-12973.
Arciero, D. M., Orville, A. M., Lipscomb, J. D. (1985) [17O]Water and nitric oxide
binding by protocatechuate 4,5-dioxygenase and catechol 2,3-dioxygenase. Evidence for
binding of exogenous ligands to the active site Fe2+ of extradiol dioxygenases. J. Biol.
Chem., 260, 14035–14044.
Berra, E., Benizri, E., Ginouves, A., Volmat, V., Roux, D., Pouyssegur, J. (2003) HIFprolyl hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α
in normoxia. EMBO J, 22:16, 4082-4090.
Bleijlevens, B., Shivarattan, T., Flashman, E., Yang, Y., Simpson, P.J., Koivisto, P.,
Sedgwick, B., Schofield, C.J., Matthews, S.J. (2008) Dynamic states of the DNA repair
enzyme AlkB regulate product release. EMBO Reports, 9:9, 872-877.
Brahimi-Horn, C.M. and Pouyssegur, J. (2007) Oxygen, a source of life and stress. FEBS
Letters, 581, 3582-3591.
Brown, R.S. and Lennon, J.J. (1995) Sequence-specific fragmentation of matrix-assisted
laser–desorbed protein/peptide ions. Anal. Chem., 67, 3990-3999.
Brown, C. A., Pavlosky, M. A., Westre, T. E., Zhang, Y., Hedman, B., Hodgson, K. O.,
Solomon, E. I. (1995) Spectroscopic and theoretical description of the electronic structure
of S = 3/2 iron-nitrosyl complexes and their relation to O2 activation by non-heme iron
enzyme active sites. J. Am. Chem. Soc., 117, 715–732.
Bruick, R.K. and McKnight, S.L. (2001) A conserved family of prolyl-4-hydroxylases
that modify HIF. Science, 294, 1337-1340.
Bruick, R.K. (2003) Oxygen sensing in the hypoxic response pathway: regulation of the
hypoxia-inducible transcription factor. Genes and Development, 17, 2614-2623.
Bulynko, Y. A. and O’Malley, B.W. (2011) Nuclear Receptor Coactivators: Structural
and Functional Biochemistry. Biochemistry, 50:3, 313-328.
Burdock, G.A., Madhusudan, G.S., Carabin, I.G. (2001) Evaluation of health aspects of
kojic acid in food. Reg. Toxicol. Pharmacol. 33, 80-101.

	
  

142	
  

Burstein, E.A. (1977) Intrinsic protein luminescence. The nature and application.
Advances in Science and Technology, ser. Biophysics, 7, VINITI, Moscow.
Calligaris, D., Villard, C., Lafitte, D. (2011) Advances in top-down proteomics for
disease biomarker discovery. J Proteomics, 74:7, 920-934.
Camenisch, G., Stroka, D.M., Gassmann, M., Wenger, R.H. (2001) Attenuation of HIF-1
DNA-binding activity limits hypoxia–inducible endothelin-1 expression. Eur. J Physiol.,
443, 240-249.
Carrero, P., Okamato, K., Coumailleau, P., O’Brien, S., Tanaka, H., Poellinger, L. (2000)
Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein
and SRC-1 to hypoxia-inducible factor 1α. Mol. Cell. Biol., 20, 402-415.
Chen, Y.H., Comeaux, L.M., Eyles, S.J., Knapp, M.J. (2008) Auto-hydroxylation of FIH1, an Fe(II) , α-ketoglutarate dependent human hypoxia sensor. Chem. Commun., 47684770.
Chen, Y.H., Comeaux, L.M., Herbst, R.W., Saban, E., Kennedy, D.C., Maroney, M.J.,
Knapp, M.J. (2008) Coordination changes and auto-hydroxylation of FIH-1: uncoupled
O2 activation in a human hypoxia sensor. J Inorg. Biochem., 102:12, 2120-2129.
Clifton, I. J., McDonough, M. A., Ehrismann, D., Kershaw, N. J., Granatino, N.,
Schofield, C.J. (2006). Structural studies on 2-oxoglutarate oxygenases and related
double-stranded beta-helix fold proteins. Journal of Inorganic Biochemistry, 100:4, 644669.
Cockman, M.E., Webb, J.D., Kramer, H.B., Kessler, B.M, Ratcliffe, P.J. (2009)
Proteomics-based identification of novel factor inhibiting hypoxia-inducible factor (FIH)
substrates indicates widespread asparaginyl hydroxylation of ankyrin repeat domaincontaining proteins. Mol.Cell Proteomics, 8:3, 535-546.
Cohen, A.R., Galanello, R., Piga, R., De Sanctis, V., Tricta, F. (2003) Safety and
effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood, 102,
1583-1587.
Coleman, M.L., McDonough, M.A., Hewitson, K.S., Coles, C., Mecinovic, J., Edelmann,
M., Cook, K.M., Cockman, M.E., Lancaster, D.E., Kessler, B.M., Oldham, N.J.,
Ratcliffe, P.J., Schofield, C.J (2007). Asparaginyl hydroxylation of the notch ankyrin
repeat domain by factor inhibiting hypoxia-inducible factor. Journal of Biological
Chemistry, 282(33), 24027-24038.
Conejo-Garcia, A., McDonough, M.A., Loenarz, C., McNeill, L.A., Hewitson, K.S., Ge,
W., Lienard, B.M., Schofield, C.J., Clifton, I.J. (2010) Structural basis for binding of
cyclic 2-oxoglutarate analogues to factor inhibiting hypoxia-inducible factor. Bioorg.
Med. Chem. Lett., 20:20, 6125-6128.
	
  

143	
  

Costas, M., Mehn, M.P., Jensen, M.P., Que Jr, L. (2004) Dioxygen activation at
mononuclear nonheme iron active sites: enzymes, models, and intermediates. Chem. Rev.,
104, 939-986.
Cummins, E.P., Berra, E., Comerford, K.M., Ginouves, A., Fitzgerald, K.T., Seeballuck,
F., Godson, C., Nielsen, J.E., Moynagh, P., Pouyseggur, J., Taylor, C.T. (2006) Prolyl
hydroxylase-1 negatively regulates IκB kinase-β, giving insight into hypoxia-induced
NFκB. Proc. Natl. Acad. Sci. USA, 103:48, 18154-18159.
Dames, S.A., Martinez-Yamout, M., De Guzman, R.N., Dyson, H.J., Wright, P.E. (2002)
Structural basis for Hif-1α/CBP recognition in the cellular hypoxic response. Proc. Natl.
Acad. Sci. USA, 99:8, 5271-5276.
Dann III, C. E., Bruick, R. K., Deisenhofer, J. (2002). Structure of factor-inhibiting
hypoxia-inducible factor 1: An asparaginyl hydroxylase involved in the hypoxic response
pathway. Proc. Natl. Acad. Sci. USA, 99:24, 15351-15356.
Dann III, C.E. and Bruick, R.K (2005). Dioxygenases as O2-dependent regulators of the
hypoxic response pathway. Biochem Biophys Res Comm, 338, 639-647.
Deschamps, J.D., Gautschi, J.T., Whitman, S., Johnson, T.A., Gassner, N.C., Crews, P.,
Holman, T.R. (2007) Discovery of platelet-type 12-human lipoxygenase selective
inhibitors by high-throughput screening of structurally diverse libraries. Bioorg. Med.
Chem., 15:22, 6900-6908.
Diebold, A.R., Straganz, G.D., Solomon, E.I. (2011) Spectroscopic and computational
studies of alpha-keto acid binding to Dke1: understanding the role of the facial triad and
the reactivity of beta-diketones. J Am. Chem. Soc., 133, 15979-11991.
Diebold, A. R., Brown-Marshall, C. D., Neidig, M. L., Brownlee, J. M., Moran, G. R.,
Solomon, E. I. (2011) Activation of alpha-keto acid-dependent dioxygenases: application
of an {FeNO}(7)/{FeO2}(8) methodology for characterizing the initial steps of O-2
activation. J. Am. Chem. Soc., 133, 18148–18160.
Dolwick, K.M., Swanson, H.I., Bradfield, C.A. (1993) In vitro analysis of Ah receptor
domains involved in ligand-activated DNA recognition. Proc. Natl. Acad. Sci. USA, 90,
8566-8570.
Dunning Hotopp, J.C., Auchtung, T.A., Hogan, D.A., Hausinger, R.P. (2003) Intrinsic
fluorescence as a probe of metal and alpha-ketoglutarate binding to TfdA, a mononuclear
non-heme iron dioxygenase. J Inorg Biochem, 93:1-2, 66-70.
Durrant, J.D., de Oliveira, C.A.F., Andrew McCammon, J. (2011) Pyrone-based
inhibitors of metalloproteinases types 2 and 3 may work as conformation-selective
inhibitors. Chemical Biology and Drug Design, 78:2, 191-198.
	
  

144	
  

Ehrismann, D., Flashman, E., Genn, D.N., Mathioudakis, N., Hewitson, K.S., Ratcliffe,
P.J., Schofield, C.J. (2007) Studies on the activity of the hypoxia-inducible factor
hydroxylases using an oxygen consumption assay. Biochem J, 401:1, 227-234.
Elkins, J.M., Clifton, I.J., Hernandez, H., Doan, L.X., Robinson, C.V., Schofield, C.J.,
Hewitson, K.S. (2002) Oligomeric structure of proclavaminic acid amidino hydrolase:
evolution of a hydrolytic enzyme in clavulanic acid biosynthesis. Biochem J, 366, 423434.
Elkins, J. M., Hewitson, K. S., McNeill, L. A., Seibel, J. F., Schlemminger, I., Pugh, C.
W., Schofield, C.J. (2003). Structure of factor-inhibiting hypoxia-inducible factor (HIF)
reveals mechanism of oxidative modification of HIF-1α. Journal of Biological
Chemistry, 278:3, 1802-1806.
Ema, M., Taya, S., Yokotani, N., Sogawa, K., Matsuda, Y., Fujii-Kuriyama, Y. (1997) A
novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α
regulates the VEGF expression and is potentially involved in lung and vascular
development. Proc. Natl. Acad. Sci. USA, 94, 4273-4278.
Ema, M., Hirota, K., Mimura, J., Abe, H., Yodoi, J., Sogawa, K., Poellinger, L., FujiiKuriyama, Y. (1999) Molecular mechanisms of transcription activation by HLF and
HIFα in response to hypoxia: their stabilization and redox signal-induced interaction with
CBP/p300. EMBO J, 18, 1905-1914.
Epstein, A.C.R., Gleadle, J.M., McNeill, L.A., Hewitson, K.S., O’Rourke, J., Mole, D.R.,
Mukherji, M., Metzen, E., Wilson, M.I., Dhanda, A., Tian, Y.M., Masson, N., Hamilton,
D.L., Jaakkola, P., Barstead, R., Hodgkin, J., Maxwell, P.H., Pugh, C.W., Schofield, C.J.,
Ratcliffe, P.J. (2001) C. elegans EGL-9 and mammalian homologs define a family of
dioxygenases that regulate HIF by prolyl hydroxylation. Cell, 107, 43-54.
Fandrey, J., Gorr, T.A., Gassmann, M. (2006) Regulating cellular oxygen sensing by
hydroxylation. Cardio. Res., 642-651.
Ferguson III, J.E., Wu, Y., Smith, K., Charles, P., Powers, K., Wang, H., Patterson, C.
(2007) ASB4 is a hydroxylation substrate of FIH and promotes vascular differentiation
via an oxygen-dependent manner. Mol. Cell. Biol., 27, 6407-6419.
Flamme, I., Frohlich, T., von Reutern, M., Kappel, A., Damert, A., Risau, W. (1997)
HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related
to hypoxia-inducible factor 1α and developmentally expressed in blood vessels.
Mechanisms of Development, 63, 51-60.
Flamme, I., Oehme, F., Ellinghaus, P., Jeske, M., Keldenich, J., Thuss, U. (2014)
Mimicking hypoxia to treat anemia: HIF stabilizer BAY 85-3934 (Molidustat) stimulates
erythropoietin production without hypertensive effects. PLoS One, 9:11.
	
  

145	
  

Flashman, E., Bagg, E.A.L, Chowdhury, R., Mecinovic, J., Loenarz, C., McDonough,
M.A., Hewitson, K.S., Schofield, C.J. (2007) Kinetic rationale for selectivity toward Nand C-terminal oxygen-dependent degradation domain substrates mediated by a loop
region of hypoxia-inducible factor prolyl hydroxylases. J Biol. Chem., 283, 3808-3815.
Fong, G.H. and Takeda, K. (2008) Role and regulation of prolyl hydroxylase domain
proteins. Nature Cell Death and Differentiation, 15, 635-641.
Fontana, A., de Laureto, P.P., Spolaore, B., Frare, E., Picotti, P., Zambonin, M. (2004)
Probing protein structure by limited proteolysis. Acta Biochim. Pol., 51:2, 299-321.
Fraczkiewicz, R. and Braun, W. (1998) Exact and efficient analytical calculation of the
accessible surface areas and their gradients for macromolecules. J Comp. Chem., 19, 319333.
Fromm, H.J. (1983) Use of competitive inhibitors to study substrate binding order.
Contemporary Enzyme Kinetics and Mechanism, Purich D.L. (ed.), Academic Press, ,
Orlando, Florida, 233-252.
Genbacev, O., Zhou, Y., Ludlow, J.W., Fisher, S.J. (1997) Regulation of human placental
development by oxygen tension. Science, 277, 1669-1672.
Gerber, H.P., Condorelli, F., Park, J., Ferrara, N. (1997) Differential transcriptional
regulation of the two vascular endothelial growth factor receptor genes. J Biol. Chem.,
272:38, 23659-23667.
Goldberg, M.A., Dunning, S.P, Bunn, H.F. (1988) Regulation of the erythropoietin gene:
evidence that the oxygen sensor is a heme protein. Science, 242, 1412-1415.
Gorlach, A., Camenisch, G., Kvietikova, I., Vogt, L., Wenger, R.H., Gassmann, M.
(2000) Efficient translation of mouse hypoxia-inducible factor-1α under normoxic and
hypoxic conditions. Biochimica et Biophysica Acta, 1493, 125-134.
Groves, J.T. and McClusky, G.A. (1976) Aliphatic hydroxylation via oxygen rebound.
Oxygen transfer catalyzed by iron. J Am. Chem. Soc., 98, 859-861.
Grzyska, P.K., Ryle, M.J., Monterosso, G.R., Liu, J., Ballou, D.P., Hausinger, R.P.
(2005) Steady-state and transient kinetic analyses of taurine/α-ketoglutarate dioxygenase:
Effects of oxygen concentration, alternative sulfonates, and active-site variants on the
FeIV-oxo intermediate. Biochemistry, 44, 3845-3855.
Gu, Y.Z., Moran, S.M., Hogenesch, J.B., Wartman, L., Bradfield, C.A. (1998) Molecular
characterization and chromosomal localization of a third alpha-class hypoxia-inducible
factor subunit, HIF3alpha. Gene Expr., 7, 205-213.

	
  

146	
  

Han, A. Y., Lee, A. Q., Abu-Omar, M. M. (2006) EPR and UV-vis studies of the nitric
oxide adducts of bacterial phenylalanine hydroxylase: effects of cofactor and substrate on
the iron environment. Inorg. Chem., 45, 4277–4283.
Hanauske-Abel, H.M. and Gunzler, V. (1982) A stereochemical concept for the catalytic
mechanism of prolylhydroxylase: applicability to classification and design of inhibitors. J
Theor. Biol., 94:2, 421-455.
Hanauske-Abel, H.M. and Popowicz, A.M. (2003) The HAG mechanism: a molecular
rationale for the therapeutic application of iron chelators in human diseases involving the
2-oxoacid utilizing dioxygenases. Curr. Med. Chem., 10:12, 1005-1019.
Hangasky, J., Taabazuing, C.T., Valliere, M., Knapp, M.J. (2013) Imposing function
down a (cupin) barrel: secondary structure and metal stereochemistry in the αKGdependent oxygenases. Metallomics, 5, 287-301.
Hangasky, J.A., Saban, E., Knapp, M. J. (2013). Inverse solvent isotope effects arising
from substrate triggering in the factor inhibiting hypoxia inducible factor. Biochemistry,
52:9, 1594–602.
Hangasky, J., Ivison, G., Knapp, M.J. (2014) Substrate positioning by Gln(239)
stimulates turnover in factor inhibiting HIF, an αKG-dependent hydroxylase.
Biochemistry, 53:36, 5750-5758.
Hausinger, R. P. (2004). Fe(II)/α-ketoglutarate-dependent hydroxylases and related
enzymes. Crit. Rev. Biochem. Mol. Biol., 39, 21-68.
Hausinger, R. (2015) 2-oxoglutarate-dependent oxygenases. RSC Metallobiology Series
3, The Royal Society of Chemistry.
Hewitson, K.S., McNeill, L.A., Riordan, M.V., Tian, Y.M., Bullock, A.N., Welford,
R.W., Elkins, J.M., Oldham, N.J., Bhattacharya, S., Gleadle, J.M., Ratcliffe, P.M., Pugh,
C.W., Schofield, C.J. (2002) Hypoxia-inducible factor (HIF) asparagine hydroxylase is
identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J
Biol. Chem., 277:29, 26351-26355.
Hewitson, K.S. and Schofield, C.J. (2004) The HIF pathway as a therapeutic target. Drug
Discov. Today, 9:16, 704-711.
Hewitson, KS., Holmes, S.L., Ehrismann, D., Hardy, A.P., Chowdhury, R., Schofield,
C.J., McDonough, M.A. (2008) Evidence that two enzyme-derived histidine ligands are
sufficient for iron binding and catalysis by factor inhibiting HIF (FIH). J Biol. Chem.,
283:38, 25971-25978.

	
  

147	
  

Hirsila, M., Koivunen, P., Gunzler, V., Kivirikko, K.I., Myllyharju, J. (2003)
Characterization of the human prolyl-4-hydroxylases that modify the hypoxia-inducible
factor. J Biol. Chem., 278:33, 30772-30780.
Hirsila, M., Koivunen, P., Xu, L., Seeley, T., Kivirikko, K. I., Myllyharju, J. (2005)
Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway.
The FASEB J., 19, 1308-1310.
Ho, R.Y.N., Mehn, M.P., Hegg, E.L., Liu, A., Ryle, M.J., Hausinger, R.P., Que Jr., L.
(2001) Resonance raman studies of the iron (II)-α-keto acid chromophore in model and
enzyme complexes. J Am. Chem. Soc., 123, 5022-5029.
Hon, W.C., Wilson, M.I., Harlos, K., Claridge, T.D.W., Schofield, C.J., Pugh, C.W.,
Maxwell, P.H., Ratcliffe, P.J., Stuart, D.I., Jones, E.Y. (2002) Structural basis for the
recognition of hydroxyproline in HIF-1α by pVHL. Nature, 417, 975-978.
Huang, Z.J., Edery, I., Rosbash, M. (1993) PAS is a dimerization domain common to
Drosophila period and several transcription factors. Nature, 364, 259-262.
Huang, L.E., Gu, J., Schau, M., Bunn, F. (1998) Regulation of hypoxia-inducible factor1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome
pathway. Proc. Natl. Acad. Sci. USA, 95, 7987-7992.
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J.M.,
Lane, W.S., Kaelin, W.G. Jr. (2001) HIFα targeted for VHL-mediated destruction by
proline hydroxylation: Implications for O2 sensing. Science, 292, 464-468.
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H.,
Gassmann, M., Gearhart, J.D., Lawler, A.M., Yu, A.Y., Semenza, G.L. (1998) Cellular
and developmental control of O2 homeostasis by hypoxia-inducible factor 1α. Genes and
Development, 12:2, 149-162.
Jaakkola, P., Mole, D.R., Tian, Y.M., Wilson, M.I., Gielbert, J., Gaskell, S.J.,
Kriegsheim, A., Hebestreit, H.F., Mukherji, M., Schofield, C.J., Maxwell, P.H., Pugh,
C.W. et al (2001) Targeting of HIFα to the von Hippel Lindau ubiquitylation complex by
O2-regulated prolyl hydroxylation. Science, 292, 468-472.
Jacobsen, J.A., Fullagar, J.L., Miller, M.T., Cohen, S.M. (2011) Identifying chelators for
metalloprotein inhibitors using a fragment-based approach. J Med. Chem., 54:2, 591-602.
Janke, K., Brockmeier, U., Kuhlmann, K., Eisenacher, M., Nolde, J., Meyer, H.E.,
Mairbaurl, H., Metzen, E. (2013) Factor inhibiting HIF-1 (FIH-1) modulates protein
interactions of apoptosis–stimulating p53 binding protein 2 (ASPP2). J Cell Science, 126,
2629-2640.

	
  

148	
  

Jewell, U.R., Kvietikove, I., Scheid, A., Bauer, C., Wenger, R.H., Gassmann, M. (2001)
Induction of HIF-1α in response to hypoxia is instantenous. FASEB J, 7, 1312-1314.
Jiang, B.H., Rue, E., Wang, G.L., Roe, R., Semenza, G.L. (1996) Dimerization, DNA
binding, and transactivation properties of hypoxia-inducible factor 1. J Biol. Chem.,
271:30, 17771-17778.
Jiang, B.H., Agani, F., Passaniti, A., Semenza, G.L. (1997) v-SRC induces expression of
hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular
endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression.
Cancer Res., 57, 5328-5335.
Jorgensen, W. (1991) Rusting of the lock and key model for protein-ligand binding.
Science, 254, 954-955.
Kallio, P.J., Pongratz, I., Gradin, K., McGuire, J., Poellinger, L. (1997) Activation of
hypoxia-inducible factor 1α: Posttranscriptional regulation and conformational change by
recruitment of the ARNT transcription factor. Proc. Natl. Acad. Sci. USA, 94, 5567-5572.
Keefer, L. K., Nims, R. W., Davies, K. M., Wink, D. A. (1996) NONOates’' (1substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide
dosage forms. Meth. Enzym., 268, 281–293.
Kemsley, J.N., Mitic, N., Zaleski, K.L., Caradonna, J.P., Solomon, E.I. (1999) Circular
dichroism and magnetic circular dichroism spectroscopy of the catalytically competent
ferrous active site of phenylalanine hydroxylase and its interactions with pterin cofactor.
J Am. Chem. Soc., 121, 1528-1536.
Khare, D., Wang, B., Gu, L., Razelun, J., Sherman, D.H., Gerwick, W.H., Hakansson, K.,
Smith, J.L. (2010) Conformational switch triggered by α-ketoglutarate in a halogenase of
curacin A biosynthesis. Proc. Natl. Acad. Sci. USA, 107:32, 14099-14104.
Kibel, A., Iliopoulos, O., DeCaprio, J.A., Kaelin Jr., W.G. (1995) Binding of the von
Hippel-Lindau tumor suppressor to elongin B and C. Science, 269, 1444-1446.
Kim, T.K., Kim, T.H., Maniatis, T. (1998) Efficient recruitment of TFIIIB and CBPRNA polymerase II holoenzyme by an interferon–beta enhanceosome in vitro. Proc.
Natl. Acad. Sci. USA, 95, 12191-12196.
Kim, J.W., Tchernyshyov, I., Semenza, G.L., Dang, C.V. (2006) HIF-1 mediated
expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular
adaptation to hypoxia. Cell Metab., 3, 177-185.
Klinman, J.P. (2001) Life as aerobes: are there simple rules for activation of dioxygen by
enzymes? J Biol Inorg Chem, 6, 1-13.

	
  

149	
  

Knowles, H.J., Raval, R.R., Harris, A.L, Ratcliffe, P.J. (2003) Effect of ascorbate on the
activity of hypoxia-inducible factor in cancer cells. Cancer Res., 63, 1764-1768.
Koditz, J., Nesper, J., Wottawa, M., Stiehl, D.P., Camenisch, G., Franke, C., Myllyharju,
J., Wenger, R.H., Katchinski, D.M. (2007) Oxygen-dependent ATF-4 stability is
mediated by the PHD3 oxygen sensor. Blood, 110, 3610-3617.
Koehntop, K. D., Emerson, J. P., & Que, L. (2005). The 2-His-1-carboxylate facial triad:
a versatile platform for dioxygen activation by mononuclear non-heme iron(II) enzymes.
Journal of Biological Inorganic Chemistry, 10(2), 87-93.
Koh, M.Y., Lemos Jr., R., Liu, X., Powls, G. (2011) The hypoxia-associated factor
switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell
characteristics, aggressive tumor growth and invasion. Cancer Res., 71:11, 4015-4027.
Koivunen, P., Hirsila, M., Ganzler, V., Kivirikko, K. I., Myllyharju, J. (2004). Catalytic
properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are
distinct from those of its prolyl 4-hydroxylases. Journal of Biological Chemistry, 279:11,
9899-9904.
Koivunen, P., Tiainen, P., Hyvarinen, J., Williams, K.E., Sormunen, R., Klaus, S.J.,
Kivirikko, K.I., Myllyharju, J. (2007) An endoplasmic reticulum transmembrane prolyl4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor α. J Biol.
Chem., 282:42, 30544-30552.
Koshland, D.E. (1958) Application of a theory of enzyme specificity to protein synthesis.
Proc. Natl. Acad. Sci. USA, 44:2, 98-104.
Kravtsov, A., Shurygin, A., Skorokhod, N., Khaspekov, L. (2011) Neuroprotector effect
of comenic acid against cytotoxic action of glutamate in vitro in cultured neurons of leadpoisoned rat pups. Bulletin of Experimental Biology and Medicine, 150:4, 436-439.
Laderoute, K.R., Calaoagan, J.M., Gustafson-Brown, C., Knapp, M.A., Li, G.C.,
Mendonca, H.L., Ryan, H.E., Wang, Z., Johnson, R.S. (2002) The response of c-Jun/AP1 to chronic hypoxia is hypoxia-inducible factor 1α dependent. Molecular and Cellular
Biology, 22:8, 2515-2523.
Lakowicz, J.R. (1992) Topics in fluorescence spectroscopy – biological applications.
Volume 3, Plenum Press, New York.
Lancaster, D.E., McNeill, L.A., McDonough, M.A., Aplin, R.T., Hewitson, K.S., Pugh,
C.W., et al. (2004). Disruption of dimerization and substrate phosphorylation inhibit
factor inhibiting hypoxia-inducible factor (FIH) activity. Biochemical Journal, 383:3,
429-437.

	
  

150	
  

Lando, D., Peet, D.J., Gorman, J.J., Whelan, D.A., Whitelaw, M.L., Bruick, R.K. (2002)
FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of
hypoxia-inducible factor. Genes Dev, 16, 1466-1471.
Lee, C., Kim, S.J., Jeong, D.G., Lee, S.M., Ryu, S.E. (2003) Structure of human FIH-1
reveals a unique active site pocket and interactions sites for HIF-1 and von HippleLindau. J Biol. Chem., 278, 7558-7563.
Levy, R.M., Karplus, M., Kushick, J., Perahia, D. (1984) Evaluation of the
configurational entropy for proteins – application to molecular-dynamics simulations of
an alpha-helix. Macromolecules, 17, 1370-1374.
Li, Q.F., Wang, X.W., Yang, Y.W., Lin, H. (2006) Hypoxia upregulates hypoxia
inducible factor (HIF)-3α expression in lung epithelial cells: characterization and
comparison with HIF-1α. Cell Research, 16, 548-558.
Licata, V.J. and Allewell, N.M. (1997) Is substrate inhibition a consequence of allostery
in aspartate transcarbamylase? Biophysical Chemistry, 64, 225-234.
Light, K.M., Hangasky, J.A., Knapp, M.J., Solomon, E.I. (2013) Spectroscopic studies of
the mononuclear non-heme Fe(II) enzyme FIH: second-sphere contributions to reactivity.
J Am. Chem. Soc., 135:26, 9665-9674.
Linke, S., Stojkoski, C., Kewley, R. J., Booker, G. W., Whitelaw, M. L., Peet, D. J.
(2004). Substrate requirements of the oxygen-sensing asparaginyl hydroxylase factorinhibiting hypoxia-inducible factor. Journal of Biological Chemistry, 279(14), 1439114397.
Liu, Y., Cox, S.R., Morita, T., Kourembanas, S. (1995) Hypoxia regulates vascular
endothelial factor gene expression in endothelial cells: identification of a 5’ enhancer.
Circulation Research, 77, 638-643.
Liu, A., Ho, R.Y., Que Jr., L. (2001) Alternative reactivity of an α-ketoglutaratedependent iron(II) oxygenase: enzyme self-hydroxylation. J Am. Chem. Soc., 123, 51265127.
Liu, Y.H. and Konermann, L. (2006). Enzyme conformational dynamics during catalysis
and in the resting state monitored by hydrogen/deuterium exchange mass spectrometry.
FEBS Letters, 580, 5137-5142.
Lo, M.C., Aulabaugh, A., Jin, G., Cowling, R., Bard, J., Malamas, M., Ellestad, G.
(2004) Evaluation of fluorescence-based thermal shift assays for hit identification in drug
discovery. Anal. Biochem., 332:1, 153-159.
Lok, C.N. and Ponka, P. (1999) Identification of a hypoxia response element in the
transferrin receptor gene. J Biol. Chem., 274:34, 24147-24152.
	
  

151	
  

Lonergan, K.M., Iliopoulos, O., Ohh, M., Kamura, T., Conaway, R.C., Conaway, J.W.,
Kaelin Jr., W.G. (1998) Regulation of hypoxia-inducible mRNAs by the von HippelLindau tumor suppressor protein requires binding to complexes containing elongins B/C
and Cul2. Molecular and Cellular Biology, 18:2, 732-741.
Mahon, P.C., Hirota, K., Semenza, G.L. (2001). FIH-1: a novel protein that interacts with
HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes and
Development, 15, 2675-2686.
Maragos, C. M., Morley, D., Wink, D. A., Dunams, T. M., Saavedra, J. E., Hoffman, A.,
Bove, A. A., Isaac, L., Hrabie, J. A., Keefer, L. K. (1991) Complexes of NO with
nucleophiles as agents for the controlled biological release of nitric-oxide-vasorelaxant
effects. J. Med. Chem., 34, 3242–3247.
Masson, N., Willam, C., Maxwell, P.H., Pugh, C.W., Ratcliffe, P.J. (2001) Independent
function of two destruction domains in hypoxia-inducible factor-α chains activated by
prolyl hydroxylation. EMBO J, 20:18, 5197-5206.
Matthews, M.L., Krest, C.M., Barr, E.W., Vaillancourt, F.H., Walsh, C.T., Green, M.T.,
Krebs, C., Bollinger, J.M. (2009) Substrate-triggered formation and remarkable stability
of the C-H bond-cleaving chloroferryl intermediate in the aliphatic halogenase, SyrB2.
Biochemistry, 48:20, 4331-4343.
Maxwell, P.H., Dachs, G.U., Gleadle, J.M., Nicholls, L.G., Harris, A.L., Stratford, I.J.,
Hankinson, O., Pugh, C.W., Ratcliffe, P.J. (1997) Hypoxia-inducible factor-1 modulates
gene expression in solid tumors and influences both angiogenesis and tumor growth.
Proc. Natl. Acad. Sci. USA, 94, 8104-8109.
Maxwell, P.H., Wiesener, M.S., Chang, G.W., Clifford, S.C., Vaux, E.C., Cockman,
M.E., Wykoff, C.C., Pugh, C.W., Maher, E.R., Ratcliffe, P.J. (1999) The tumor
suppressor VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
Nature, 399, 271-275.
McCusker, K.P. and Klinman, J.P. (2009) Modular behavior of tauD provides insight into
the origin of specificity in α-ketoglutarate-dependent nonheme iron oxygenases.
Proceedings of the National Academy of Sciences of the United States of America,
106:47, 19791-19795.
McDonough, M.A., McNeill, L.A., Tilliet, M., Papamicael, C.A., Chen, Q.Y., Banerji,
B., Hewitson, K.S., Schofield, C.J. (2005) Selective inhibition of factor inhibiting
hypoxia-inducible factor. J Am. Chem. Soc., 127:21, 7680-7681.

	
  

152	
  

McDonough, M. A., Li, V., Flashman, E., Chowdhury, R., Mohr, C., Lienard, B.M.R.,
Zondlo, J., Oldham, N.J., Clifton, I.J., Lewis, J., McNeill, L.A., Kurzeja, R.J.M.,
Hewitson, K.S., Yang, E., Jordan, S., Syed, R.S., Schofield, C.J. (2006). Cellular oxygen
sensing: Crystal structure of hypoxia- inducible factor prolyl hydroxylase (PHD2). Proc.
Natl. Acad. Sci. USA, 103:26, 9814-9819.
McNeill, L.A., Hewitson, K.S., Claridge, T.D., Seibel, J.F., Horsfall, L.E., Schofield, C.J.
(2002) Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyzes
hydroxylation at the β-carbon of asparagine-803. Biochem J, 367, 571-575.
McNeill, L.A., Bethge, L., Hewitson, K.S., Schofield, C.J. (2005) A fluorescence –based
assay for 2-oxoglutarate-dependent oxygenases. Anal. Biochem., 336:1, 125-131.
Mehn, M.P., Fujisawa, K., Hegg, E.L., Que Jr., L. (2003) Oxygen activation by nonheme
iron(II) complexes: alpha-keto carboxylate versus carboxylate. J Am. Chem. Soc., 125:26,
7828-7842.
Metzen, E., Wolff, M., Fandrey, J., Jelkmann, J. (1995) Pericellular PO2 and O2
consumption in monolayer cell cultures. Respir. Physiol., 100, 101-106.
Metzler, D.E. (2003) Biochemistry (2 Volume Set): The chemical reactions of living
cells. Burlington, Elsevier.
Michiels, C. (2004) Physiological and pathological responses to hypoxia. American J
Pathol, 164:6, 1875-1882.
Min, J.H., Yang, H., Ivan, M., Gertler, F., Kaelin Jr, W.G., Pavletich, N. (2002) Structure
of an HIF-1α-pVHL complex: Hydroxyproline recognition in signaling. Science, 296,
1886-1889.
Minchenko, A., Leshchinsky, I., Opentanova, I., Sang, N., Srinivas, V., Armstead, V.,
Caro, J. (2002) Hypoxia-inducible factor 1-mediated expression of the 6-phosphofructo2-kinase /fructose-2,6-bisphosphatase-3 (PFKFB3) gene. J Biol. Chem., 277:8, 61836187.
Monod, J., Wyman, J., Changeux, J.P. (1965) On the nature of allosteric transitions: a
plausible model. J Mol Biol, 12, 88-118.
Montero-Moran, G.M., Li, M., Rendon-Huerta, E., Jourdan, F., Lowe, D.J., StumpffKane, A.W., Feig, M., Scazzochio, C., Hausinger, R.P. (2007) Purification and
characterization of the Fe(II)- and alpha-ketoglutarate-dependent xanthine hydroxylase
from Aspergillus nidulans. Biochemistry, 46:18, 5293-5304.
Mukhopadhyay, C.K., Mazumder, B., Fox, P.L. (2000) Role of hypoxia–inducible factor1 in transcriptional activation of ceruloplasmin by iron deficiency. J Biol. Chem., 275:28,
21048-21054.
	
  

153	
  

Muthukumaran, R.B., Grzyska, P.K., Hausinger, R.P., McCracken, J. (2007) Probing the
iron-substrate orientation for taurine/alpha-ketoglutarate dioxygenase using deuterium
electron spin echo envelope modulation spectroscopy. Biochemistry, 46, 5951-5959.
Myllyla, R., Schubotz, L.M., Weser, U., Kivirikko, K.I. (1979) Involvement of
superoxide in the prolyl and lysyl hydroxylase reactions. Biochem. Biophys. Res. Comm.,
89:1, 98-102.
Nagel, S., Talbot, N.P., Mecinovic, J., Smith, T.G., Buchan, A.M., Schofield, C.J. (2010)
Therapeutic manipulation of the HIF hydroxylases. Antioxid Redox Signal, 12, 481-501.
Neidig, M.L., Brown, C.D., Light, K.M., Fujimori, D.G., Nolan, E.M., Price, J.C., Barr,
E.W., Bollinger Jr, J.M., Krebs, C., Walsh, C.T., Solomon, E.I. (2007) CD and MCD of
CytC3 and taurine dioxygenase: role of the facial triad in α-KG-dependent oxygenases. J
Am. Chem. Soc., 129:46, 14224-14231.
Ohh, M., Park, C.W., Ivan, M., Hoffman, M.A., Kim, T.Y., Huang, L.E., Pavletich, N.,
Chau, V., Kaelin, W.G. (2000) Ubiquitination of hypoxia-inducible factor requires direct
binding to the β-domain of the von Hippel-Lindau protein. Nature Cell Biology, 2, 423427.
Ozer A. and Bruick R.K. (2007) Non-heme dioxygenases: cellular sensors and regulators
jelly rolled into one? Nat. Chem. Biol. 3:3, 144-153.
Park, H., Ko, S., Ho Jeon, Y. (2010) Force field design and molecular dynamic
simulations of factor-inhibiting HIF-1 and its complex with known inhibitors:
implications for rational inhibitor design. J Mol. Graphics Modelling, 29, 221-228.
Pastra-Landis, S.C., Evans, D.R., Lipscomb, W.N. (1978) The effect of pH on the
cooperative behavior of aspartate transcarbamylase from Escherichia coli. J Biol Chem,
253, 4624-2630.
Pause, A., Lee, S., Worrell, R.A., Chen, D.Y.T., Burgess, W.H., Linehan, W.M.,
Klausner, R.D. (1997) The von Hippel-Lindau tumor suppressor gene product forms a
stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc.
Natl. Acad. Sci. USA, 94, 2156-2161.
Pavel, E.G., Martins, L.J., Ellis Jr, W.R., Solomon, E.I. (1994) Magnetic circular
dichroism studies of exogenous ligand and substrate binding to the non-heme ferrous
active site in phthalate dioxygenase. Chem. Biol., 1:3, 173-183.
Pavel, E.G., Zhou, J., Busby, R.W., Gunsior, M., Townsend, C.A., Solomon, E.I. (1998)
Circular dichroism and magnetic circular dichroism spectroscopic studies of the nonheme ferrous active site in clavaminate synthase and its interaction with alphaketoglutarate cosubstrate. J Am. Chem. Soc., 120, 743-753.
	
  

154	
  

Pektas, S. and Knapp, M.J. (2013) Substrate preference of the HIF-prolyl hydroxylase-2
(PHD2) and substrate-induced conformational change. J Inorg. Biochem., 126, 55-60.
Price, J.C., Barr, E.W., Tirupati, B., Martin Bollinger Jr, J., Krebs, C. (2003) The first
direct characterization of a high-valent iron intermediate in the reaction of an αketoglutarate-dependent dioxygenase: A high-spin Fe(IV) complex in taurine/αketoglutarate dioxygenase (TauD) from Escherichia coli. Biochemistry, 42, 7497-7508.
Price, J.C., Barr, E.W., Hoffart, L.M., Krebs, C., Bollinger, J.M. (2005) Kientic
dissection of the catalytic mechanism of taurine: α-ketoglutarate dioxygenase (TauD)
from Escherichia coli. Biochemistry, 44, 8138-8147.
Proshlyakov, D.A., Henshaw, T.F., Monterosso, G.R., Ryle, M.J., Hausinger, R.P. (2004)
Direct detection of oxygen intermediates in the non-heme Fe enzyme taurine/αketoglutarate dioxygenase. J Am. Chem. Soc., 126, 1022-1023.
Pugh, C.W., O’Rourke, J.F., Nagao, M., Gleadle, J.M., Ratcliffe, P.J. (1997) Activation
of hypoxia-inducible factor-1: definition of regulatory domains within the α subunit. J
Biol. Chem., 272, 11205-11214.
Ramanathan, A., Savol, A.J., Agarwal, P.K., Chennubhotla, C.S. (2012) Event detection
and sub-state discovery from biomolecular simulations using higher-order statistics:
application to enzyme adenylate kinase. Protein, 80, 2536-2551.
Reisz-Proszasz, S., Probst, M.R., Fukunaga, B.N., Hankinson, O. (1994) Identification of
functional domains of the aryl hydrocarbon receptor nuclear translocator protein
(ARNT). Mol. Cell. Biol., 14:9, 6075-6086.
Rolfs, A., Kvietikova, I., Gassmann, M., Wenger, R.H. (1997) Oxygen-regulated
transferrin expression is mediated by hypoxia-inducible factor-1. J Biol. Chem., 272:32,
20055-20062.
Rouffet, M. and Cohen, S.M. (2011) Emerging trends in metalloprotein inhibition.
Dalton Trans., 40:14, 3445-3454.
Ruas, J.L., Poellinger, L., Pereira, T. (2002) Functional analysis of hypoxia-inducible
factor-1 alpha-mediated transactivation. Identification of amino acid residues critical for
transcriptional activation and/or interaction with CREB-binding protein. J Biol. Chem.,
277, 38723-38730.
Ryle, M. J., Padmakumar, R., & Hausinger, R. P. (1999). Stopped-flow kinetic analysis
of Escherichia coli taurine/alpha-detoglutarate dioxygenase: interactions with alphaketoglutarate, taurine, and oxygen. Biochemistry, 38:46, 15278-15286.

	
  

155	
  

Ryle, M.J., Liu, A., Muthukumaran, R.R., Ho, R.Y., Koenhtop, K.D., McCracken, J., Que
Jr., L., Hausinger, R.P. (2003) O2 and α-ketoglutarate-dependent trysoyl radical
formation in TauD, an α-keto acid-dependent non-heme iron dioxygenase. Biochemistry,
42:7, 1854-1862.
Saban, E., Chen, Y.H., Hangasky, J., Taabazuing, C., Holmes, B.E., Knapp, M.J. (2011)
The second coordination sphere of FIH controls hydroxylation. Biochemistry, 50:21,
4733-4740.
Saban, E., Flagg, S.C., Knapp, M.J. (2011) Uncoupled O2 activation in the human HIFasparaginyl hydroxylase, FIH, does not produce reactive oxygen species. J Inorg.
Biochem., 105, 630-636.
Salceda, S., Beck, I., Caro, J. (1996) Absolute requirement of aryl hydrocarbon receptor
nuclear translocator protein for gene activation by hypoxia. Archives of Biochemistry and
Biophysics, 334:2, 389-394.
Salceda, S., and Caro, J. (1997) Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly
degraded by the ubiquitin-proteasome system under normoxic conditions. J Biol. Chem.,
272:36, 22642-22647.
Sang, N., Fang, J., Srinivas, V., Leshchinsky, I., Caro, J. (2002) Carboxy-terminal
transactivation activity of hypoxia-inducible factor 1α is governed by a von HippelLindau protein-independent, hydroxylation–regulated association with p300/CBP.
Molecular and Cellular Biology, 22:9, 2984-2992.
Schodel, J., Oikonomopoulos, S., Ragoussis, J., Pugh, C.W., Ratcliffe, P.J., Mole, D.R.
(2011) High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood,
117, 207-217.
Schofield, C.J. and Ratcliffe, P.J. (2004) Oxygen sensing by HIF hydroxylases. Nature
Reviews Molecular Cell Biology, 5, 343-354.
Seagroves, T.N., Ryan, H.E., Lu, H., Wouters, B.G., Knapp, M., Thibault, P., Laderoute,
K., Johnson, R.S. (2001) Transcription factor HIF-1 is a necessary mediator of the
Pasteur effect in mammalian cells. Molecular and Cellular Biology, 21:10, 3436-3444.
Semenza, G.L. and Wang, G.L. (1992) A nuclear factor induced by hypoxia via de novo
protein synthesis binds to the human erythropoietin gene enhancer at a site required for
transcriptional activation. Mol. Cell. Biol., 12:12, 5447-5454.
Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. Nature Reviews Cancer,
3(10), 721-732.
Semenza, G.L. (2004) Hydroxylation of HIF-1: oxygen sensing at the molecular level.
Physiology, 19, 176-182.
	
  

156	
  

Semenza, G. L. (2007). Life with Oxygen. Science, 318:5847, 62-64.
Smirnova, N.A., Rakhman, I., Moroz, N., Basso, M., Payappilly, J., Kazakov, S.,
Hernandez-Guzman, F., Gaisina, I.N., Kozikowski, A.P., Ratan, R.R., Gazaryan, I.G.
(2010) Utilization of an in vivo reporter for high throughput identification of branched
small molecule regulators of hypoxic adaptation. Chem. Biol., 17:4, 380-391.
Solomon, E.I., Brunold, T.C., Davis, M.I., Kemsley, J.N., Lee, S.K., Lehnert, N., Neese,
F., Skulan, A.J., Yang, Y.S., Zhou, J. (2000) Geometric and electronic structure/function
correlations in non-heme iron enzymes. Chem. Rev., 100, 235-249.
Solomon, E.I., Decker, A., Lehnert, N. (2003) Non-heme iron enzymes: contrasts to
heme catalysis. Proc. Natl. Acad. Sci. USA, 100:7, 3589-3594.
Srinivas, V., Zhang, L.P., Zhu, X.H., Caro, J. (1999) Characterization of an
oxygen/redox-dependent degradation domain of hypoxia-inducible factor α (HIF-α)
proteins. Biochemical and Biophysical Research Communications, 260, 557-561.
Stolze, I.P., Tian, Y.M., Appelhoff, R.J., Turley, H., Wykoff, C.C., Gleadle, J.M.,
Ratcliffe, P.J. (2004) Genetic analysis of the role of the asparaginyl hydroxylase factor
inhibiting hypoxia-inducible factor (FIH) in regulating hypoxia-inducible factor (HIF)
transcriptional target genes. J Biol. Chem., 279:41, 42719-42725.
Stubbs, C.J., Loenarz, C., Mecinovic, J., Yeoh, K.K., Hindley, N., Lienard, B.M., Sobott,
F., Schofield, C.J., Flashman, E. (2009) Application of a proteolysis/mass spectrometry
method for investigating the effects of inhibitors on hydroxylase structure. J Med. Chem.,
52, 2799-2805.
Suckau, D. and Resemann, A. (2003) T3-sequencing: Targeted characterization of the Nand C-termini of undigested proteins by mass spectrometry. Anal. Chem., 75:21, 58175824.
Tanimoto, K., Makino, Y., Pereira, T., Poellinger, L. (2000) Mechanism of regulation of
the hypoxia-inducible factor-1α by the von Hippel-Lindau tumor suppressor protein.
EMBO J, 19:16, 4298-4309.
Tipton, K.F. (1990) Essays in Biochemistry. United States Edition, Academic Press Inc,
San Diego, CA, Volume 25, 96.
Tsuzuki, S., Honda, K., Uchimaru, T., Mikami, M., Tanabe, K. (2000) The magnitude of
the CH/π interaction between benzene and some model hydrocarbons. J Am. Chem. Soc.,
122, 3746-3753.

	
  

157	
  

Tsuzuki, S., Honda, K., Uchimaru, T., Mikami, M., Tanabe, K. (2000) Origin of the
attraction and directionality of the NH/π interaction: comparison with OH/π and CH/π. J
Am. Chem. Soc., 122, 11450-11458.
Valegard, K., Terwisscha van Scheltinga, A.C., Lloyd, M.D., Hara, T., Ramaswamy, S.,
Perrakis, A., Thompson, A., Lee, H.J., Baldwin, J.E., Schofield, C.J., Hajdu, J.,
Andersson, I. (1998) Structure of a cephalosporin synthase. Nature, 394, 805-809.
Valegard, K., Terwisscha van Scheltinga, A.C., Dubus, A., Ranghino, G., Oster, L.M.,
Hajdu, J., Anderson, I. (2004) The structural basis of cephalosporin formation in
mononuclear ferrous enzyme. Nat. Struct. Biol., 11, 95-101.
Wang, G.L. and Semenza, G.L. (1993) Characterization of hypoxia-inducible factor 1
and regulation of DNA binding activity by hypoxia. J Biol. Chem. 268:29, 21513-21518.
Wang, G.L., Jiang, B.H., Rue, E.A., Semenza, G.L. (1995) Hypoxia-inducible factor 1 is
a basic–helix-loop-helix-PAS heterodimer regulated by O2 tension. Proc. Natl. Acad. Sci.
USA, 92, 5510-5514.
Warshakoon, N. C., Wu, S., Boyer, A., Kawamoto, R., Sheville, J., Renock, S., Xu, K.,
Pokross, M., Zhou, S., Winter, C., Walter, R., Mekel, M., Evdokimov, A.G. (2006).
Structure-based design, synthesis, and SAR evaluation of a new series of 8hydroxyquinolines as HIF-1alpha prolyl hydroxylase inhibitors. Bioorg. Med. Chem.
Lett., 16:21, 5517-5522.
Warshakoon, N. C., Wu, S., Boyer, A., Kawamoto, R., Sheville, J., Renock, S., Xu, K.,
Pokross, M., Zhou, S., Winter, C., Walter, R., Mekel, M., Evdokimov, A.G. (2006). A
novel series of imidazo[1,2-a]pyridine derivatives as HIF-1alpha prolyl hydroxylase
inhibitors. Bioorg. Med. Chem. Lett., 16:21, 5598-5601.
Webb, J.D., Muranyi, A., Pugh, C.W., Ratcliffe, P.J., Coleman, M.L. (2009) MYPT1, the
targeting subunit of smooth muscle myosin phosphatase, is a substrate for the asparaginyl
hydroxylase factor inhibiting hypoxia-inducible factor (FIH). Biochem. J, 420, 327-333.
Wenger, R.H., Rolfs, A., Marti, H.H., Guenet, J.L., Gassmann, M. (1996) Nucleotide
sequence, chromosomal assignment and mRNA expression of mouse hypoxia –inducible
factor 1α. Biochem. Biophys. Res. Commun., 223, 54-59.
Wiener, C.M., Booth, G., Semenza, G.L. (1996) In vivo expression of mRNAs encoding
hypoxia-inducible factor 1. Biochem. Biophys. Res. Commun., 225, 485-488.
Wilmouth, R.C., Turnbull, J.J., Welford, R.W., Clifton, I.J., Prescott, A.G., Schofield,
C.J. (2002) Structure and mechanism of anthocyanidin synthase from Arabidopsis
thaliana. Structure, 10:1, 93-103.

	
  

158	
  

Wu, M., Moon, H.S., Begley, T.P. (1999) Mechanism-based inactivation of the human
prolyl-4-hydroxylase by 5-oxoproline-containing peptides: evidence for a prolyl radical
intermediate. J Am. Chem. Soc., 121, 587-588.
Wykoff, C.C., Beasley, N.J.P., Watson, P.H., Turner, K.J., Pastorek, J., Sibstain, J.,
Wilson, G.D., Turley, H., Talks, K.L., Maxwell, P.H., Pugh, C.W., Ratcliffe, P.J., Harris,
A.L. (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases.
Cancer Research, 60, 7075-7083.
Xia, X. Lemieux, M.E., Li, W., Carroll, J.S., Brown, M., Liu, X.S., Kung, A.L. (2009)
Integrative analysis of HIF binding and transactivation reveals its role in maintaining
histone methylation homeostasis. Proc. Natl. Acad. Sci. USA, 106:11, 4260-4265.
Yang, L.W., Xiong Liu, Christopher Jon Jursa, Mark Holliman, A.J. Rader, Hassan
Karimi, Ivet Bahar. (2005) iGNM: a database of protein functional motions based on
gaussian network model. Bioinformatics, 21, 2978-2987.
Yang, M., Ge, W., Chowdhury, R., Claridge, T.D., Kramer, H.B., Schmierer, B.,
McDonough, M.A., Gong, L., Kessler, B.M., Ratcliffe, P.J., Coleman, M.L., Schofield,
C.J. (2011) Asparagine and aspartate hydroxylation of the cytoskeletal ankyrin family is
catalyzed by factor-inhibiting hypoxia-inducible factor. J Biol. Chem., 286, 7648-7660.
Yang, M., Chowdhury, R., Ge, W., Hamed, R.B., McDonough, M.A., Claridge, T.D.,
Kessler, B.M., Cockman, M.E., Ratcliffe, P.J., Schofield, C.J. (2011) Factor-inhibiting
hypoxia-inducible factor (FIH) catalyzes the post-translational hydroxylation of histidinyl
residues wihin ankyrin repeat domains. FEBS J, 278, 1086-1097.
Ye, S., Price, J. C., Barr, E. W., Green, M. T., Bollinger Jr., J. M., Krebs, C., Neese, F.
(2010) Cryoreduction of the NO-adduct of taurine:alpha-ketoglutarate dioxygenase
(TauD) yields an elusive {FeNO}(8) species. J. Am. Chem. Soc., 132, 4739–4751.
Yu, A.Y., Shimoda, L.A., Iyer, N.V., Huso, D.L., Sun, X., McWilliams, R., Beaty, T.,
Sham, J.S.K, Wiener, C.M., Sylvester, J.T., Semenza, G.L. (1999) Impaired
physiological responses to chronic hypoxia in mice partially deficient for hypoxiainducible factor 1α. J Clin. Invest., 101:5, 691-696.
Yu, F., White, S.B., Zhao, Q., Lee, F.S. (2001) HIF-1α binding to VHL is regulated by
stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. USA, 98:17, 9630-9635.
Zhang, Z.H., Ren, J., Stammers, D.K., Baldwin, J.E., Harlos, K., Schofield, C.J. (2000)
Structural origins of the selectivity of the trifunctional oxygenase clavaminic acid
synthase. Nat. Struct. Biol., 7, 127-133.
Zhang, N., Stewart, B.G., Moore, J.C., Greasham, R.L., Robinson, D.K., Buckland, B.C.,
Lee, C. (2000) Metab. Eng., 2:4, 339-348.

	
  

159	
  

Zhou, J., Gunsior, M., Bachmann, B., Townsend, C.A., Solomon, E.I. (1998) Substrate
binding to the α-ketoglutarate-dependent non-haem iron enzyme clavaminate synthase 2:
coupling mechanism of oxidative decarboxylation and hydroxylation. J Am. Chem. Soc.,
120, 13539-13540.
Zhou, J., Kelly, W.L., Bachmann, B.O., Gunsior, M., Townsend, C.A., Solomon, E.I.
(2001) Spectrocopic studies of substrate interactions with clavaminate synsthase 2, a
multifunctional αKG-dependent non-heme iron enzyme: correlation with mechanism and
reactivities. J Am. Chem. Soc., 123, 7388-7398.
http://www.ezbiolab.com/peptide_tech.html
http://curie.utmb.edu/area_man.html
https://clinicaltrials.gov/ct2/show/NCT01750190
http://ignm.ccbb.pitt.edu/index.php

	
  

	
  

160	
  

